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Introduction 9
INTRODUCTION
The immune system protects the host against invading pathogens like viruses, bac-
teria, and fungi. The defense mechanisms consist of a non-specifi c (innate) and a 
specifi c (acquired) immune system. The non-specifi c defense mechanisms include 
physical barriers formed by our skin and mucosa, humoral systems, such as the 
complement system, and cellular components represented mainly by phagocytic 
cells (monocytes, macrophages, granulocytes). 
The specifi c immune system involves responses directed against specifi c patho-
gens, which is classifi ed into two types, the humoral and cell-mediated immune 
system. The humoral system consists of B-cells, which respond to foreign antigens 
by developing into antibody-producing cells. The cell-mediated immune system 
consists of T cells and natural killer (NK) cells, where T cells are divided in CD4+ 
T helper (Th) lymphocytes and CD8+ cytotoxic T cells [1]. Several types of Th cells, 
designated Th0, Th1, and Th2, have been identifi ed. Th0 cells are believed to be 
precursor cells that develop into either Th1 or Th2 cells. 
The interplay between cells of the immune system is in part regulated by protein 
hormones, called cytokines. Cytokines are known for their role in the regulation of 
differentiation of Th cells into the subtypes and to infl uence the ratios of Th1 and 
Th2 cells. Th1 cells stimulate cell-mediated immune responses, in general directed 
against most bacterial and fungal pathogens with a distinct cytokine profi le; secre-
tion of interleukin-2 (IL-2), interferon-γ (IFN-γ), and tumor necrosis factor-β (TNF-β) 
[2]. Th2 cells evoke a strong antibody response (humoral immune response), often 
effective against extracellular pathogens. Their cytokine pattern consists of secretion 
of IL-4, IL-5, IL-6, IL-10, and IL-13 [3, 4]. 
CYTOKINES
Cytokines are small (8-26 kilodaltons), non-structural, highly active proteins which 
play an essential role in the immune system. They are produced by monocytes/
macrophages, lymphocytes, granulocytes, epithelial cells, endothelial cells, keratino-
cytes, and fi broblasts mediating complex interactions between cells. In the normal 
state they are absent or produced in very low amounts with a transient short range 
of activity, and their production is stimulated by infectious stimuli. The cytokine 
network consists of pro- and anti-infl ammatory cytokines, and natural inhibitors 
of these cytokines, which interact with each other. TNF-α and IL-1β are the most 
important proinfl ammatory cytokines [5, 6]. Other cytokines with proinfl ammatory 
properties are IL-18, IL-12, and INF-γ [7-9]. IL-4, IL-10 and IL-13 are anti-infl ammatory 
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cytokines which can counteract some of the activities generated by the proinfl amma-
tory cytokines. Cytokines are pleiotropic and overlap their activities, a result from a 
cascade where one cytokine induces the other. The host response to infection is in 
part regulated by the balance between pro- and anti-infl ammatory cytokines. One of 
the most important proinfl ammatory cytokines, which is the object of detailed study 
in the present thesis is IL-18.
INTERLEUKIN18
IL-18, a member of the IL-1 family, is a cytokine initially described as a co-stimulus 
for IFN-γ produced in mice injected with Propionibacterium acnes and lipopoly-
saccharide (LPS) [10, 11]. It is produced by many cells of the immune system like 
macrophages, human peripheral blood mononuclear cells (PBMC), dendritic cells, 
epidermal cells, osteoblastic stromal cells, and cells of the central nervous system 
[12]. In the presence of secondary stimulants, particularly IL-12 and microbial agents, 
IL-18 is able to induce large amounts of IFN-γ by T cells and NK cells [13]. The IL-18 
receptor is upregulated by IL-12, and accounts for the synergism of IL-12 and IL-18 
[14, 15]. 
IL-18 displays proinfl ammatory effects by inducing the production of proinfl amma-
tory cytokines such as TNF-α, IL-1α/β, IL-6, and chemokines such as IL-8, macro-
phage infl ammatory protein-1α (MIP-1α), and monocyte chemoattractant protein-1 
(MCP-1) [7]. In humans, IL-18 initially induces TNF production by CD3+/CD4+ T 
cells and NK cells, leading to a subsequent production of IL-1β and IL-8 by CD14+ 
cells [7]. In mice, it seems that the proinfl ammatory cytokine cascade is regulated 
differentially. The production of TNF-α, IL-1, and IL-6 by peritoneal macrophages is 
independent on the intermediate induction of TNF-α or IL-1β [16]. In human articular 
chondrocytes IL-18 induces IL-6 [17]. Other proinfl ammatory effects of IL-18 include 
the upregulation of adhesion molecules. Intercellular adhesion molecule-1 (ICAM-1) 
and vascular adhesion molecule-1 (VCAM-1) expression are stimulated by IL-18 on 
different cell types [18-20]. In addition, IL-18 inhibits osteoclast-like multinucleated 
cells through induction of GM-CSF [21].
IL-18 and IL-1β share many common effects, which is not surprising considering 
that IL-18 is structurally related to IL-1β [22]. Both cytokines require caspase-1 (also 
known as IL-1β converting enzyme (ICE)) for cleavage and release of their active 
mature form into the extracellular compartment [23]. Moreover, the ligand-binding 
IL-18 receptor (IL-18R) α chain is similar to the IL-1R type I and the signaling IL-18Rβ 
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chain is similar to the IL-1R accessory protein [24, 25]. Furthermore, IL-18 and IL-1β 
signal transduction involves activation of identical cytoplasmic messengers: MyD88, 
IL-1 receptor-associated kinase, and tumor necrosis factor (TNF) receptor-associated 
factor-6.
Like the IL-1 system, which is counterbalanced by several molecules including the 
decoy receptor IL-1RII and IL-1 receptor antagonist (IL-1Ra), the actions of IL-18 
are counteracted by a molecule called IL-18 binding protein (IL-18BP). IL-18BP is a 
naturally occurring secreted protein with high affi nity binding to IL-18 and therefore 
neutralizes the biological activity of IL-18 [26, 27]. 
IL-18 possesses broad and potent immunomodulatory properties and therefore it is 
not surprising that it plays an important role in host defenses against various infec-
tious microbes. Through induction of IFN-γ, leading to production of nitric oxide 
(NO), IL-18 is particularly effective in the clearance of intracellular bacteria, fungi, 
and protozoa. A protective role has been demonstrated in infections due to Myco-
bacterium [28], Cryptococcus [29], and Leishmania species [30]. In mice susceptible 
to lethal Salmonella typhimurium infection, the administration of IL-18 increased 
survival and was associated with lower tissue burden of the bacteria [31]. Mice 
defi cient in IL-18 have an almost, but not absolute, absence of IFN-γ production [32], 
and this manifested in a more severe mycobacterial infection [28].
As described above, IL-18 contributes to host defense in various infections. However, 
IL-18 is a proinfl ammatory cytokine which also may be harmful. High levels of IL-
18 have been found in sepsis [33], many autoimmune diseases (insulin-dependent 
diabetes mellitus, rheumatoid arthritis, and multiple sclerosis) and infl ammatory 
disorders (Crohn’s diseases, graft-versus-host disease) [12]. Reduction of disease se-
verity has been reported with neutralization of endogenous IL-18. In streptococcal 
cell wall-induced arthritis in mice, IL-18 blockade resulted in suppression of joint 
swelling independent of IFN-γ [34]. Neutralization of IL-18 reduced disease severity 
in mouse models of colitis [35, 36].
AIM OF THIS THESIS
Although much has been learned about IL-18, several important aspects of IL-18 
are still unknown, especially its role in the host defense. The aim of this thesis is to 
assess the position of IL-18 in the activation of the innate immunity and elimination 
of an invading pathogen. Several aspects have been investigated in this thesis; the 
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place of IL-18 in the activation of the cytokine network, the direct proinfl ammatory 
properties of IL-18, and the role of IL-18 in severe infections. To assess this we used 
several experimental models:
1. Whole-blood stimulation assay, in which the role of endogenous IL-18 for the 
induction of subsequent cytokine activation has been investigated.
2. In vitro stimulation of adhesion molecules by IL-18.
3. The role of IL-18 in endotoxemia and the acute-phase response in vivo.
4. The role of IL-18 in an experimental model of infection with Candida albicans.
1. WHOLEBLOOD MODEL
The use of whole-blood cultures is a simple and effective method to study cytokine 
production [37, 38]. The culture conditions most closely recreate the in vivo situation 
because cells (e.g. monocytes, neutrophils, and lymphocytes) and serum factors (e.g. 
complement and antibodies) are present that are important for defense against infec-
tious organisms. In our model, total cytokine production (intracellular and secreted) 
is measured through addition of Triton X-100 to lyse the blood cells. 
Staphylococcal sepsis and toxic shock syndrome (TSS) are two clinical syndromes 
in which the systemic infl ammation caused by overwhelming production of pro-
infl ammatory cytokines, such as TNF-α, IL-1β, and IFN-γ, is thought to play a im-
portant role [39, 40]. Whereas, in the former, the cytokine release is triggered by 
invasion by intact microorganisms in the circulation, in the latter the staphylococci 
rarely invade the host and the cytokine release is triggered by exotoxins acting as 
superantigens. Staphylococcal cell wall components such as lipoteichoic acids (LTA) 
and peptidoglycans (PG) [41, 42] and the superantigens staphylococcal enterotoxin 
B (SEB) and toxic shock syndrome toxin-1 (TSST-1) [43] are believed to be main 
inducers of cytokine production. LTA and PG stimulate monocytes through CD14 
or Toll-like receptor 2 (TLR-2) (PG) or TLR-4 (LTA). In contrast, superantigens are a 
family of proteins with particular structural and sequence features that result in the 
shared ability to bypass the mechanisms of conventional, MHC-restricted, antigen 
processing. They have the ability to trigger excessive and aberrant activation of T 
cells leading to the release of proinfl ammatory cytokines. This uncoordinated release 
of proinfl ammatory mediators is thought to be responsible for many of the features 
of toxic shock syndrome [44]. We used whole-blood cultures to further characterize 
the cytokine network induced by whole staphylococcal microorganisms and staphy-
lococcal components.
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2. INVITRO STIMULATION OF ADHESION MOLECULES
Besides the important role of IL-18 as a costimulus for IFN-γ production, IL-18 dis-
plays a series of proinfl ammatory effects. It induces proinfl ammatory cytokines such 
as TNF-α, IL-1β, IL-6 and IL-8 [7, 17]. Furthermore, IL-18 mediates cartilage damage 
in IFN-γ-defi cient mice with collagen arthritis [34]. Increased expression of adhesion 
molecules may play a role in these infl ammatory effects of IL-18. Adhesion molecule 
expression is an important step in the induction of infl ammation. In response to 
microbial antigens, host cells are triggered to release cytokines such as IL-1β, TNF-α, 
and IFN-γ, and these are able to upregulate expression of various adhesion mol-
ecules on monocytes and endothelial cells [45]. ICAM-1 (CD54) is a transmembrane 
glycoprotein and member of the immunoglobulin supergene family that is constitu-
tively expressed on a wide variety of cell types [46]. ICAM-1 is involved in cell-cell 
interactions and leukocyte extravasation at infl ammatory sites by binding to two 
integrins, CD11a/CD18 (LFA-1) and CD11b/CD18 (Mac-1), both belonging to the β
2
 
integrin subfamily [47, 48]. To obtain more insight in this subject, we used monocytes 
from PBMC to study the effect of IL-18 on various adhesion molecules.
3. THE ROLE OF IL18 IN ENDOTOXEMIA AND THE ACUTEPHASE RESPONSE IN 
VIVO.
3a. Experimental endotoxemia. 
Most of the deleterious effects of Gram-negative bacterial sepsis are believed to be 
due to endotoxin, the lipopolysaccharide component of the cell wall of Gram-nega-
tive bacteria [49]. Lethal endotoxemia has been extensively used as an experimental 
model of Gram-negative septic shock. Binding of LPS to various receptors on leu-
kocytes triggers the production and release of pro-infl ammatory cytokines such as 
TNF-α, IL-1β, and IL-6 [49, 50]. ICE-defi cient mice express neither mature IL-1β nor 
IL-18 and exhibit a decreased sensitivity to LPS [51]. The fact that IL-1β defi cient 
mice are susceptible to lethal endotoxemia [52] suggests that the protection of ICE-
defi cient mice is mediated by the lack of mature IL-18 or IFN-γ. Mice defi cient for the 
INF-γ receptor (IFN-γR) showed decreased sensitivity to LPS [53]. We have assessed 
the effect of IL-18 neutralization in endotoxic shock using two methods: the use of 
ICE-defi cient mice known to be defi cient in mature active IL-18, and neutralization 
of IL-18 by treatment with anti-IL-18 antibodies.
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3b. Acute-phase response. 
The acute-phase response comprises a constellation of metabolic, endocrinologic, 
neurological, and immunologic alterations starting after an initiating stimulus. These 
changes are meant to participate in initiating, sustaining or modulating the infl am-
matory process [54]. Induction of fever, increased synthesis of glucocorticosteroids, 
increased production of leukocytes, and production of acute-phase proteins are 
some of the components of the acute-phase response. Fever is a representative 
of the neuroendocrine changes that characterize the acute-phase response. Several 
cytokines are important in the induction of fever [55]; IL-1 [56], TNF [57], IL-6 [58], 
and IFNs [59]. These proinfl ammatory cytokines reach the central nervous system 
where, through induction of central mediators such as prostaglandins, they are able 
to increase the temperature setpoint and cause fever [55, 60]. A well-established 
method to study the pyrogenic properties of cytokines is their injection into rabbits 
and mice that undergo continuous core temperature registration. We have studied 
the pyrogenic properties of IL-18 in a rabbit model of fever. The ability of IL-18 to 
modulate other components of the acute-phase response, such as leukocytosis, lipid 
profi le and glucocorticoid production, was assessed in mice.
4. EXPERIMENTAL MODEL OF DISSEMINATED CANDIDIASIS
The pathogenic fungus Candida albicans may cause disseminated candidiasis, 
which is one of the life-threatening diseases in immunocompromised hosts [61]. The 
host response to C. albicans infection is a complex interplay between cellular and 
humoral immunity, usually providing a suffi cient defense against the microorganism 
in the healthy host. An important risk factor for developing C. albicans infection 
is an impaired host defense. IFN-γ is a key cytokine for innate as well as acquired 
resistance to candidiasis [62]. IFN-γ has stimulatory effects on the phagocytosis and 
killing of C. albicans by neutrophils and macrophages [63, 64], whereas administra-
tion of IFN-γ to mice infected with C. albicans has had a benefi cial effect on the out-
come of the infection [62]. The important role of endogenous IFN-γ in the resistance 
against both gastrointestinal and systemic candidiasis has also been demonstrated by 
the increased susceptibility of knock-out mice defi cient in IFN-γ or IFN-γ-receptors 
infected with the yeast [65, 66]. In addition to IFN-γ, proinfl ammatory cytokines such 
as TNF and IL-1, and chemokines such as IL-8 also play an important role in the 
host defense against C. albicans infection [63, 67, 68]. In view of the important role 
of IL-18 in the induction of IFN-γ, we hypothesized that IL-18 has a role in the host 
defense against C. albicans using a mouse model of disseminated candidiasis.
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OUTLINE OF THIS THESIS
In this thesis we focus on the role of IL-18 in the immune response during infections, 
using in vitro models for studying the cytokine network and different experimental 
models in mice.
In chapter 2 and 3 we investigated the cytokine network induced by whole sta-
phylococcal microorganisms (S. epidermidis and S. aureus) on the one hand and 
by the staphylococcal cell wall components LTA, PG, TSST-1, and SEB on the other 
hand. The role of endogenous IL-18, IL-1, TNF, and IL-12 in the induction of IFN-γ, 
TNF-α, and IL-8 by these microbial products was assessed in human whole-blood 
cultures using specifi c cytokine inhibitors.
The second part of this thesis deals with the proinfl ammatory properties of IL-18. 
In this respect, in chapter 4 we studied the effect of IL-18 on adhesion molecule 
expression on human PBMC and human monocyte and T-cell lines. In chapter 5, 
we investigated the direct proinfl ammatory effect of IL-18 in lethal endotoxemia in 
mice, using ICE-defi cient mice (defi cient in mature active IL-18) and neutralization 
of IL-18 by anti-IL-18 antibodies. Because IL−1β is a potent inducer of fever and the 
acute-phase response, and IL-1β and IL-18 share many similarities, in chapter 6 we 
ask the question whether IL-18 also has these pyrogenic properties. 
The last three chapters deal with role of IL-18 in host defense against C. albicans 
infection in mice. IFN-γ is a key cytokine for innate as well as acquired resistance 
to candidiasis, but little is known about the pathway leading to its stimulation. In 
chapter 7 we describe the relative importance of endogenous IL-18, IL-1, TNF, and 
IL-12 in the induction of IFN-γ production by C. albicans in whole-blood cultures. 
The infl uence of IL-18 in experimental disseminated candidiasis was assessed by 
blocking IL-18 with anti-IL-18 antibodies in chapter 8. Moreover, we investigated 
whether this effect was mediated through production of IFN-γ with the use of IFN-γ-
defi cient mice. In chapter 9 we report the therapeutical effect of recombinant IL-18 
in the same model of experimental candidiasis.
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ABSTRACT
The roles of endogenous cytokines induced by either intact staphylococcal micro-
organisms or staphylococcal exotoxins were examined using human whole-blood 
cultures. To accomplish this, interleukin-18 binding protein (IL-18BP) and tumor 
necrosis factor binding protein (TNFbp) were used to neutralize IL-18 and TNF, 
respectively, whereas an anti-IL-12 monoclonal antibody (anti-IL-12 Ab) was used 
to neutralize IL-12 and the IL-1 receptor antagonist (IL-1Ra) to block IL-1 receptors. 
Heat-killed Staphylococcus epidermidis and Staphylococcus aureus, as well as the 
staphylococcal superantigens toxic shock syndrome toxin-1 (TSST-1) and staphylo-
coccus enterotoxin B (SEB) induced gamma interferon (IFN-γ) production. Staphylo-
coccus spp.-induced production of IFN-γ required the presence of endogenous IL-18, 
IL-12 and TNF. In contrast, TSST-1 induced IFN-γ was not signifi cantly reduced in the 
presence of IL-18BP, anti-IL-12 antibodies, IL-1Ra or TNFbp. SEB-induced IFN-γ was 
signifi cantly inhibited only by anti-IL-12 antibodies, indicating that endogenous IL-18, 
IL-1 and TNF are not required for SEB-induced IFN-γ. In conclusion, the mechanisms 
of IFN-γ stimulation by intact staphylococcal microorganisms and exotoxins differ, 
and this is likely to be due to the different receptors which are triggered on the cell 
membranes. In contrast to its role in the interactions between staphylococci and host 
cells, IL-18 does not appear to play a major role in superantigen-induced IFN-γ.
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INTRODUCTION
Sepsis due to Gram-positive bacteria is a life-threatening disease in which the pre-
sence of microorganisms in the bloodstream induce an overwhelming production 
of proinfl ammatory cytokines such as tumor necrosis factor (TNF), interleukin-1β 
(IL-1β), and gamma interferon (IFN-γ), which are thought to play a central role in 
the pathogenesis of this syndrome [1]. In contrast, in staphylococcal toxic shock 
syndrome (TSS), the bacteria rarely invade the host, and the symptoms are caused 
by superantigen-induced systemic infl ammation. Staphylococcal components such as 
lipoteichoic acids (LTA) and peptidoglycans (PG) [2, 3], as well as the superantigens 
TSS toxin-1 (TSST-1) and staphylococcal enterotoxin B (SEB) [4], are believed to be 
the main inducers of the cytokine production during these two severe illnesses. 
LTA and PG are major components of Staphylococcus aureus, which induces a 
strong cytokine response [2]. These constituents of the cell wall of most Gram-
positive bacteria stimulates monocytes through CD14 and Toll-like receptor (TLR)-2 
(PG) or TLR-4 (LTA) [5-7]. In contrast, the superantigens TSST-1 and SEB lead to the 
activation of both lymphocytes and monocytes through the major histocompatibility 
complex class II molecules on antigen-presenting cells and the specifi c Vβ elements 
of the T-cell receptor [4, 8]. Through these two distinct pathways, macrophages are 
triggered to produce and release proinfl ammatory cytokines including IL-1, IL-18, 
TNF-α and IL-12. IFN-γ production is likely originating from lymphocytes and NK 
cells upon secondary stimulation with IL-18 and IL-12 [9].
IL-18, originally described as IFN-γ inducing factor [10], has the ability to induce 
the synthesis of IL-1β, TNF-α, IL-8 and chemokines [11], probably through activation 
of nuclear factor-κB [12]. This places IL-18 in the group of proinfl ammatory cyto-
kines. IL-18 alone does not induce signifi cant IFN-γ production from T-lymphocytes 
[13], but in the presence of secondary stimulants, particularly IL-12, IL-2, mitogens 
or microbial agents, large amounts of IL-18-induced IFN-γ production are observed 
[9, 13]. Although IL-12 alone is able to induce IFN-γ synthesis, addition of IL-18 
increases this production several folds. IL-1, TNF, and IL-18 potentiate the synthesis 
of each other and in turn, they stimulate production of the second-wave cytokines 
such as IL-8 and IL-6 [9, 14, 15]. Recently, IL-18 binding protein (IL-18BP), which 
binds and prevents IL-18 activity was described [16, 17].
The aim of the present study was to characterize the cytokine network induced by 
whole staphylococcal microorganisms on the one hand and by the staphylococcal 
components LTA, PG, TSST-1, and SEB on the other hand. We have assessed the role 
of endogenous IL-18, IL-1, TNF and IL-12 in the induction of IFN-γ, TNF-α and IL-8 
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by S. epidermidis and S. aureus, TSST-1, SEB, PG, and LTA in human whole-blood 
cultures, by using specifi c cytokine inhibitors such as IL-18BP, IL-1 receptor antagonist 
(IL-1Ra), TNF-binding protein (TNFbp) and anti-IL-12 antibodies (anti-IL-12 Ab).
MATERIALS AND METHODS
Volunteer selection. 
The study was approved by the Combined Colorado Investigational Review Board and 
each blood donor gave informed consent. For this study we used whole blood from 
seven healthy, non-smoking volunteers between 23 and 45 years of age. The volunteers 
did not report recent infectious or infl ammatory disease and had abstained from using 
cyclooxgenase inhibitors two weeks before the study. Blood was collected by venipun-
ture into heparinized tubes (sodium heparin: fi nal concentration 20 U/mL; Elkins-Sinn, 
Cherry Hill, NJ). We have performed separate replicate experiments (sets of three experi-
ments for each stimulus), and we have pooled the data to perform the statistics.
Reagents. 
RPMI culture medium (Cellgro Mediatech, Herndon, VA) was supplemented with 
10 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin (Gibco BRL, 
Grand Island, NY). S. epidermidis and S. aureus were grown in brain-heart infusion 
broth for 24 hours, washed in pyrogen free saline, and boiled as described previ-
ously [18]. Concentration of the heat-killed organisms was adjusted to 10 organisms 
per white blood cells. Purifi ed TSST-1, SEB, PG and LTA were obtained from Sigma 
Chemical Co. (St. Louis, MO). LPS contamination of the stimuli used in this study was 
excluded in control experiments using polymyxin B preincubation (2 μg/ml, 2h) of 
the various stimuli. Polymyxin B did not alter the cytokine response induced by the 
various stimuli, demonstrating the absence of LPS contamination.
IL-18BP was expressed in COS cells as the “a” isoform and purifi ed as a his-tagged 
protein purifi ed over talon as previously described [16, 17]. Recombinant human IL-1 
receptor antagonist (IL-1Ra) was a kind gift of Dr. Daniel Tracey (Upjohn, Kalama-
zoo, MI). TNF-binding protein (p55 TNF soluble receptor [19] - TNFbp) was a kind 
gift of Dr. Carl Edwards (Amgen, Boulder, CO). Murine anti-human IL-12 Ab (clone 
11.5.14) was kindly supplied by Genetics Institute (Cambridge, MA).
Whole-blood cultures. 
One-half mL of either RPMI culture medium or RPMI containing S. epidermidis, 
TSST-1, SEB or LTA in the presence of the various specifi c inhibitors (IL-18BP, IL-1Ra, 
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TNF-BP, and anti-IL-12 Ab) was added to 12x75mm round-bottom polypropylene 
tubes (Falcon, Becton Dickinson Labware, Franklin Lakes, NJ), and 0.5 mL blood 
was added. The loose capped tubes were incubated at 37ºC (5% CO2) in an upright 
position. After 24 hours of incubation, the blood was mixed by rapid vortex and 0.5 
mL was transferred into 1.5 mL Eppendorf tubes (Brinkmann Instruments, Westbury, 
NY). Triton X-100 (Bio-Rad Laboratories, Richmond, CA) was then added (1% fi nal 
concentration) and the blood mixed until lysed. The remaining 0.5 mL blood was 
incubated for an additional 24 hours, mixed by rapid vortex and lysed with Triton-
X-100. The lysed blood was stored at -70ºC until assay. In these studies, intracellular 
and secreted cytokine concentrations were determined together and the results rep-
resent “total” cytokine production [11, 20].
Cytokine assays. 
Measurement of IFN-γ, IL-8 and TNF-α were performed by electrochemilumines-
cence (ECL), as previously described [11][20]. The detection limit of the IFN-γ assay 
was 62 pg/ml and for the IL-8 and TNF-α assay 40 pg/ml.
Statistical analysis. 
Data were expressed as mean ± SEM. Differences between groups were analyzed 
with the Wilcoxon test (double-sided). The signifi cance of the dose-response inhibi-
tory effects presented in Fig. 1A was analyzed by Kruskal-Wallis test.
RESULTS
Staphylococcus spp.-induced IFN-γ production in whole-blood. 
Human whole-blood stimulated with heat-killed S. epidermidis induced signifi cant 
amounts of IFN-γ, and this production was inhibited by IL-18BP in a dose-dependent 
manner (Fig.1A). In addition to IL-18BP, anti-IL-12 Ab and TNFbp were also able to 
inhibit S. epidermidis-induced IFN-γ, whereas IL-1Ra did not have a signifi cant effect 
(Fig.1B). No effect of IL-18BP, IL-1Ra, TNFbp or anti-IL-12 Ab on S. epidermidis-
induced synthesis of IL-8 was apparent (not shown). Similarly, IFN-γ production in-
duced by S. aureus was signifi cantly inhibited by IL-18BP (67%, p<0.05) and TNFbp 
(44%, p<0.05), but not IL-1Ra (9%, p>0.05).
Induction of IFN-γ, TNF-α and IL-8 by TSST-1, SEB, PG and LTA in whole-blood cultures. 
The stimulation of whole-blood with TSST-1 resulted in a marked stimulation of IFN-
γ (47 ± 24 ng/ml), TNF-α (240 ± 53 pg/ml) and IL-8 (25 ± 6 ng/ml) corresponding to a 
29, 10 and 26 fold-increase over unstimulated cultures respectively. SEB stimulation 
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led to production of IFN-γ (143 ± 55 ng/ml), TNF-α (459 ± 89 pg/ml) and IL-8 (66 ± 
12 ng/ml) with a 48, 37 and 43 fold-increase over unstimulated cultures respectively. 
LTA also induced TNF-α (139 ± 73 pg/ml) and IL-8 (52 ± 27 ng/ml) corresponding 
with a 12 and 38 fold-increase over unstimulated cultures respectively. However, 
IFN-γ concentrations after LTA stimulation were below the detection limit (N=7 do-
nors). PG induced signifi cant amounts of IFN-γ (49 ± 19 pg/ml) and IL-8 (417 ± 108 
pg/ml), representing a 9 and 23 fold-increase over the unstimulated cells.
Figure 1. S. epidermidis-induced IFN-γ production in whole-blood.
Whole-blood was stimulated with S. epidermidis (10:1 ratio to leukocytes) in the absence or in the presence of various concentrations of IL-18BP 
(A) or with ﬁ xed amounts of IL-18BP (125 ng/mL), IL-1Ra (10 μg/mL), TNFbp (10 μg/mL) or anti-IL-12 Ab (2.5 μg/mL) (B). After 48 hours the 
culture was assayed for IFN-γ. The amount of IFN-γ induced by S. epidermidis was set at 100% for each donor and the mean ± SEM percent change 
for each condition is shown. 100% S. epidermidis stimulation represents 11.1 ± 2.5 ng/ml IFN-γ. * P <0.05 vs. S. epidermidis alone. N=7 donors.
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Role of endogenous cytokines in TSST-1-induced cytokine production. 
As shown in fi gure 2A, in the presence of IL-18BP or IL-1Ra, there was a non-sig-
nifi cant reduction in IFN-γ. However, the combination of both IL-18BP and IL-1Ra 
reduced the IFN-γ level by 47% (P<0.05). Similarly, anti-IL-12 Ab reduced IFN-γ 
by 39% and the combination of anti-IL-12 Ab plus IL-18BP inhibited IFN-γ by 49% 
(P<0.05). The addition of TNFbp or the combination of TNFbp plus IL-18BP to the 
whole-blood culture did not affect IFN-γ production (data not shown). 
IL-8 production was not reduced by any of the cytokine inhibitors. In contrast, 
neutralizing IL-12 resulted in a signifi cant increase in IL-8 production (85% increase 
of TSST-1 production, P<0.05) (Fig. 2B). Although this increase was less in the 
presence of both anti-IL-12 Ab plus IL-18BP, IL-8 levels were still greater than TSST-
1 alone (31% increase of TSST-1 production, P<0.05) (Fig. 2B). The addition of 
IL-1Ra or TNFbp or the combination of either IL-1Ra or TNFbp plus IL-18BP to the 
whole blood culture did not decrease IL-8 production (data not shown). IL-1Ra 
suppressed TSST-1-induced TNF-α production by 25% (P>0.05) and the combina-
tion of IL-1Ra and IL-18BP did not have an additional effect on TNF-α production. 
Neutralizing IL-18 and IL-12 did not infl uence TSST-1-induced TNF-α production 
(data not shown). 
Role of endogenous cytokines in SEB-induced cytokine production.
As shown in fi gure 3A, only anti-IL-12 Ab signifi cantly inhibited the IFN-γ produc-
tion (40% of SEB-induced IFN-γ production (P<0.05). IL-18BP did not decrease IFN-γ 
and the combination of anti-IL-12 Ab plus IL-18BP was less effective than anti-IL-12 
Ab. Blocking IL-1 receptors also had no effect on SEB induction of IFN-γ (data not 
shown). Neutralization of TNF-α by TNFbp either alone or in combination with IL-
18BP also had no effect (data not shown).
IL-8 production was strongly decreased by TNFbp (53%, P<0.05). The combination 
of IL-18BP and TNFbp did not reduce IL-8 any further. In fact, the neutralization 
of IL-18 and TNF led to less inhibition of SEB-induced IL-8 (28%, n.s.). In contrast, 
blocking IL-12 had a signifi cant stimulating effect on SEB-induced IL-8 production 
(52%, P<0.05) (Fig. 3B). IL-18BP had no effect on SEB-induced IL-8. The addition of 
IL-1Ra or the combination of IL-1Ra plus IL-18BP did not affect IL-8 production (data 
not shown). TNF-α concentrations in whole-blood were not infl uenced by neutral-
izing IL-18, IL-1 or IL-12 (data not shown) indicating that TNF-α synthesis by SEB is 
independent of these cytokines. 
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Role of endogenous cytokines in LTA and PG-induced cytokine production.
In contrast to the production of TNF-α and IL-8, LTA did not induce signifi cant 
production of IFN-γ in whole-blood. LTA-induced IL-8 was signifi cantly inhibited 
by IL-1Ra (55%, P<0.01). The combination of IL-18BP plus IL-1Ra resulted in a 69% 
decrease of IL-8 (P<0.05) (Fig. 4). The addition of TNFbp or anti-IL-12 Ab or the 
combination of either TNFbp or anti-IL-12 Ab plus IL-18BP to the whole blood 
culture did not decrease IL-8 production (data not shown). TNF-α production was 
not modulated by neutralizing endogenous IL-18 and IL-1, although a trend towards 
Figure 2. TSST-1-induced IFN-γ and IL-8 production in whole-blood.
Whole-blood was stimulated with TSST-1 (1.5 μg/mL) in the absence or in the presence of IL-18BP (125 ng/mL), IL-1Ra (10 μg/mL) or anti-
IL-12 Ab (2.5 μg/mL). After 24 hours the culture was assayed for IL-8 (B) and after 48 hours, for IFN-γ (A). The amount of either IL-8 or IFN-γ 
induced by TSST-1 was set at 100% for each donor and the mean ± SEM percent change for each condition is shown. 100% TSST-1 stimulation 
represents 47 ± 24 ng/ml (IFN-γ) and 25 ± 6 ng/ml (IL-8). * P <0.05 vs. TSST-1 alone. N=7 donors.
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increased production was measured when anti-IL-12 Ab alone or IL-18BP and anti-
IL-12 Ab together were added (59% vs. LTA production, P>0.05)(data not shown).
PG-induced production of IFN-γ was signifi cantly inhibited by IL-18BP (58 ± 19 %, p<0.05), 
IL-1Ra (61 ± 5 %, p<0.05) and TNFbp (77 ± 13 %, p<0.05). Combination of IL-18BP with 
both IL-1Ra and TNFbp further reduced the IFN-γ production to less than 5% (p<0.01). In 
contrast, IL-18BP and TNFbp had no effects on PG-induced IL-8 synthesis (p>0.05 in n=5), 
and only IL-1Ra had a moderate, but signifi cant, inhibitory effect (43 ± 17 %, p<0.05).
Figure 3. SEB-induced IFN-γ and IL-8 production in whole-blood.
Whole-blood was stimulated with SEB (2 μg/mL) in the absence or in the presence of IL-18BP (125 ng/mL), TNF-BP (10 μg/ml) or anti-IL-12 Ab 
(2.5 μg/mL). After 24 hours the culture was assayed for IL-8 (B) and after 48 hours, for IFN-γ (A). The amount of either IL-8 or IFN-γ induced by 
SEB was set at 100% for each donor and the mean ± SEM percent change for each condition is shown. 100% SEB stimulation represents 143 ± 
55 ng/ml (IFN-γ) and 66 ± 12 ng/ml (IL-8). * P <0.05 vs. SEB alone. N=6 donors.
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DISCUSSION
As previously reported in the literature, both whole staphylococcal microorganisms, 
as well as the staphylococcal antigens LTA, PG, TSST-1 and SEB are potent stimuli 
of TNF, IFN-γ, and IL-8 production [2, 4, 21]. Only cell-associated IL-18 could be 
measured after stimulation of cells with the various stimuli (not shown), suggesting 
that either cell-associated IL-18 is responsible for the biological effects, or that small, 
undetectable amounts of IL-18 act in a paracrine or autocrine manner to exert its 
effects. In our experiments, whereas S. epidermidis and S. aureus -induced IFN-γ 
production was strongly reduced by IL-18BP, anti-IL-12 Ab and TNFbp, only anti-IL-
12 Ab decreased SEB-induced and TSST-1-induced IFN-γ. Even the effect of anti-IL-
12 Ab was much less pronounced for the superantigen-stimulated IFN-γ compared 
to the S. epidermidis stimulation, and IL-18BP, TNFbp and IL-1Ra had no effects. 
It is therefore apparent that the cytokine pathways leading to IFN-γ induction by 
intact microorganisms and superantigens are different. In contrast to Staphylococcus-
induced IFN-γ synthesis, the IFN-γ production induced by SEB and TSST-1 was not 
reduced by IL-18BP, indicating that endogenous IL-18 does not play a central role in 
superantigen-induced IFN-γ. We summarized these results in Table 1. Our data are 
in line with those of Lauw and colleagues showing no effect of anti-IL-18 Ab in a 
SEB-model of TSS in mice (Lauw et al., unpublished data). 
Figure 4. LTA-induced IL-8 production in whole-blood. 
Whole-blood was stimulated with LTA (2 μg/mL) in the absence or in the presence of IL-18BP (125 ng/mL) or IL-1Ra (10 μg/mL). After 24 hours 
the culture was assayed for IL-8. The amount of IL-8 induced by LTA was set at 100% for each donor and the mean ± SEM percent change for 
each condition is shown. 100% LTA stimulation represents 52 ± 27 ng/ml IL-8. *P <0.05 vs. LTA alone. N=6 donors.
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Table 1. Diﬀ erential roles of IL-18, IL-12, IL-1 and TNF for the induction of interferon-γ by staphylococcal cell wall components and 
superantigens.
IL-18BP anti-IL-12 Ab IL-1Ra TNFbp
Staphylococcus
organisms
 ++  ++  -  +
PG  ++  n.d.  ++  ++
SEB   -  +  -  -
TSST-1   -  +  +/-  -
Inhibitory eﬀ ect: ++, strong; +, moderate; ±, weak; -, none.
The importance of Staphylococcus-induced cytokine production is emphasized by 
the severity of the two clinical syndromes caused by staphylococcal infections in 
which the systemic infl ammation caused by overwhelming cytokinemia is thought 
to play a pivotal role: Staphylococcus sepsis and TSS [22]. Whereas in the former the 
cytokine release is triggered by invasion of the circulation by intact microorganisms, 
in the latter the staphylococci rarely invade the host and the cytokine production is 
triggered by exotoxins acting as superantigens. In the present study, we investigated 
whether the cytokine network induced by either intact S. aureus and S. epidermidis 
microorganisms or the staphylococcal superantigens is divergent. 
Several cytokines are known to be involved in IFN-γ production, either directly or 
following co-stimulation with other cytokines or microbial agents. An important role 
for IFN-γ induction was attributed to endogenous IL-18. Reduction of LPS-induced 
IFN-γ in ICE-defi cient macrophages lacking a functional IL-18 can be greater than 
90%, despite normal IL-12 levels [23-25], a cytokine which appears to be essential for 
IFN-γ production [26]. IL-12, produced by phagocytic cells in response to bacteria, 
is able to induce IFN-γ production by NK and T cells [27]. Two mechanisms may ac-
count for the stimulatory effects of IL-12 on IFN-γ production. First, IL-12 upregulates 
production of IL-18 [28], and second, IL-12 increases the responsiveness of T- and 
B-cells to IL-18 by up-regulation of IL-18R expression [29]. In addition to IL-12 and 
IL-18, other cytokines important for the induction of IFN-γ are IL-1 and TNF, which 
potentiate IFN-γ production together with IL-12 [30-32]. In the present study we show 
that stimulation of human whole blood with heat-killed Staphylococcus spp. induces 
release of IFN-γ in an IL-18, IL-12, and TNF-dependent manner. This is probably 
due to effects exerted at the level of PG-stimulation of cytokine synthesis, as similar 
effects of the cytokine inhibitors were seen when cells were incubated with PG. In 
contrast, TSST-1 and SEB induced IFN-γ production is not signifi cantly reduced by 
IL-18BP, TNFbp and IL-1Ra, whereas it is slightly inhibited by anti-IL-12 Abs.
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Differences were also apparent when production of the chemokine IL-8 was as-
sessed: direct IL-8 stimulation by intact microorganisms, and at least partial depen-
dency of IL-8 production on endogenous TNF in the case of SEB. In addition, the 
TNF production was not inhibited by any of the cytokine inhibitors used, confi rming 
the proximal place of TNF in the cytokine cascade.
The differences between the cytokine patterns induced either by intact staphylococci 
or staphylococcal exotoxins are probably mediated by the differential receptors they 
stimulate on the cell membranes to trigger the cytokine synthesis. The Gram-positive 
microorganisms are recognized by pattern-recognition receptors such as TLR-2 and 
TLR-6 on the cell membrane [6, 7, 33], and CD14 can facilitate this process [5]. Gram-
positive components such as LTA has been suggested to be involved, but LTA did not 
stimulate IFN-γ synthesis, possible due to the absence of alanine substituents lost in 
the purifi cation procedures [34]. In contrast, staphylococcal PG strongly stimulated 
IFN-γ synthesis and play a pivotal role in TLR-2- and CD14-mediated cytokine induc-
tion by Staphylococcus [7, 33]. Disintegration of the microorganisms and release of 
bacterial DNA, which would stimulate monocytes through TLR-9, are also likely to 
be important [35].
In contrast to this pathway, the staphylococcal exotoxins TSST-1 and SEB induce 
proliferation of T-cells through direct binding to the major histocompatibility com-
plex class II molecules on antigen-presenting cells and stimulation of T-cell receptor-
specifi c Vβ elements. This pathway leads to induction of proinfl ammatory cytokines 
[2, 5, 8]. Our observation that TSST-1 and SEB induce IFN-γ, TNF-α and IL-8 is 
consistent with previous studies [9, 15, 24]. Several investigators have reported that 
direct contact is needed between monocytes and T cells to induce TNF-α and IL-1β 
by superantigens. In contrast, other reports show the release of IL-1, TNF-α, and IL-6 
in response to TSST-1 and SEB by monocytes in the absence of T cells [6, 9, 24, 27]. 
In whole-blood cultures, contact between monocytes and T cells likely takes place. 
This pathway of IFN-γ stimulation appears to be independent of endogenous IL-18, 
TNF and IL-1, and only marginally dependent on IL-12.
In conclusion, Staphylococcus microorganisms and the staphylococcal exotoxins 
TSST-1 and SEB are potent stimuli of IFN-γ, TNF-α, and IL-8 production. However, 
the cytokine pathways leading to production of IFN-γ and IL-8 by these stimuli are 
different, and this is likely to be due to differential receptors which are recognized 
and triggered on the cell membranes. These differences may in part explain the clini-
cal differences between staphylococcal sepsis and staphylococcal TSS. 
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ABSTRACT
Interleukin-12 (IL-12) and IL-18 act synergistically to stimulate interferon gamma 
(IFN-γ) production; moreover, IL-1 and tumor necrosis factor (TNF) may also augment 
IFN-γ synthesis. We have investigated the relative contributions of these cytokines 
in the production of IFN-γ and TNF by the Gram-positive bacterium Staphylococcus 
epidermidis, using the specifi c cytokine inhibitors IL-18 binding protein (IL-18BP), 
IL-1 receptor antagonist (IL-1Ra), anti-IL-12 antibodies (anti-IL-12 Ab), and TNF bind-
ing protein. Inhibition of caspase-1 reduced IFN-γ and IL-1β levels (by 80% and 67%, 
respectively) when heat-killed S. epidermidis was added to whole-human blood 
cultures. IL-18BP reduced S. epidermidis-induced IFN-γ (77% maximal suppression). 
In contrast, blocking IL-1 receptors by IL-1Ra had no effect on IFN-γ production. 
Blocking endogenous IL-12 and TNF reduced IFN-γ production by 69 and 36%. S. 
epidermidis-induced TNF-α was inhibited by IL-18BP and IL-1Ra, but not anti-IL-12 
Ab, whereas IL-8 production was unaffected by any of the specifi c cytokine block-
ing agents. In conclusion, S. epidermidis stimulates IFN-γ which is IL-18, IL-12- and 
TNF-dependent, but IL-1 independent. 
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INTRODUCTION
Despite appropriate antibiotics, sepsis due to Gram-positive bacteria is a life-threat-
ening disease marked by signifi cant mortality. Elevated levels of proinfl ammatory 
cytokines, e.g. interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α) and interferon-γ 
(IFN-γ) have been reported during these infections [1, 2]. On the one hand, these 
cytokines activate the innate immune system and facilitate the defense against invad-
ing pathogens. On the other hand, overproduction of cytokines is deleterious by 
inducing systemic infl ammation which can lead to hemodynamic shock and death. 
Understanding the cytokine network during Gram-positive infections could have a 
major impact for understanding the pathogenesis of these conditions, as well as for 
designing strategies to alter the dysequilibrium in the cytokine production away from 
infl ammation in the direction of host defense and elimination of the infection.
IL-18, produced by activated macrophages, has direct proinfl ammatory properties by 
inducing TNF-α, IL-1 and the chemokine IL-8 [3, 4]. IL-18, similar to IL-1β, requires 
cleavage from the inactive precursor form to the mature, active form by caspase-1 
(also known as IL-1β converting enzyme or ICE) [5]. IL-18 increases IFN-γ production 
by T cells and NK cells but IL-18 requires presence of co-stimuli such as IL-12, IL-15 
or microbial agents to induce IFN-γ production [6-8]. The IL-18 receptor is upregu-
lated by IL-12, and accounts for the synergism of IL-12 and IL-18 [9, 10]. Similar to 
IL-18, IL-1β and TNF-α also have co-stimulatory activities on IFN-γ production in 
the context of IL-12 or bacterial stimulation [11-14]. IL-18 binding protein (IL-18BP) 
is a constitutively secreted natural IL-18 inhibitor [15]. Since IL-18BP binds to and 
neutralizes IL-18 activities, this protein likely plays an important role in infl ammation 
and immune responses to infection.
In the present study, we investigated the contribution of endogenous IL-18, IL-1, TNF, 
and IL-12 in the induction of IFN-γ, TNF-α and IL-8 by S. epidermidis. To accomplish 
this we assessed the capacity of an ICE-inhibitor (ICEi) to infl uence S. epidermidis-
induced production of IFN-γ and IL-1β. Furthermore, we stimulated whole human 
blood with heat-killed S. epidermidis in the presence of specifi c cytokine blocking 
agents: for neutralization of IL-18 the IL-18BP was used; for IL-1 neutralization, the 
IL-1 receptor antagonist (IL-1Ra) was employed. For TNF neutralization, we used the 
soluble form of the TNF receptor type I termed tumor necrosis factor binding protein 
(TNFbp), and for IL-12 neutralization, a neutralizing monoclonal antibody was added 
to the cultures. 
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MATERIALS AND METHODS
Volunteer selection. 
The study was approved by the Combined Colorado Investigational Review Board 
and each blood donor gave informed consent. For this study, fresh blood from 
healthy, non-smoking volunteers between 23 and 45 years of age was obtained. The 
volunteers denied recent infectious or infl ammatory disease and had abstained from 
using cyclooxgenase inhibitors two weeks prior to study. Blood was collected by 
venipunture into heparinized tubes (sodium heparin: fi nal concentration 20 U/mL; 
Elkins-Sinn, Cherry Hill, NJ). 
Reagents. 
RPMI culture medium (Cellgro Mediatech, Herndon, VA) was supplemented with 10 
mM L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin (Gibco BRL, Grand 
Island, NY). S. epidermidis was grown in brain-heart infusion broth (Difo, Detroit, MI) 
for 24 h, washed in pyrogen-free saline and boiled as previously described [16]. The 
concentration of the heat-killed S. epidermidis was adjusted to 10 organisms per white 
blood cell assuming the average WBC in whole human blood to be 7000/mm3. 
The reversible ICEi Ac-Tyr-Val-Ala-Asp-2,6-dimethylbezoyloxymethylketone 
(YVAD) was purchased from Alexis Biochemicals (San Diego, CA) and solubililized 
in dimethyl sulfoxide (DMSO) at 10 mg/mL. The ICEi was diluted to the desired 
concentration in RPMI. IL-18BP was expressed in COS cells as the “a” isoform and 
purifi ed as a 6 histidine-tagged protein purifi ed over talon as previously described 
[15]. TNF-binding protein (p55 TNF soluble receptor [17]) (TNFbp) and recombinant 
human IL-1 receptor antagonist (IL-1Ra) were a kind gift of Dr. Carl Edwards (Am-
gen, Inc., Thousand Oaks, CA). Murine anti-human IL-12 Ab (clone 11.5.14) was 
kindly supplied by Genetics Institute (Cambridge, Mass.). 
Whole-blood cultures. 
One-half milliliter of heparinized blood was added to 12 by 75-mm round-bottom poly-
propylene tubes (Falcon; Becton Dickinson Labware, Franklin Lakes, NJ). One-half mil-
liliter of either RPMI culture medium or RPMI containing S. epidermidis in the presence 
of the various specifi c inhibitors (IL-18BP, IL-1Ra, TNFbp or anti-IL-12 Ab at the concen-
trations indicated) was added and mixed. The loosely capped tubes were incubated at 
37ºC (5% CO2) in an upright position. After 24 h at 37ºC, the blood was mixed by rapid 
vortexing and 0.5 ml was transferred into 1.5-ml Eppendorf tubes (Brinkmann Instru-
ments, Westbury, NY). Triton X-100 (Bio-Rad Laboratories, Richmond, CA) was then 
added (0.5% fi nal concentration), and the blood was mixed until lysed. The remaining 
0.5 ml of blood was incubated for an additional 24 h, mixed by rapid vortexing, and 
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lysed with Triton X-100. The lysed blood was stored at -70ºC until used for the assay. 
Using lysis of whole-blood, both intracellular and secreted cytokine concentrations 
were present and determined together as total cytokine production [18].
Cytokine assays.
Measurement of IFN-γ, IL-8 and TNF-α were performed by electrochemilumines-
cence (ECL) as previously described [3, 18]. The detection limit of the IFN-γ assay 
was 62 pg/mL and of the IL-8 and TNF-α assays was 40 pg/mL. For IL-18 measure-
ment, a similar procedure was employed. An affi nity-purifi ed goat anti-human IL-18 
polyclonal antibody (R&D Systems, Inc., Minneapolis, MN) was labeled with biotin 
(Igen, Gaithersburg, MD), and a monoclonal anti-human IL-18 antibody (R&D Sys-
tems) was labeled with ruthenium (II) trisbipyridae chelate (Igen). The biotinylated 
antibody was diluted to 0.5 μg/mL in PBS (pH 7.4) with 0.25% BSA, 0.5% Tween-20 
and 0.01% sodium azide (ECL buffer). Twenty-fi ve microliters of this antibody was 
combined in 6.0 mL polypropylene tubes with 25 μL of a 1 mg/mL suspension of 
streptavidin-coated paramagnetic beads (Dynal, Lake Succes, NY) diluted in ECL 
buffer. Tubes were shaken for 30 min at room temperature, after which 25 μL of 
samples or standard concentrations of recombinant human IL-18 (Peprotech) was 
added. Twenty-fi ve microliters of ruthenylated antibody (1 μg/mL in ECL buffer) was 
then added, and the tubes were shaken overnight at room temperature. The reaction 
was quenched by the addition of 200 μL of PBS per tube and ECL was measured 
using the Origin 1.5 Analyzer (Igen). The ECL IL-18 assay detects both pro-IL-18 and 
mature-IL-18. The detection limit of the assay was 40 pg/mL. A specifi c ELISA was 
used to measure mature IL-1β (Cistron, Pine Brook, NJ).
Statistical analysis.
Data were expressed as means ± SEM. Data were analyzed with the paired Student’s 
t-test.
RESULTS
The eﬀ ect of an ICEi and IL-18BP on S. epidermidis-induced IFN-γ production in whole-blood cultures. 
The effect of an ICEi on S. epidermidis-induced IL-18 and IFN-γ production was 
studied because of the importance of caspase-1 in the processing of pro-IL-1β and 
pro-IL-18 into the mature active forms. S. epidermidis induced signifi cant amounts 
of IFN-γ (5.8 ± 1.6 ng/mL, n=6). Inhibition of ICE dose-dependently decreased IFN-γ 
production induced by S. epidermidis. At 20 nM, IFN-γ production was reduced 
maximally by 80% (Fig. 1A). 
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We next studied the effect IL-18BP on S. epidermidis-induced IFN-γ production. 
IL-18BP dose-dependently inhibited IFN-γ production. At 500 ng/mL, a 77% maximal 
inhibition by IL-18BP was observed (Fig. 1B). Fifty percent IFN-γ inhibition occurred 
at 115 ng/mL IL-18BP. Therefore, in subsequent experiments we use a lower con-
centration of IL-18BP (125 ng/mL) to reduce endogenous IL-18 in order to observe 
the effects of concomitant blocking of endogenous IL-18 and other cytokines: IL-1, 
IL-12, and TNF.
S. epidermidis signifi cantly increased total IL-18 levels (pro- and mature-IL-18) 
compared to control (2.5-fold increase over control). The addition of the ICEi signifi -
cantly decreased S. epidermidis-induced IL-18 production by 21% (data not shown). 
Since the IL-18 ECL assay detects both pro- and mature-IL-18, these experiments do 
not address the issue of inhibiting processing by ICE.
Figure 1. Eﬀ ect of an ICEi and IL-18BP on S. epidermidis-induced IFN-γ production in whole-blood. Whole-blood was stimulated with S. 
epidermidis (10:1 ratio of organisms to leukocytes) in the absence or presence of increasing concentrations of an ICEi (A) or IL-18BP (B) shown 
under the horizontal axis. After 48 hours the blood culture was lysed with Triton X and was assayed for IFN-γ. The amount of IFN-γ induced by S. 
epidermidis was set at 100% for each donor and the mean ± SEM percent change for each condition is shown. A 100% S. epidermidis stimulation 
represents 5.8 ± 1.6 ng of IFN-γ /mL. * P <0.05, ** P <0.01 versus S. epidermidis alone. N= 4 and 6 donors respectively.
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The role of endogenous IL-1β in S. epidermidis-induced IFN-γ production in whole-blood cultures. 
The contribution of IL-1β in IFN-γ production was assessed by measuring IL-1β levels 
and using IL-1Ra in S. epidermidis-induced IFN-γ production. S. epidermidis induced 
signifi cant amounts of IL-1β (4.5 ± 1.3 ng/mL, n=8). IL-1β was signifi cantly reduced 
with 20 nM of ICEi, to a maximal inhibition of 67% (Fig. 2A). However, IL-1Ra only 
marginally reduced S. epidermidis-induced IFN-γ production (9% decrease), which 
was not statistically signifi cant (Fig. 2B). The combination of IL-1Ra with IL-18BP 
reduced of IFN-γ production by 68%, although this was not signifi cantly different 
from IL-18BP alone (57%, P>0.05).
The role of endogenous TNF and IL-12 in S. epidermidis-induced IFN-γ production in whole-blood cultures. 
TNFbp alone signifi cantly reduced IFN-γ levels by 36%. In combination with IL-18BP, 
this reduction was potentiated to 41%, although not statistically signifi cant (Fig. 3A). 
Figure 2. The role of endogenous IL-1β on S. epidermidis-induced IFN-γ production in whole-blood. Whole-blood was stimulated with S. 
epidermidis (10:1 ratio of organisms to leukocytes) in the absence or presence of increasing concentrations of an ICEi (A) or IL-18BP (125 ng/mL) 
and/or IL-1Ra (10 μg/mL) (B). After 48 hours the cultures were lysed with Triton X and were assayed for IL-1β (A) or IFN-γ (B). The amount of 
IL-1β and IFN-γ induced by S. epidermidis was set at 100% for each donor and the mean ± SEM percent change for each condition is shown. A 
100% S. epidermidis stimulation represents 4.5 ± 1.3 ng of IL-1β /mL or 5.8 ± 1.6 ng of IFN-γ /mL. * P <0.05, ** P <0.01 versus S. epidermidis 
alone. N=8 and 6 donors respectively.
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IFN-γ inhibition was seen with anti-IL-12 Ab alone (69% decrease) and in combina-
tion with IL-18BP, the IFN-γ level was reduced by 91% (P<0.01) (Fig. 3B).
The role of endogenous cytokines in S. epidermidis-induced TNF-α and IL-8 production in whole-blood cultures. 
TNF-α and IL-8 are elevated in patients with Gram-positive sepsis [1, 2]; therefore, 
these cytokines were also measured under conditions of specifi c cytokine blockade. 
S. epidermidis induced signifi cant increases in TNF-α and IL-8 (1.9 ± 0.9 ng/mL 
and 94.7 ± 67.2 ng/mL, respectively). As shown in Fig. 4, TNF-α production was 
modestly, although signifi cantly, decreased by IL-18BP and IL-1Ra (18%; P<0.01 and 
27%; P<0.05, respectively). The combination of double cytokine blockade resulted 
in a 36% reduction. However, the reduction in TNF-α by the combination of IL-18BP 
and IL-1Ra was not signifi cantly greater than either anti-cytokine alone. Anti-IL-12 Ab 
did not affect TNF-α production. 
In six whole-blood cultures using S. epidermidis-induced IL-8, no reduction was 
observed by IL-18BP, IL-1Ra, TNFbp or anti-IL-12 Ab (data not shown).
Figure 3. The role of endogenous TNF and IL-12 on S. epidermidis-induced IFN-γ production in whole-blood. Whole-blood was stimulated with 
S. epidermidis (10:1 ratio of organisms to leukocytes) in the absence or presence of IL-18BP (125 ng/mL), TNFbp (10 μg/mL) (A) or anti-IL-12 Ab 
(2.5 μg/mL) (B). After 48 hours the cultures were lysed with Triton X and were assayed for IFN-γ. The amount of IFN-γ induced by S. epidermidis 
was set at 100% for each donor and the mean ± SEM percent change for each condition is shown. A 100% S. epidermidis stimulation represents 
5.8 ± 1.6 ng of IFN-γ /mL. ** P <0.01 versus S. epidermidis alone. N=6 donors.
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DISCUSSION
The present study shows that IL-18, IL-12 and TNF are important cytokines in the 
induction of IFN-γ by S. epidermidis. In contrast, blocking endogenous IL-1 with 
IL-1Ra had no effect on S. epidermidis-induced IFN-γ production. The induction of 
TNF was dependent on endogenous production of IL-18 and IL-1, but not IL-12. 
S. epidermidis-induced IL-8 production was not infl uenced by any of the cytokine 
inhibitors used.
In Staphylococcal sepsis and Toxic Shock Syndrome (TSS) overwhelming production 
of cytokines are thought to play an important role in the pathogenesis. The release of 
cytokines such as TNF, IL-1β, and IFN-γ is triggered by intact microorganisms which 
invade the circulation [2]. In TSS, the staphylococci rarely invade the host; how-
ever, cytokine production is triggered by exotoxins acting as superantigens, such a 
TSS toxin-1 (TSST-1) and staphylococcal enterotoxin B (SEB) [19]. Other important 
components of the staphylococcal cell-wall responsible for cytokine release are pep-
tidoglycan (PG) and lipoteichoic acid (LTA) [20, 21]. In the present study, we inves-
tigated the role of endogenous cytokines using heat-killed S. epidermidis-induced 
IFN-γ, TNF, and IL-8 production. Therefore, using heat-killed, washed staphylococcal 
microorganisms, we have eliminated a role for TSST-1 or any soluble toxins. The 
induction of cytokines by heat-killed S. epidermidis is thus due to phagocytosis or 
triggering TLR-2 by PG or LTA [22].
IL-18 was initially described as IFN-γ inducing factor [6]. Traditionally, IL-18 is thought 
to serve as a co-stimulus for IFN-γ production in the context of leukocyte stimulation 
with bacterial products or IL-12 [4]. In this study, the important role of IL-18 in IFN-γ 
Figure 4. The role of endogenous cytokines in S. epidermidis-induced TNF-α production in whole-blood. Whole-blood was stimulated with S. 
epidermidis (10:1 ratio of organisms to leukocytes) in the absence or presence of IL-18BP (125 ng/mL), IL-1Ra (10 μg/mL) or anti-IL-12 Ab (2.5 
μg/mL). After 24 hours the culture was lysed with Triton X and was assayed for TNF-α. The amount of TNF-α induced by S. epidermidis was set 
at 100% for each donor and the mean ± SEM percent change for each condition is shown. A 100% S. epidermidis stimulation represents 1.9 ± 
0.9 ng of TNF-α/mL. * P <0.05, ** P <0.01 versus S. epidermidis alone. N=6 donors.
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production induced by the Gram-positive bacteria S. epidermidis is demonstrated 
by the effect of ICE-inhibition or IL-18BP. Blocking the cleavage of pro-IL-1β and 
pro-IL-18 by an ICEi reduced the S. epidermidis-induction of IFN-γ and IL-1β. More-
over, total IL-18 was inhibited by ICEi, although this does not deal with the issue 
of inhibiting processing by ICE. Oberholzer et al. demonstrate an almost complete 
inhibition of mature IL-18 by an ICEi in whole blood stimulated with Staphylococ-
cus aureus Cowan strain [23]. More importantly, the effect of ICE inhibition on 
IFN-γ production was due to reducing IL-18 secretion and not IL-1β secretion since 
IL-18BP, even not a its highest concentration, reduced IFN-γ production induced by 
S. epidermidis, whereas IL-1Ra had no effect. Our data are supported by Puren et al, 
who showed that IL-18 is an important cytokine in the induction of IFN-γ in whole-
blood [18]. They compared the effect of IL-1Ra and an ICEi on LPS-induced IFN-γ 
production. Since only the ICEi diminished the IFN-γ production, the reduction in the 
processing and secretion of IL-18 by the ICEi accounted for the reduction in IFN-γ 
[24]. In various studies, endogenous IL-18 has been shown to be important for IFN-γ 
induction by the infl ammatory stimuli LPS and zymosan [25] and by the intracellular 
pathogens Mycobacterium tuberculosis [26], Leishmania major [27], and Legionella 
pneumophila [28]. In contrast, IFN-γ production by the staphylococcal superantigens 
TSST-1 and SEB was independent of endogenous IL-18 [29].
The present data suggest that endogenous IL-1 is not involved in S. epidermidis-
induced IFN-γ production, indicating that different cytokine-pathways are involved 
in the induction of IFN-γ by various bacterial stimuli. However, there is a role for 
IL-1β in C. albicans-induced IFN-γ production since IL-1Ra, by blocking IL-1 recep-
tors, or IL-1β antibodies had a similar effect on reducing IFN-γ [30]. These data are 
in agreement with results obtained by others who reported inhibition of IFN-γ by 
IL-1β antibodies by bacterial stimuli such as LPS, heat-killed Toxoplasma gondii, 
Salmonella typhimurium, L. pneumophila, and Yersinia pseudotuberculosis [12]. In 
contrast, others were unable to fi nd an effect of anti-IL-1β antibodies when IFN-γ 
production was induced by Listeria monocytogenes [31]. In the present study we 
also show that in addition to IL-12 and IL-18, endogenous TNF contributes to IFN-γ 
production. This is in line with Wherry et al who showed that IFN-γ production is 
dependent on TNF upon stimulation of the cells with Listeria monocytogenes [32]. 
Another co-stimulus involved in the induction of IFN-γ is IL-12. IL-12 and IL-18 act 
synergistically to increase IFN-γ production by T cells [8]. In the present study, block-
ing endogenous IL-12 with monoclonal antibodies leads to a signifi cant reduction 
in IFN-γ production, demonstrating an important role for IL-12 in S. epidermidis-
induced IFN-γ production. IL-12 is required for IL-18-induced IFN-γ production and 
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IL-18 induces IFN-γ when its receptor is upregulated by IL-12 [9, 10]. Resting T cells 
do not express the IL-18 receptor, but pretreatment of IL-12 increased expression of 
the IL-18 receptor [9].
In addition to the production of IFN-γ, S. epidermidis also induced TNF-α and IL-
8, two important cytokines involved in the pathogenesis of septic shock [33, 34]. 
However, the effect of IL-18 on TNF-α and IL-8 production was far less pronounced 
than on IFN-γ production. TNF-α is mainly produced by the monocyte/macrophage 
[35] and is important for host defense against Gram-positive microorganisms [36]. 
In this study we show that S. epidermidis-induced TNF-α production is slightly in-
fl uenced by IL-18 and IL-1β-dependent pathways, whereas most of TNF is directly 
induced by S. epidermidis. IL-8 is a member of the chemokine family and produced 
by several cell-types including monocytes and neutrophils. IL-8 induces neutrophil 
infi ltration and increases bacterial clearance [37]. This chemokine can be induced 
in the presence of bacterial stimuli and the cytokines IL-1 and TNF. However, our 
results demonstrate that S. epidermidis-induced IL-8 production was independent on 
IL-18, IL-12, IL-1 or TNF. 
In conclusion, S. epidermidis stimulates IFN-γ in an IL-18, IL-12- and TNF-dependent 
manner, whereas production of TNF-α is infl uenced by IL-18 and IL-1, but not IL-12. 
Because both IFN-γ and TNF-α are crucial for host defense against Gram-positive mi-
croorganisms [36], blocking the biological activities of these cytokines may increase 
susceptibility to Gram-positive sepsis. Anti-cytokine therapy with TNF-neutralizing 
strategies is presently being used in over 250,000 patients. Increased infections have 
been reported, particularly reactivation of M. tuberculosis and opportunistic infec-
tions [38, 39]. Because of inconsistent reporting, the true incidence of these infections 
is likely higher. IFN-γ, more than any other cytokine studied in the present report, 
contributes to host defense in mycobacterial, Salmonella and Candida-infections 
[40-44]. Therefore, the reduction in IFN-γ by blocking endogenous IL-18, IL-12 or 
TNF-α may predict clinical infections when these cytokines are targets in clinical 
setting. On the other hand, since IL-1Ra had no effect on IFN-γ production, one 
could predict that treatment of rheumatoid arthritis patients with IL-1Ra will not 
place patients at risk.
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Abbreviations used in this paper: Ab: antibody; NK cells: natural killer cells; IL-18BP: 
interleukin-18 binding protein; IL: interleukin; TNF-α: tumor necrosis factor-α; IFN-
γ: interferon-γ; TNFbp: tumor necrosis factor binding protein; Th1: T helper 1; ICE: 
IL-1β-converting enzyme
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ABSTRACT
Induction of expression of adhesion molecules is a crucial step in infl ammation. The 
role of interleukin-18 (IL-18) in induction of various adhesion molecules was inves-
tigated in freshly isolated peripheral blood mononuclear cells and human mono-
cyte and T-cell lines. IL-18 selectively upregulated intercellular adhesion molecule-1 
(ICAM-1) expression on freshly isolated human monocytes, but not on lymphocytes. 
The expression of other adhesion molecules was not infl uenced. Induction of ICAM-
1 by IL-18 was dependent on endogenous tumor necrosis factor-α (TNF-α), and IL-12 
had an additive effect on that of IL-18. No changes in adhesion molecule expression 
were observed on the monocytic cell line THP-1 and on the T-cell lines HSB-2 and 
Jurkat J16. In addition, induction of ICAM-1 on monocytes by lipopolysaccharide 
was slightly, but signifi cantly, inhibited by blockade of either endogenous IL-18 or 
TNF-α with IL-18 binding protein or TNF binding protein, respectively. Blocking 
IL-1 effects with IL-1 receptor antagonist did not infl uence ICAM-1 levels. In conclu-
sion, IL-18 selectively upregulates the expression of ICAM-1 on monocytes, and this 
contributes to the proinfl ammatory effects of this cytokine.
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INTRODUCTION
Interleukin-18 (IL-18) is a cytokine initially described as a costimulus for interferon-γ 
(IFN-γ) production [1]. In the context of microbial costimulation, IL-18 is able to 
induce large amounts of IFN-γ [2]. It is however often overlooked that IL-18 displays 
a series of proinfl ammatory effects independent of IFN-γ. IL-18 induces proinfl am-
matory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), 
IL-6 and IL-8 [3, 4], probably through activation of NF-κB [5]. In experimental animals 
challenged with lipopolysaccharide (LPS), IL-18 contributes to lethality even in the 
absence of IFN-γ [6]. Likewise, IL-18 mediates cartilage damage in IFN-γ-defi cient 
mice with collagen arthritis [7]. These infl ammatory effects of IL-18 are not well 
understood, and it is possible that increased expression of adhesion molecules plays 
a role.
Adhesion molecule expression is an important step in the induction of infl ammation. 
In response to microbial antigens, host cells are triggered to release cytokines such 
as IL-1β, TNF-α, and IFN-γ, and these are able to upregulate expression of various 
adhesion molecules on monocytes and endothelial cells [8]. Intercellular adhesion 
molecule-1 (ICAM-1, CD54) is a transmembrane glycoprotein and member of the im-
munoglobulin supergene family that is constitutively expressed on a wide variety of 
cell types [9]. ICAM-1 is involved in cell-cell interactions and leukocyte extravasation 
at infl ammatory sites by binding to two integrins, CD11a/CD18 (leukocyte function-
associated antigen-1; LFA-1) and CD11b/CD18 (Mac-1), both belonging to the β
2
 
integrin subfamily [10, 11]. 
In the present study, the effect of IL-18 on adhesion molecule expression on mono-
cytes from freshly isolated peripheral blood mononuclear cells (PBMC) was investi-
gated. The role of endogenous IL-18, TNF, and IL-1 in LPS-induced ICAM-1 upregula-
tion was studied by using specifi c cytokine inhibitors such as IL-18 binding protein 
(IL-18BP), TNF binding protein (TNFbp), and IL-1 receptor antagonist (IL-1Ra). We 
demonstrate that IL-18 selectively upregulates ICAM-1 expression on human mono-
cytes, whereas IL-18 does not affect any of the other adhesion molecules tested: 
CD14, LFA-1, Mac-1, P150, very late antigen-4 (VLA-4), VLA-5, ICAM-2, ICAM-3 or 
activated leukocyte cell adhesion molecule (ALCAM). 
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MATERIAL AND METHODS
Reagents. 
Recombinant human IL-18 was kindly provided by Dr. M. Kurimoto (Fujisaki Insti-
tute, Hayashibara Biochemical Laboratories, Okayama, Japan). Recombinant human 
IL-12 was purchased from Peprotech (Rocky Hill, NJ). LPS was obtained from Sigma 
Chemical Co (E.Coli 055:B5, St. Louis, MO). IL-18BP was expressed in COS cells as 
the “a” isoform and purifi ed as a 6 histidine-tagged protein over talon as previously 
described [12]. TNFbp (p55 TNF soluble receptor [13]) and recombinant human IL-1Ra 
were a kind gift of Dr. Carl Edwards (Amgen, Thousand Oaks, CA). The following 
primary antibodies were used: anti-CD14 (Pharmingen, San Diego, CA), antibodies 
to CD11a (L7; [14]), CD11b (Kim225; [15]), CD11c (SHCI3; [16]), CD29 (TS2/16; [17]), 
CD49d (HP2/1; [18]), CD49e (SAM-1; [19]), ICAM-1 (Rek-1; [20]), ICAM-2 (CBR2/2; 
[21]), and ALCAM (1F2; [22]). Antibodies to CD18
 
(AZN-L19) and ICAM-3 (AZN-IC3) 
were developed at the Department of Tumor Immunology, University Medical Cen-
ter St. Radboud, Nijmegen, The Netherlands.
Isolation of PBMC, induction of adhesion molecule expression, and stimulation of TNF production. 
Separation and stimulation of PBMC was performed as described elsewhere [23], 
with minor modifi cations. Briefl y, 10 ml EDTA tubes (Terumo, Leuven, Belgium) 
were fi lled with venous blood drawn from 9 healthy volunteers between 9 and 10 
a.m. The PBMC fraction was obtained by density centrifugation of diluted blood 
(1 part blood to 1 part pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech, 
Uppsala, Sweden). PBMC were washed twice in saline and suspended in culture me-
dium (RPMI 1640 Dutch modifi cation, ICN Biomedicals, Aurora, Ohio) supplemented 
with human serum 5%, gentamicin 1%, L-glutamine 1%, and pyruvate 1%. The cells 
were counted in a Coulter counter (Coulter Electronics, Mijdrecht, The Netherlands) 
and the number was adjusted to 2x106 cells/ml. 1x106 cells/tube were incubated 
in 5 ml polypropylene round-bottom tubes (Becton Dickinson, Franklin Lakes, NJ) 
with IL-18 (1 μg/mL), IL-12 (10 ng/ml), or LPS (1 μg/mL) in the absence or presence 
of the cytokine inhibitors, IL-18BP (500 ng/ml), TNFbp (10 μg/ml), or IL-1Ra (10 
μg/ml), for 24 h at 37ºC. In a single experiment PBMC were stimulated with 0, 100 
ng/mL, 1 μg/mL, and 10 μg/mL of IL-18 and incubated for 4, 8, 24, and 48 h. After 
the incubation period the cells were collected and assayed for adhesion molecule 
expression. In the supernatants TNF-α concentrations were measured in duplicate 
by radioimmunoassay (RIA) as previously described [24]. 
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Cell lines. 
THP-1, a monocytic cell line [25], and, Jurkat J16, a human T-cell leukemia cell 
line [26], were maintained in RPMI 1640 supplemented with fetal calf serum 10%, 
gentamicin 1%, L-glutamine 1%, and pyruvate 1%. HSB-2, a human T-cell leukemia 
cell line [27], was maintained in Iscove’s Modifi ed Dulbecco’s Medium (Gibco, Grand 
Island, NY) supplemented with fetal calf serum 5%, gentamicin 1%, L-glutamine 
1%, and pyruvate 1%. For assay, the cells were suspended at 2x106 cells/mL. 1x106 
cells/well were incubated in 24-wells plates (Costar, Corning, NY) with or without 
IL-18 (1 μg/mL) for 24 h at 37ºC.
Flow Cytometry. 
For fl ow cytometric analysis 1x105 cells/well were plated in a 96-well V-shaped-bot-
tom plate, washed with PBA (PBS containing 1% BSA and 0.05% NaN
3
) and stained 
for 30 min at 4°C with primary antibodies (5 μg/ml). The cells were washed with 
PBA and incubated for 30 min at 4°C with FITC-conjugated goat anti-mouse (Fab’)
2
 
secondary antibody (Zymed, San Francisco, CA). After washing, the cells were an-
alysed on a FACScan (Becton Dickinson, Oxnard, CA). The gates were set to exclude 
dead cells, and 5000 gated cells were analysed. Monocytes and lymphocytes were 
gated based on their forward-side-scatter pattern. 
Statistical analysis. 
The experiments were repeated at least two times with 3 volunteers and the data 
represent cumulative results. Data were expressed as means ± standard error of the 
means (SEM). Differences between groups were analysed with the Wilcoxon signed 
test (double sided).
RESULTS
Eﬀ ect of IL-18 on the expression of adhesion molecules on human freshly isolated monocytes. 
The effect of IL-18 (1 μg/mL) on the expression of the following molecules was 
investigated: CD14, LFA-1, Mac-1, P150, VLA-4, VLA-5, ICAM-1, ICAM-2, ICAM-3 and 
ALCAM. On human monocytes, ICAM-1 was constitutively expressed. IL-18 induced 
signifi cant upregulation of ICAM-1 expression on monocytes (119% increase, P<0.01) 
(Fig. 1A). The other molecules tested were not infl uenced by IL-18. The expression 
of ICAM-1 and other adhesion molecules on lymphocytes did not change after incu-
bation with IL-18 (Fig. 1B and Table 1). 
C
ha
p
te
r 4
58
Table 1. Eﬀ ect of IL-18 on expression of adhesion molecules on human monocytes and lymphocytes*
Monocytes Lymphocytes
Molecule Control IL-18 P-valueb Control IL-18 P-valueb
ICAM-1 309±68 623 ±89 P<0.01 15 ±3 19 ±3 NS
CD14 810 ±60 818 ±96 NS 15 ±11 10 ±5 NS
CD18 570 ±39 681 ±10 NS 151 ±17 156 ±7 NS
CD11a 451 ±42 474 ±46 NS 157 ±22 175 ±11 NS
CD11b 563 ±119 581 ±41 NS 47 ±26 48 ±15 NS
CD11c 395 ±41 526 ±33 NS 8 ±1 14 ±2 NS
CD29 557 ±76 543 ±117 NS 80 ±15 77 ±12 NS
CD49d 64 ±3 115 ±47 NS 43 ±4 46 ±4 NS
CD49e 305 ±47 287 ±74 NS 24 ±22 7 ±5 NS
ICAM-2 89 ±13 86 ±20 NS 51 ±7 50 ±7 NS
ICAM-3 272 ±51 253 ±59 NS 140 ±22 135 ±25 NS
ALCAM 126 ±10 101 ±24 NS 13 ±1 11 ±1 NS
*PBMC were stimulated with IL-18 (1 μg/ml). The expression of the various molecules was assesses after 24 h of incubation. Data represent the 
mean ﬂ uorescence ± SEM of four separate experiments.
bNS, not signiﬁ cant.
Dose and time-response of IL-18 on ICAM-1 expression. 
PBMC were stimulated with various concentrations of IL-18. At different time points, 
ICAM-1 expression was determined. At a concentration of 1 μg/mL IL-18 a maximum 
level of ICAM-1 expression on monocytes was reached after 24 h of incubation 
(mean fl uorescence of 455 ± 26; Fig.2). Similar kinetics of ICAM-1 expression were 
Figure 1. Eﬀ ect of IL-18 on ICAM-1 expression on freshly isolated PBMC. PBMC were stimulated with or without IL-18 (1 μg/mL), and ICAM-1 
expression on monocytes (A) and lymphocytes (B) was assessed after 24 h of incubation. Data are representative of 4 similar experiments.
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observed when PBMC were stimulated with either 100 ng/mL or 10 μg/mL IL-18, 
with maximal stimulation at 24 hours (mean fl uorescence of 430 ± 24, and 436 ± 43, 
respectively). In subsequent experiments a concentration of 1 μg/mL IL-18 was used 
with an incubation period of 24 h.
Induction of ICAM-1 by IL-18 and IL-12. 
The potential synergistic effect of IL-18 and IL-12 on ICAM-1 expression was investi-
gated by assessing ICAM-1 expression in the presence of either of the two cytokines 
alone and the combination. As shown in Fig. 3, stimulation of PBMC with IL-18 
alone, IL-12 alone, and IL-18 plus IL-12 for 24 h induced a 119%, 208% and 324 % 
increase of ICAM-1 expression on monocytes, respectively. The combination of IL-18 
and IL-12 induced signifi cantly more ICAM-1 expression on monocytes compared to 
either IL-18 or IL-12 alone (P<0.05).
The role of IL-18 on adhesion molecule expression on THP-1, HSB-2, and Jurkat J16 cells. 
To investigate if the selective upregulation of ICAM-1 on human freshly isolated 
monocytes was also apparent in isolated cell types, we tested the effect of IL-18 on 
Figure 2. Time-response of IL-18 on ICAM-1 expression. PBMC were stimulated with (open squares) or without (closed squares) IL-18 (1 
μg/mL), and ICAM-1 expression on monocytes was assessed after 4, 8, 24, and 48 h of incubation. Data represent the mean ± SEM of 3 donors, 
expressed as mean ﬂ uorescence of ICAM-1.
Figure 3. Induction of ICAM-1 by IL-18 and IL-12. PBMC were stimulated with IL-18 (1 μg/mL) and / or IL-12 (10 ng/mL). ICAM-1 expression 
was assessed after 24 h of incubation. Data represent the mean ± SEM of 9 donors, expressed as mean ﬂ uorescence of ICAM-1. *, P<0.01 versus 
control. **, P<0.05 versus either cytokine alone.
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adhesion molecule expression on the monocytic cell line THP-1, and on two T-cell 
lines, HSB-2 and Jurkat J16. IL-18 did not infl uence ICAM-1 expression (THP-1, 118% 
of control; HSB-2, 139% of control; Jurkat J16, 100% of control, all not signifi cant). 
Moreover, the other adhesion molecules tested did not change after incubation with 
IL-18 (data not shown).
Induction of ICAM-1 by IL-18 and IL-12 is partially TNF-dependent. 
It has been shown previously that IL-18 has direct proinfl ammatory effects inde-
pendent of IFN-γ [3]. As shown in Fig. 4A, both IL-18 and IL-12 were able to induce 
signifi cant amounts of TNF-α in the supernatant. The combination of IL-18 plus 
IL-12 signifi cantly augmented the production of TNF-α. To evaluate whether ICAM-1 
upregulation by IL-18 and IL-18 plus IL-12 was dependent on TNF-α production, we 
used TNFbp to neutralize the activity of endogenously released TNF-α. As shown in 
Fig. 4B, TNFbp signifi cantly reduced both the ICAM-1 expression induced by IL-18 
(-28%) and by IL-18 plus IL-12 (-36%) (P<0.05).
Figure 4. Induction of ICAM-1 by IL-18 and IL-12 is TNF-dependent. (A) PBMC were stimulated with IL-18 (1 μg/mL) or IL-12 (10 ng/mL). 
TNF-α was measured after 24 h of incubation. Data represent the mean ± SEM of 9 donors. **, P<0.01 versus control. *, P<0.05 versus control. 
(B) PBMC were stimulated with IL-18 (1 μg/mL) or IL-12 (10 ng/mL) in the absence or presence of TNFbp (10 μg/mL). ICAM-1 expression was 
assessed after 24 hours of incubation. Data represent the mean ± SEM of 5 donors, expressed as mean ﬂ uorescence of ICAM-1. *, P<0.05.
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The role of IL-18 in LPS-induced adhesion molecule expression. 
LPS induced a signifi cant increase in ICAM-1 expression by 172%, and CD14 expres-
sion by 25% on human freshly isolated monocytes. The other adhesion molecules 
tested were not infl uenced by LPS (Table 2). Expression of ICAM-1 and other adhe-
sion molecules on lymphocytes did not change after stimulation with LPS (Table 2). 
To investigate the role of endogenous IL-18, TNF and IL-1 in the induction of ICAM-1 
by LPS, specifi c cytokine inhibitors were used. As shown in Fig. 5, neutralization of 
IL-18 and of TNF by the respective binding proteins slightly, but signifi cantly, de-
creased LPS-induced ICAM-1 expression by 13% and 20%, respectively. In contrast, 
blocking IL-1 receptors by IL-1Ra did not infl uence the LPS-induced ICAM-1 expres-
sion. Blocking both endogenous IL-18 and TNF reduced ICAM-1 levels with 23% 
(P<0.05). There was no signifi cant additive effect of IL-18BP and TNFbp.
Table 2. Eﬀ ect of LPS on expression of adhesion molecules on human monocytes and lymphocytes*
Monocytes Lymphocytes
Molecule Control LPS P-valueb Control LPS P-valueb
ICAM-1 315 ±41 857 ±60 P<0.01 11 ±1 17 ±2 NS
CD14 870 ±54 1087 ±95 P<0.01 10 ±5 5 ±1 NS
CD18 640 ±88 525 ±66 NS 152 ±20 169 ±20 NS
CD11a 404 ±52 343 ±33 NS 175 ±71 95 ±32 NS
CD11b 530 ±90 514 ±105 NS 50 ±16 63 ±19 NS
CD11c 291 ±56 290 ±29 NS 7 ±1 9 ±1 NS
CD29 703 ±39 625 ±78 NS 86 ±11 91 ±15 NS
CD49d 50 ±6 43 ±4 NS 40 ±3 39 ±2 NS
CD49e 337 ±9 277 ±32 NS 19 ±3 18 ±3 NS
ICAM-2 101 ±8 109 ±22 NS 53 ±2 54 ±3 NS
ICAM-3 191 ±28 178 ±33 NS 106 ±5 105 ±7 NS
ALCAM 107 ±12 82 ±6 NS 11 ±1 11 ±1 NS 
*PBMC were stimulated with LPS (1 μg/ml). The expression of the various molecules was assesses after 24 h of incubation. Data represent the 
mean ﬂ uorescence ± SEM of four separate experiments.
bNS, not signiﬁ cant.
Figure 5. Role of endogenous IL-18, TNF, and IL-1 in LPS-induced ICAM-1 production. PBMC were stimulated with LPS (1 μg/ml) in the absence 
or presence of IL-18BP (500 ng/mL), TNFbp (10 μg /mL) or IL-1Ra (10 μg /mL). ICAM-1 expression was assessed after 24 h of incubation. Data 
represent the mean ± SEM of 6 donors, expressed as mean ﬂ uorescence of ICAM-1. *, P<0.05 versus LPS.
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DISCUSSION
In this study, investigating the effect of IL-18 on adhesion molecule expression on 
human monocytes, we found that IL-18 selectively upregulates ICAM-1 expression, 
whereas the expression of other adhesion molecules is not affected. IL-12 had an 
additive effect on ICAM-1 induction by IL-18, and upregulation of ICAM-1 by IL-18 
was partially dependent on initial induction of TNF-α production. The microbial 
stimulus LPS upregulated ICAM-1 and CD14 expression, and ICAM-1 induction by 
LPS was slightly, but signifi cantly, reduced by blocking endogenous IL-18 or TNF-α 
with their specifi c inhibitors.
Our fi nding of increased ICAM-1 expression on monocytes in primary culture ex-
posed to IL-18 does not stand alone. Others have found that IL-18 induces expres-
sion of ICAM-1 on glomerular cells in a model of murine glomerulonephritis [28], 
on endothelial cells and synovial fi broblasts [29], and on a monocytic cell line KG-1 
[30]. Interestingly, lymphocytes do not respond to IL-18 with increased expression of 
adhesion molecules. In addition, it is remarkable that the adhesion molecule expres-
sion on monocytes is selective for ICAM-1, and not for any of the other adhesion 
molecules. VCAM-1, an adhesion molecule not present on monocytes, has been 
shown to be induced by IL-18 on hepatic sinusoidal cells [31], endothelial cells and 
synovial fi broblasts [29]. 
We also tested if the selective upregulation of ICAM-1 on monocytes applied for 
specifi c leukocyte cell lines. In contrast to the monocytes in the PBMC culture, 
none of the adhesion molecules in the monocytic cell line THP-1 was affected by 
stimulation with IL-18. For the two T-cell lines, HSB-2 and Jurkat J16, results were 
similar to those with the lymphocytes in the PBMC culture. Apparently, either the 
leukemic source of these cell lines or the in vitro culture may have led to specifi c 
changes of the reactivity of the cells (e.g. altered IL-18 receptor expression) com-
pared to monocytes from healthy individuals. Another explanation may be that the 
interplay between different cell types (monocytes, lymphocytes) and the presence 
of cytokines, for instance TNF-α, in peripheral blood is important for upregulation 
of ICAM-1 by IL-18 on monocytes.
Because TNF-α is able to induce ICAM-1 [32], we tested whether the upregulation 
of ICAM-1 by IL-18 was dependent on intermediate induction of TNF-α. Addition of 
TNFbp resulted in 28% reduction of IL-18-induced ICAM-1, demonstrating that IL-
18-induced ICAM-1 expression is partially dependent on endogenous TNF-α. Others 
were unable to show a role for endogenous TNF-α in the ICAM-1 upregulation by 
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IL-18 [33]. The reason for this difference is unclear, but may be explained by the use 
of different reagents to neutralise the effect of TNF. We have used a soluble TNF 
receptor whereas Yoshida et al. applied an antibody against TNF [33]. 
It is known that IL-18 and IL-12 exert synergistic effects on IFN-γ production [2], and 
our data suggest similar synergistic activity on the stimulation of TNF. In contrast, 
the effect of the combination of IL-18 plus IL-12 seems to have an additive effect on 
expression of ICAM-1, rather than synergistic. We cannot exclude an intermediary 
role of IFN-γ induction in the expression of ICAM-1. However, Kohka et al. have 
shown that blocking endogenous IFN-γ does not infl uence IL-18-induced ICAM-1 
upregulation [30]. Moreover, IL-18-induced ICAM-1 expression reached a maximum 
after 24 h of incubation, while IL-18-stimulated IFN-γ production is maximal only 
after 48 h. This makes it unlikely that endogenous IFN-γ is responsible for the IL-18 
induction of ICAM-1.
We also investigated the involvement of endogenous IL-18 in the stimulation of ICAM-
1 by bacterial stimuli. LPS, a component of Gram-negative bacteria, is consi dered 
to be a central mediator in the pathogenesis of Gram-negative shock. Proinfl amma-
tory cytokines such as TNF-α, IL-1β, and IL-18, are released into the circulation in 
response to LPS, and are thought to be responsible for the deleterious effects of LPS. 
LPS is known for its upregulation of ICAM-1 [34]. In the present study, endogenous 
IL-18 and TNF-α were involved in LPS-induced ICAM-1 expression, since blocking 
the effects of these two cytokines with IL-18BP and TNFbp, was able to partially 
inhibit this effect of LPS. There is no role for endogenous IL-1 in LPS-induced ICAM-1 
upregulation. Although the effect of blocking IL-18 and TNF on LPS-induced ICAM-1 
is subtle, our fi ndings are sustained by those of Beck-Schimmer et al. who showed 
that endogenous TNF plays a role in LPS-induced upregulation of ICAM-1 [35]. Oth-
ers, however, have reported that LPS-induced ICAM-1 is independent of endogenous 
IL-1 and TNF [36, 37]. Given the relatively small contributions of IL-18 and TNF to 
ICAM-1 upregulation by LPS, it is tempting to speculate whether this effect of LPS is 
direct (e.g. through the TLR-4 pathway) or needs other unknown mediators.
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Abbreviations used in this paper: IL-18BP: interleukin-18 binding protein; IFN-γ: 
interferon-γ; TNFbp: tumor necrosis factor binding protein; IL-1Ra: interleukin-1 
receptor antagonist; ICAM-1: intercellular adhesion molecule-1; LFA-1: lymphocyte 
function-associated antigen-1; VCAM-1: vascular cell adhesion molecule-1.
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ABSTRACT
In addition to stimulating IFN-γ synthesis, IL-18 also possesses infl ammatory effects 
by inducing synthesis of the proinfl ammatory cytokines TNF, IL-1β, and the chemo-
kines IL-8 and macrophage infl ammatory protein-1α (MIP-1α). We hypothesized that 
neutralization of IL-18 would have a benefi cial effect in lethal endotoxemia in mice. 
IL-1β converting enzyme (ICE)-defi cient mice, lacking ability to process mature IL-18 
and IL-1β, were completely resistant to lethal endotoxemia induced by LPS derived 
from either Escherichia coli or Salmonella typhimurium. In contrast, both wild-type 
and IL-1β-/- mice were equally susceptible to the lethal effects of LPS, implicating 
that absence of mature IL-18 or IFN-γ, but not IL-1β, in ICE-/- mice is responsible for 
this resistance. IFN-γ-defi cient mice, however, were not resistant to S. typhimurium 
LPS, suggesting an IFN-γ-independent role for IL-18. Anti-IL-18 antibodies protected 
mice against a lethal injection of either LPS. Anti-IL-18 treatment also reduced neu-
trophil accumulation in liver and lungs. The increased survival was accompanied by 
decreased levels of IFN-γ and MIP-2 in anti-IL-18 treated animals challenged with 
E.coli LPS, whereas IFN-γ and TNF concentrations were decreased in treated mice 
challenged with S. typhimurium. In conclusion, neutralization of IL-18 during lethal 
endotoxemia protects mice against lethal effects of LPS. This protection is partly me-
diated through inhibition of IFN-γ production, but mechanisms involving decreased 
neutrophil-mediated tissue damage due to the reduction of either chemokines (E.coli 
LPS) or TNF (S. typhimurium LPS) synthesis by anti-IL-18 treatment may also be 
involved.
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INTRODUCTION
The poor outcome of Gram-negative bacterial sepsis is believed to be due to LPS, 
and lethal endotoxemia has been extensively used as an experimental model of 
Gram-negative septic shock [1]. Binding of LPS to receptors on leukocyte triggers the 
production of highly active mediators such as the proinfl ammatory cytokines TNF, 
IL-1α and IL-1β, and the chemokines IL-8, macrophage infl ammatory protein-1α 
(MIP-1α) and MIP-2 [2, 3]. Stimulation of cytokines and chemokines is of pivotal 
importance in the pathogenesis of sepsis, as they are believed to be the main endo-
genous mediators of organ injury in endotoxic shock [1, 2]. IL-18 (initially described 
as interferon-gamma inducing factor - IGIF) is a newly-discovered proinfl ammatory 
cytokine that serves as a costimulus for IFN-γ production in the context of micro-
bial stimulation of macrophage cytokines such as IL-12 [4]. IL-18 is synthesized as 
an inactive precursor which requires cleavage by IL-1β converting enzyme (ICE, 
caspase-1) in order to release the mature active form [5, 6]. ICE-defi cient (ICE-/-) 
mice lacking both mature IL-18 and IL-1β are protected against lethal endotoxemia. 
The fact that IL-1β-/- mice are susceptible to lethal endotoxemia [7] suggests that the 
protection of ICE-defi cient animals is mediated by the lack of mature IL-18 or IFN-γ. 
However, controversial data exist regarding the susceptibility of IFN-γ-R-/- mice to 
LPS [8, 9], suggesting that IFN-γ-independent mechanisms may also be involved in 
the modulatory activity of IL-18. 
Although IL-18 exerts some of its proinfl ammatory effects through induction of IFN-γ, 
recent data suggest that IL-18 has direct proinfl ammatory properties. In this respect, 
IL-18 stimulates activation of NF-kB [10], induces production of proinfl ammatory 
cytokines such as TNF and IL-1β, and chemokines such as IL-8 and MIP-1α [11], and 
upregulates expression of adhesion molecules such as ICAM-1 [12]. The hypothesis 
that these direct infl ammatory effects may contribute to disease prompted us to 
investigate the role of IL-18 in lethal endotoxemia. We have assessed the effect of 
IL-18 neutralization in endotoxic shock using two methods: the use of ICE-/- mice 
known to be defi cient in mature active IL-18 [5, 6], and neutralization of IL-18 by 
treatment with anti-IL-18 antibodies. Because the precise effects of Escherichia coli 
and Salmonella typhimurium LPS in various types of knock-out mice are divergent 
[8, 9], suggesting differential pathogenic mechanisms involved in mortality induced 
by these two species of LPS, we have assessed the effect of IL-18 blockade in 
mice challenged with either E. coli or S. typhimurium LPS. We have investigated 
the mechanisms through which anti-IL-18 strategies may benefi cially infl uence the 
course of lethal endotoxemia.
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MATERIALS AND METHODS
Materials. 
LPS (Esche richia coli serotype O55:B5, cat.nr. L4005; and Salmonella typhimurium 
cat.nr. L1519) was obtained from Sigma Chemical Co (St.Lou is, MO). The anti-IL-
18 antiserum was obtained from a New Zealand rabbit immunized by intradermal 
injection of murine IL-18 (Peprotech Inc., Princeton, NJ) in the presence of Hunter’s 
Titermax adjuvant. This antibody has been shown to inhibit LPS-induced IFN-γ pro-
duction in vivo [13].
Animals. 
The in vivo experimental studies were approved by the Animal Use and Care Com-
mittee at the University of Colorado Health Sciences Center. The generation and 
background of ICE-/- and IL-1β-/- mice were previously described [14, 15]. The wild 
type mice used as controls were of the same genetic background, sex and age as the 
knock-out mice. IFN-γ-/- mice and their wild-type littermates were a kind gift from 
Organon Corp (Oss, the Netherlands). C57Bl/6J mice were obtained from Taconic 
Laboratory (Germantown, NY). For the experi ments, 6-8 week old mice, weighing 
20-25 g, were used. The animals were fed standard laborato ry food and housed 
under specifi c patho gen-free conditions.
Lethal endotoxemia model. 
Knock-out and control mice were injec ted intraperitoneally (i.p.) with LPS suspended 
in PBS (40 mg/kg, unless otherwise indicated). In separate experiments, C57Bl/6J 
mice were treated i.p. with 200 μl of either normal rabbit serum (NRS) as con-
trol or anti-IL-18 antiserum, 30 min. before the LPS administration. The neutralizing 
characteristics of the anti-IL-18 antiserum were previously reported for in vitro [13] 
and in vivo [16] experiments. Ninety min after challen ge with LPS, 5 animals from 
each group were anestheti zed with ether and bled from the retroor bi tal plexus for 
measure ment of TNF-α and MIP-2 circulating con cen trations. Another 5 animals per 
group were bled 6h after LPS challenge, for the measu rement of IFN-γ circula ting 
concentrations. In addition, lungs and livers from the sacrifi ced mice were aseptically 
removed, placed into liquid nitrogen and stored at -70°C. Half of the tissue material 
was used for myeloperoxidase (MPO) measurements, and the rest for tissue cytokine 
determinations. For cytokine measurements, the tissue was suspended and homo-
genized 1:4 (w:v) in sterile PBS containing 0.1% Tween 20, centrifuged at 20,000g 
for 15 min, and the supernatant collected and stored at -70°C until assay. In the 
remaining mice (5 to 7 animals/group), survival was assessed daily for 7 days.
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Cytokine measurements. 
Murine IL-18 was measured by electrochemiluminescence (ECL), as previously des-
cribed (Fantuzzi et al, submitted). Murine TNF concentrations were assessed by 
ECL [17]. The detection limits were 160 pg/ml (IL-18) and 62 pg/ml (TNF). IFN-γ 
measurements were performed with an ELISA kit (Endogen, Woburn, MA) (detection 
limit 20 pg/ml). MIP-2 concentrations were measured using a commercial ELISA kit 
(Quantikine, R&D Systems, Minneapolis, MN), with a detection limit of 7 pg/ml .
MPO assay. 
The content of MPO in the tissues was measured as previously described [18]. Briefl y, 
organs were weighed and then either both lungs or a segment of the liver (150-200 
mg of tissue) was homogenized (Virtishear homogenizer, Virtis, Gardner, NY) for 30 
seconds in 4 ml of 20 mM potassium phosphate buffer, pH 7.4, and then centrifuged 
for 30 minutes at 40,000 x g at 4°C (Beckman L-80 Ultracentrifuge, Beckman Instru-
ments, Palo Alto, CA). The pellet was resuspended in 4 ml of 50 mM potassium phos-
phate buffer, pH 6.0, containing 0.5g/dl cetrimonium bromide. The samples were 
sonicated for 90 seconds at full power (Ultrasonic homogenizer, Cole-Parmer Instru-
ment Co., Chicago, IL), incubated in a 60°C water bath for 2 hours, and centrifuged 
for 10 minutes at 20,000 x g. The supernatant (25 μl) was added to 725 μl of 50 mM 
phosphate buffer, pH 6.0, containing 0.167 mg/ml o-dianisidine (Sigma) and 5x10-4 
% hydrogen peroxide. Absorbance of 460 nm visible light was measured between 
1 and 3 minutes (Beckman DU7 spectrophotometer, Beckman Instruments, Irvine, 
CA). MPO activity per g of wet tissue was calculated as: MPO activity (units/g wet 
tissue) = (A
460
)(13.5)/tissue weight (g) where A
460
 is the change in the absorbance of 
460 nm light from 1 to 3 minutes after the initiation of the reaction. The coeffi cient 
13.5 was empirically determined such that 1 unit MPO activity is the amount of 
enzyme that will reduce 1 μmol peroxide/min.
Statistical analysis. 
The differences between groups were analyzed by Mann-Whitney U test, and where 
appropriate by Kruskal-Wallis ANOVA test. Survival curves were analyzed by the 
Kaplan-Meyer log-rank test. Experiments were performed twice on two separate 
occasions, and the data are presented as cumulative results of both experiments.
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RESULTS
Survival during endotoxemia. 
All wild-type and IL-1β-/- mice injected with 40 mg/kg LPS died within fi ve days 
following the endotoxin challenge (Fig.1A and B). In contrast, ICE-/- mice were 
completely protected against the lethal effects of LPS derived either from E. coli or 
S. typhimurium LPS (Fig.1A and B). None of the wild-type or knock-out mice died 
when they were injected with 20 mg/kg LPS (N=4 wild-type mice and N=5 each for 
IL-1β-/- and ICE-/- mice). These data suggest that the protection of ICE-/- mice to the 
lethal effects of LPS is mediated through the lack of mature IL-18, presumably result-
ing in the reduced production of IFN-γ. However, the hypothesis that the ICE-/- mice 
are protected due to the lack of IFN-γ is not supported by the observation that IFN-
γ-/- mice were only partially protected against lethal endotoxemia induced by E. coli 
LPS (Fig.1C) and were totally susceptible to S. typhimurium LPS (Fig.1D).
Figure 1. ICE-/- mice are protected against lethal endotoxemia. Mice were injected intraperitoneally with LPS from either E. coli (A, C) or S. 
typhimurium (B, D). The panels show experiments performed in ICE-/- and IL-1β-/- mice (A, B), or in IFN-γ-/- mice, respectively (C, D). Experiments 
depict cumulative data of two experiments performed on two separate occasions with 9 to 12 mice/group. *p<0.05.
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The above data suggest an important role for IL-18 during endotoxic shock, inde-
pendent of IFN-γ production. C57Bl/6J mice were injected with E. coli LPS after 
pre-treatment with a neutralizing rabbit anti-mouse IL-18 antibody. Treatment of 
C57Bl/6J mice with anti-IL-18 antiserum completely prevented the mortality induced 
by 40 mg/kg E.coli LPS (100% survival after anti-IL-18 vs. 10 % survival in NRS-treat-
ed mice, p<0.05) (Fig.2A). It is of considerable importance that anti-IL-18 -treated 
mice were also protected against S. typhimurium lethal effects (50% vs. 0% survival, 
p<0.05) (Fig.2B). 
IL-18 expression during lethal endotoxemia.
In healthy mice, circulating concentrations of IL-18 were under the detection limit 
of the assay (160 pg/ml). In contrast, constitutive expression of IL-18 was measured 
in the lungs (6020 ± 456 pg/g) and liver (9928 ± 1204 pg/g) of healthy mice. LPS 
challenge induced circulating IL-18 in the bloodstream of septic mice, 90 min after 
endotoxin administration (273 ± 41 pg/ml after E.coli LPS, and 279 ± 54 pg/ml after 
S. typhimurium LPS). At all other time points (30 min to 24h), circulating IL-18 
concentrations were below the detection limit of the assay. Ninety minutes after Sal-
monella LPS, there was an increase in the IL-18 content of the lung and liver (14326 
± 1737 and 13111 ± 993 pg/g respectively, p<0.05), whereas E.coli LPS stimulation 
led to an increase in IL-18 levels only in the lungs (9757 ± 1028 pg/g, p=0.06) and led 
to a signifi cant decrease in IL-18 levels in the liver (5027 ± 260 pg/g, p<0.05).
Figure 2. Anti-IL-18 Ab treatment protects against lethal endotoxemia. Mice were injected i.p. with normal rabbit serum (NRS) or anti-IL-18 
antiserum, 30 min before E. coli (A) or S. typhimurium (B) LPS challenge. Experiments involved 10-12 mice/group and were performed twice on 
two diﬀ erent occasions. Cumulative data are presented in the ﬁ gure. *p<0.05.
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The eﬀ ect of anti-IL-18 treatment on the in vivo proinﬂ ammatory cytokine production. 
C57Bl/6J mouse were injected i.p. with 40 mg/kg LPS, and blood was drawn 90 
min and 6h later for cytokine measurements. Administration of the anti-IL-18 Abs 
did not infl uence TNF serum concentrations measured 90 min. after E. coli LPS ad-
ministration (Fig.3A). In contrast, TNF concentrations 90 min. after S. typhimurium 
injection were higher compared to the levels obtained after E. coli LPS, and they 
were signifi cantly diminished by the anti-IL-18 treatment (Fig.3A). IFN-γ circulating 
concentrations measured 6h after the injection of both LPS species were signifi cantly 
decreased by treatment of mice with anti-IL-18 antiserum, when compared with 
NRS-treated animals (Fig.3B). It is important to note that the anti-IL-18 Ab was more 
effective in reducing IFN-γ activation after E.coli LPS (92% inhibition, p<0.01), than 
after S. typhimurium LPS (48% inhibition, p<0.05).
MPO levels in lungs and liver. 
To assess the effect of anti-IL-18 treatment on LPS-induced lung and liver neutro-
phil accumulation, we assessed the MPO content in these two organs 6h after LPS 
challenge. As shown in Fig.4, LPS injection dramatically increased MPO content in 
the lungs and liver. However, whereas E. coli LPS was more effective than S. ty-
phimurium LPS in increasing MPO content of the lung, the latter induced more MPO 
in the liver. Compared with NRS, treatment of mice with anti-IL-18 Abs signifi cantly 
reduced the MPO levels in the lungs of mice challenged with E. coli, but not of those 
challenged with S. typhimurium LPS (Fig.4A). In contrast, anti-IL-18 signifi cantly 
reduced hepatic MPO after E. coli LPS (79%, p<0.05) and S. typhimurium LPS (61%, 
p<0.05) (Fig.4B).
Figure 3. In vivo proinﬂ ammatory cytokine concentrations during endotoxemia. C57Bl/6J mice were injected i.p. with normal rabbit serum 
(NRS) (open bars) or anti-IL-18 antiserum (hatched bars), 30 min before LPS administration (40 mg/kg i.p.). A, Circulating TNF at 90 min. B, 
Circulating IFN-γ at 6h after challenge with LPS. N = 5 mice/group. * p<0.05 vs. E.coli LPS/NRS; **p<0.01 vs. E. coli LPS/NRS; # p<0.05 vs. 
S.typhymurium LPS/NRS.
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Modulation of chemokine expression by anti-IL-18 treatment. 
Because neutrophil accumulation in the organs is largely dependent on chemokines 
such as MIP-2, we investigated the content of this chemokine in the lungs and liver 
of mice treated with anti-IL-18 and challenged with LPS. In mice injected with E. 
coli LPS, anti-IL-18 treatment reduced MIP-2 expression in the lungs (52% decrease, 
p<0.05) and liver (49% decrease, p<0.05) (Fig.5). In contrast, no effects of anti-IL-18 
Ab on MIP-2 synthesis after S. typhimurium LPS injection were apparent (Fig.5).
Figure 4. Myeloperoxidase (MPO) content in lungs and liver during lethal endotoxemia. C57Bl/6J mice were injected i.p. with normal rabbit 
serum (NRS) (open bars) or anti-IL-18 antiserum (hatched bars), 30 min before LPS challenge (40 mg/kg i.p.). The MPO content of the lungs (A) 
and liver (B) is given as mean + SEM of 5 mice/group. *p<0.05 vs. E. coli LPS/NRS.
Figure 5. The eﬀ ect of anti-IL-18 treatment on MIP-2 concentrations in vivo. C57Bl/6J mice were injected i.p. with normal rabbit serum (NRS) 
(open bars) or anti-IL-18 antiserum (hatched bars), 30 min before LPS challenge (40 mg/kg i.p.). MIP-2 levels in the lungs (A) and liver (B) are 
depicted as means + SEM of 5 mice/group. * p<0.05 vs. E.coli LPS/NRS.
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DISCUSSION
The results of the present study demonstrate that a reduction of IL-18, either in 
ICE-/- mice or by administration of neutralizing anti-IL-18 Abs to wild-type mice, 
protects against the lethal effects of LPS derived from E. coli or S. typhimurium. 
Neutralizing IL-18 was accompanied by a decrease in the MPO content in the lung 
and liver, refl ecting a reduction in neutrophil accumulation. It is well established 
that infi ltration of neutrophils into vital organs plays an essential role in endotoxin 
lethality [19]. There are at least fi ve mechanisms by which anti-IL-18 affords protec-
tion in these studies. 1) Anti-IL-18 treatment reduces IFN-γ production, particularly 
after E. coli LPS [13], consistent with IFN-γ-/- mice being partially resistant to lethal E. 
coli LPS. 2) Inhibition of MIP-2 production in tissues of mice challenged with E. coli 
LPS probably resulted in decreased neutrophil infi ltration. 3) The benefi cial effects 
of anti-IL-18 administration during S. typhimurium endotoxemia may be mediated 
through decreased production of TNF, leading to protection against liver injury. 4) 
Anti-IL-18 treatment likely reduces ICAM-1 expression [12]. 5) Because IL-18 induces 
Fas ligand expression which play an important role in hepatic toxicity [20], inhibition 
of IL-18 may decrease liver toxicity through inhibition of Fas ligand expression.
The requirement for IL-18 in IFN-γ production induced by bacterial components 
has been shown in studies reporting the absence of processed mature IL-18 [5, 6], 
administration of neutralizing anti-IL-18 Abs [13, 21], or IL-18 binding protein [22] 
into experimental animals. In most of these reports, absence of IFN-γ was observed 
despite the presence of IL-12. The essential role for IL-18 in IFN-γ production in-
duced by LPS has been confi rmed in IL-18-defi cient mice [23]. 
The importance of IL-18 as a proinfl ammatory cytokine is suggested by experiments 
in which pretreatment with an anti-IL-18 Ab protected against LPS-induced liver 
injury [21]. A similar protection was reported in IL-18-/- mice [24]. Although ICE-
/- mice lacking mature forms of IL-18 and IL-1β are completely resistant to lethal 
endotoxemia as shown in the present study and by others [5, 6], IL-1β-/- mice are 
not [7]. Therefore, it has been proposed that the absence of mature, active IL-18 
determines the resistance of ICE-/- mice, via reduced IFN-γ production. However, 
in the case of S. typhimurium LPS, we have found that IFN-γ-/- are not protected 
against endotoxemia, as others have reported that absence of IFN-γ-R does not af-
ford protection [9]. One disadvantage of experiments performed in knock-out mice 
may be the modifi ed homeostasis due to the absence of some genes, which may lead 
to multiple abnormalities. Indeed, ICE-/- and IFN-γ-/- mice lack not only mature IL-
1β, IL-18, or IFN-γ respectively, but the production of other cytokines such as IL-1α, 
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TNF and IL-6 is also impaired compared to their wild-type counterparts [14, 25]. In 
contrast, this is not the case for the IL-1β-/- mice [26]. Therefore, our experiments 
with anti-IL-18 Abs are crucial, and these experiments suggest that our conclusions 
regarding the role of IL-18 in lethal endotoxemia are valid. Indeed, administration of 
an anti-IL-18 polyclonal Ab protected mice against the deleterious effects of both LPS 
species tested, supporting the concept that IL-18 has an important pathogenic role in 
both species of lethal endotoxemia.
The benefi cial effect of the anti-IL-18 Ab is consistent with the study of Xu et al. 
[27], showing protection against lethality induced by Salmonella LPS using an anti-
IL-18 receptor antibody. Interestingly, this contrasts with the observation of Sakao 
et al. who reported an increased mortality of IL-18-/- mice in the Propionibacterium 
acnes -sensitization LPS model, despite protection of animals against liver injury [24]. 
However, this model is different from the model of high-dose LPS used by Xu et al. 
and by us in the present study. The use of IL-18 knock-out mice adds a new vari-
able to the experimental outcome since defi cient animals probably upregulate other 
cytokines and cytokine receptors, with subsequent hyperreactivity to infl ammatory 
stimuli, as it has been shown for other proinfl ammatory cytokine knock-out mouse 
strains [28].
In contrast to E. coli LPS, it is unlikely that IFN-γ plays an important role in the protec-
tion afforded by anti-IL-18 Abs following S. typhimurium LPS. After S. typhimurium, 
we observed only a moderate inhibition of IFN-γ synthesis by the anti-IL-18, and a 
lack of resistance in IFN-γ-/- mice. Other studies support our observation since mice 
defi cient in IFN-γ-R are also susceptible to lethal S. typhimurium LPS injection [9]. 
Whereas anti-IL-18 had no effect on circulating TNF levels induced by E. coli LPS, the 
Ab signifi cantly decreased (55%, p<0.02) levels of TNF after challenge of mice with 
S. typhimurium LPS. This suggests that the effect of anti-IL-18 during S. typhimurium 
endotoxemia may be at least in part due to inhibition of TNF.
Lung and liver injury during endotoxemia is largely mediated through neutrophil 
accumulation [29, 30], which can be assessed by the MPO content in the respec-
tive tissues [19]. Interestingly, E.coli LPS induced more neutrophil infi ltration in the 
lungs compared with S. typhimurium LPS, whereas the latter was more effective in 
promoting neutrophil accumulation in the liver. Treatment of mice with anti-IL-18 
Abs before challenge with E. coli LPS was accompanied by a signifi cant decrease in 
the lung and liver MPO content compared with mice challenged with LPS that did 
not receive anti-IL-18. The anti-IL-18-associated decrease in MPO content may have 
been mediated through diminished chemokine production in these animals. Indeed, 
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the reduction in the neutrophil infi ltration of lung and liver in the anti-IL-18-treated 
mice after E. coli LPS challenge was accompanied by a decrease in MIP-2 levels in 
the organs of IL-18-treated animals compared to those of controls. It is therefore 
conceivable that part of the effects of anti-IL-18 treatment during E. coli endotoxemia 
is IFN-γ-independent and mediated through decreased MIP-2 expression. In con-
trast, we suggest that the benefi cial effect of anti-IL-18 treatment in S. typhimurium 
endotoxemia is mediated by the reduction in circulating TNF concentrations, which 
is supported by the observed effect of anti-IL-18 on MPO. Although anti-IL-18 treat-
ment signifi cantly decreased the MPO content of the liver after S. typhimurium 
challenge, it had no infl uence on the MPO content of the lungs. This pattern is con-
sistent with the decreased TNF concentration after anti-IL-18 Ab treatment during S. 
typhimurium endotoxemia, as TNF has been shown to be involved in LPS-mediated 
liver damage [31], but not lung injury [32]. 
The present observations of differential responses to these two LPS species may have 
important theoretical consequences. The two species differ not only at the level of 
the polysaccharide chains, but also at the level of lipid A. Compared with E. coli 
lipid A, lipid A from Salmonella contains an additional fatty acid [33] and different 
phosphate groups [34]. Since lipid A binding to LPS binding protein (LBP) and CD14 
results in cytokine production [35], it is not surprising that differences in the structure 
of lipid A may stimulate a different combination of cytokines. An additional argu-
ment is provided by studies performed in LBP defi cient (LBP-/-) mice. These mice 
responded with reduced cytokine production after stimulation with S. abortus equi 
LPS [36], compared to that after E. coli LPS [37]. This differential cytokine response 
of LBP-/- mice to E. coli or Salmonella LPS raises the interesting possibility that these 
two LPS species may interact differently with the various Toll-like receptors (TLRs) 
known to be involved in the intracellular signaling induced by LPS [38, 39]. In sup-
port of this hypothesis are the data of Yang and colleagues showing that Salmonella-
derived LPS is much more potent in inducing cytokines through TLR2 compared to 
E.coli LPS [38], whereas the two types of LPS are equally potent in inducing cytokines 
through TLR4 [40]. Alternatively, differences between the two LPS preparations may 
be due to quantitative and/or qualitative differences in the “endotoxin-associated 
proteins”. In our experiments, we have used commercial LPS chromatographically 
purifi ed by gel fi ltration, with a protein content less than 1%. However, even very 
small amounts of endotoxin-associated proteins may infl uence cytokine induction 
by LPS, as previously suggested by some [41], although not all [42] authors. Despite 
the fact that we used E. coli and S. typhimurium LPS isolated and purifi ed by identi-
cal methods, suggesting that protein contamination is similar for both preparations, 
we cannot exclude a role of these endotoxin-associated proteins in the biological 
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activities of the various LPS used. However, the importance of our data remains 
valid regardless of the exact source of differences between the two LPS used (differ-
ences in either the lipid A structure or the endotoxin-associated proteins) because 
these preparations have been used in all models of lethal endotoxemia reported in 
the literature. Therefore, our data on the differences in the cytokine network and 
pathogenic mechanisms between these two types of LPS is likely to explain some of 
the contradictory data in the literature, such as resistance of TNF-/- mice to E. coli but 
not Salmonella LPS [43, 44]. The capacity of anti-IL-18 treatment to induce resistance 
against both these two species of LPS underscores the importance of IL-18 as a 
regulator of pathological mechanisms in lethal endotoxemia.
FOOTNOTES
This study was partly supported by NIH grant AI-15614 (to CAD). MGN was sup-
ported by a grant from Stichting “De Drie Lichten”, Leiden, The Netherlands.
Abbreviations used in this paper: MIP-2 : macrophage infl ammatory protein-2; ICE : 
IL-1β converting enzyme; MPO : myeloperoxidase; NRS : normal rabbit serum; LBP 
: LPS binding protein.
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ABSTRACT
IL-18 is a proinfl ammatory cytokine of the IL-1 family and it induces IL-1, TNF, and 
IL-6, all of which endogenous pyrogens. The pyrogenic properties of recombinant 
IL-18 were studied in a rabbit model of fever. rIL-18 did not cause fever when in-
jected intravenously into rabbits. Furthermore, the ability of rIL-18 to modulate other 
components of the acute-phase response was assessed. rIL-18 did not induce leu-
kocytosis, or changes circulating concentrations of lipoproteins and corticosterone 
in mice. In conclusion, rIL-18 is not able to induce a febrile response in rabbits and 
does not modulate the acute-phase response in mice.
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INTRODUCTION
IL-18, a cytokine of the IL-1 family, plays an important role in the Th1-type cytokine 
response, primarily by its ability to induce IFN-γ production by T cells and natural 
killer cells in synergy with IL-12 and microbial products [1, 2]. In addition, IL-18 in-
duces IL-1, TNF, and IL-6, all well-established endogenous pyrogens [3, 4]. IL-18 and 
IL-1β share a series of characteristics, which is not surprising considering that IL-18 
is structurally related to IL-1β [5, 6]. Both cytokines require caspase-1 (also known as 
IL-1β converting enzyme) for cleavage and release of their active mature form into 
the extracellular compartment. The ligand-binding IL-18 receptor (IL-18R) α chain is 
similar to the IL-1R type I, and the signaling IL-18Rβ chain is similar to the IL-1R ac-
cessory protein. Furthermore, IL-18 and IL-1β signal transduction involve activation 
of identical cytoplasmic messengers: MyD88, IL-1 receptor-associated kinase, and 
tumor necrosis factor (TNF) receptor-associated factor-6. 
IL-1β is probably the most potent inducer of the acute-phase response [7, 8]. It is 
tempting to speculate that IL-18, which has proinfl ammatory properties, could also 
function as an inducer of the acute-phase response. 
The endogenous pyrogens IL-1α, IL-1β, TNF-α, and IL-6, induce synthesis of pros-
taglandin E
2
 (PGE
2
), in the thermoregulatory center of the hypothalamus, which in 
turn elevates the hypothalamic temperature setpoint, leading to fever by efferent 
mechanisms [9, 10]. 
We have studied the pyrogenic properties of recombinant human IL-18 (rIL-18) in a 
rabbit model of fever. Moreover, the ability of rIL-18 to modulate other components 
of the acute-phase response such as leukocytosis, lipid profi les and glucocorticoste-
roid production was assessed.
MATERIAL AND METHODS
Rabbit fever model. 
New-Zealand rabbits (3.0-3.5 kg) were obtained from a local colony. Seven days 
before being used in the experiments the rabbits were accustomed to the stocks. 
During the experiment, the animals were kept at 21 ± 1 ºC ambient temperature and 
housed with a 12-h light-dark cycle. They had free access to food and water. Three 
New-Zealand rabbits per group were intravenously (i.v.) injected with LPS (50 ng/
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kg) or recombinant human IL-18 (1 μg/kg) according to Dinarello et al. [11] and the 
temperature was monitored continuously for 5 hours using a rectal thermometer.
Materials. 
Recombinant human and murine IL-18 was kindly provided by Dr. M. Kurimoto (Fu-
jisaki Institute, Hayashibara Biochemical Laboratories, Okayama, Japan). LPS (E.Coli 
055:B5) was obtained from Sigma Chemical Co (St. Louis, MO, USA).
Induction of the acute-phase response in mice. 
C57Bl/6J mice (females, 20-25 g, 6-8 weeks old) were obtained from Laboratory (Bar 
Harbour, ME, USA). Animals were housed under standard laboratory conditions and 
fed sterilized laboratory chow (Hope Farms, Woerden, The Netherlands) and water 
ad libitum. Mice were injected intravenously with rmIL-18 (1 μg/mouse) in 100 μl of 
sterile pyrogen-free PBS. Control mice received 100 μl of sterile pyrogen-free PBS 
i.v. At various time-points, subgroups of four animals were killed, and blood was 
collected on EDTA for white blood cell counts, and measurements of cholesterol, 
triglycerides and corticosterone.
 Total white blood cells were counted in a Coulter counter (Coulter Electronics, Mi-
jdrecht, The Netherlands). Tail blood of mice was used to prepare thin blood fi lms, 
which were stained with May-Grunwald Giemsa’s solutions. Differential counts of 
blood cells were performed by counting 200 nucleated cells from randomly selected 
fi elds.
Cholesterol and triglycerides were determined by enzymatic methods on a Hitachi 
747 analyser. Corticosterone concentrations in plasma were determined by a specifi c 
radioimmunoassay as described by Sweep et al [12]. 
Statistical analysis. 
The differences between groups were analyzed by Mann-Whitney U test. Data are 
expressed as mean ± SD.
RESULTS
Eﬀ ect of IL-18 and LPS on core body temperature of New-Zealand rabbits. 
As shown in Figure 1, LPS produced a biphasic raise in body temperature with a 
maximum of 1.2 ºC after 80 min and of 1.0 ºC after 3 h. The temperature returned 
to normal by 4h. In contrast, intravenously injection of rhIL-18 did not induce any 
signifi cant change in the body temperature.
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Eﬀ ect of IL-18 on leukocyte counts, cholesterol, triglycerides, and corticosterone in mice. 
White blood cell counts and serum concentrations of cholesterol, triglycerides and 
corticosterone were used as markers of the acute-phase response after IL-18 injec-
tion. At various time points, mice were killed and total white blood cell counts and 
acute phase proteins were measured. As shown is Table 1, most of these parameters 
were not infl uenced by injection of rmIL-18, with the exception of the white blood 
cell counts, which were lower compared to control 1 and 6 h after injection of rmIL-
18 (1 h, 7.8 ± 1.9 vs. 5.2 ± 1.1x 106 cells/ml: 6 h, 8.2 ± 0.6 vs. 4.6 ± 0.9x 106 cells/
ml, both P<0.05). No differences were observed in the percentages of neutrophils, 
lymphocytes or monocytes. Corticosterone levels were higher 3 h after injection of 
rmIL-18 (543 ± 54 vs. 915 ± 223 nmol/l, P<0.05). No signifi cant differences in serum 
concentrations of cholesterol and triglycerides were observed between mice injected 
with PBS or rmIL-18. Circulating concentrations of IL-6 were under the detection 
limit in both groups, despite IL-6 induction in vitro in peritoneal macrophages (data 
not shown).
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Figure 1. Eﬀ ect of IL-18 on the febrile response in rabbits. LPS (50 ng/kg) or recombinant human IL-18 (1 μg/kg) was injected intravenously 
into the rabbits (n=3 per group). The body temperature (in ºC measured by rectal thermometer) was measured continuously for 5 h. The arrow 
indicates the timepoint of the injection of LPS or IL-18.
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Table 1. Eﬀ ect of recombinant murine IL-18 on leukocyte counts, cholesterol, triglycerides, and corticosterone in mice at diﬀ erent time points
White blood cell count
(x106cells/ml)
Cholesterol (mmol/l) Triglycerides (mmol/l) Corticosterone (nmol/l)
Time Control rIL-18 Control rIL-18 Control rIL-18 Control rIL-18
0 7.6 ±1.4 7.6 ±1.4 1.7 ±0.4 1.7 ±0.4 0.74 ±0.07 0.74 ±0.07 408 ±75 408 ±75
30 min 7.0 ±2.4 7.7 ±3.3 1.5 ±0.3 1.7 ±0.2 0.85 ±0.13 0.76 ±0.03 895 ±49 c 810 ±76 c
1 h 7.8 ±1.9 5.2 ±1.1 b 1.7 ±0.1 1.7 ±0.2 0.90 ±0.13 0.94 ±0.24 795 ±67 c 830 ±73 c
2 h 5.4 ±0.4 7.6 ±0.7 1.7 ±0.1 1.6 ±0.1 0.69 ±0.11 0.65 ±0.10 930 ±91 c 858 ±72 c 
3 h 4.2 ±1.7 c 4.2 ±0.6 c 1.7 ±0.1 1.7 ±0.3 0.59 ±0.03 0.69 ±0.10 543 ±54 c 915 ±223 b/c
6 h 8.2 ±0.6 4.6 ±0.9 b/c 1.8 ±0.1 1.8 ±0.2 0.52 ±0.12 0.56 ±0.10 563 ±204 750 ±87 c
24 h 9.0±1.8 8.7 ±3.5 1.7 ±0.4 1.9 ±0 1.09 ±0.48 0.78 ±0.12 385 ±176 238 ±93 c
Mice were injected intravenously with recombinant murine IL-18 (1 μg/mouse). After diﬀ erent time points, mice were killed and blood was 
collected. Data represent the mean ± SD of 4 mice.
b P<0.05 vs. control; c P<0.05 vs. time 0.
DISCUSSION
We investigated the effect of IL-18 on the acute-phase response. Injection of recom-
binant IL-18 did not induce any of the components of the acute-phase response 
studied: rIL-18 did not cause fever when injected intravenously into rabbits; rIL-18 
did not induce leukocytosis, modifi cation of circulating concentrations of lipopro-
teins, or corticosterone in mice. Thus, IL-18 is not an endogenous pyrogen, and this 
notion is in agreement with previous studies, showing no changes in temperature in 
animals treated with intraperitonial IL-18 [13-15], despite the observation that intra-
cerebroventricular administration of IL-18 does increase brain temperature [14]. 
The lack of pyrogenic effects of IL-18 may be due to the fact that despite the many 
similarities between IL-18 and IL-1β, there are also fundamental differences between 
these two cytokines. In contrast to IL-1β, which is not expressed constitutively and is 
strongly induced by bacterial stimuli, constitutive levels of IL-18 mRNA and protein 
are present in unstimulated cells and in organs of untreated, healthy animals [16]. 
These levels become only marginally increased by exogenous stimulation. The lack 
a response at the level of hypothalamus to IL-18 may also be related to the consti-
tutive expression of IL-18 in the hypothalamus of rats with a normal temperature 
[17]. In the pathogenesis of fever, a central step is represented by the induction of 
prostaglandins by pyrogenic cytokines at the level of hypothalamus. Prostaglandins 
are considered the central mediators of fever. In line with the absence of pyrogenic 
activity, it has been recently shown that unlike IL-1β, IL-18 does not induce COX-2 
expression
 
in human mononuclear cells [18]. Moreover, IL-18 was able to suppress 
the induction of PGE
2
 production by IL-1 and this suppressive effect was partly 
mediated by IFN-γ [18]. The absence of COX-2 and the lack of a pyrogenic effect of 
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IL-18 may be explained by a recent study by Lee et al. [19] showing that IL-18 signal 
transduction in epithelial cells is primarily via the MAPK p38 pathway rather than 
NF-κB. 
The other aspects of the acute-phase response studied (leukocytosis, lipoprotein 
concentrations, and steroid levels) were not, or only marginally, infl uenced by in-
jection of rIL-18 in mice. IL-1 has multiple biological effects such as leukocytosis, 
increase in lipoprotein concentrations and corticosterone levels [8, 20]. Despite the 
many similarities between IL-1 and IL-18 systems, IL-18 had no effect on leukocytosis 
and did not increase lipoprotein concentrations after administration. In addition, only 
a minor effect on corticosterone levels was observed 3 h after injection of IL-18.
CONCLUSIONS
Data presented here show that rIL-18 has a very limited role on the acute-phase 
response; it is not able to induce a febrile response in rabbits, has no effects on 
leukocytosis and lipoproteins, and modulates lipoproteins only marginally during 
the acute-phase.
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ABSTRACT
Despite the importance of interferon (IFN)-γ, tumor necrosis factor (TNF), and in-
terleukin (IL)-18 for host defense against candidiasis, the pathways leading to their 
stimulation by Candida albicans are unclear. In a whole-blood model, IL-18 neu-
tralization by IL-18 binding protein decreased C. albicans-induced IFN-γ synthesis 
by 72%. Similarly, neutralization of IL-12 or IL-1β by either neutralizing antibodies 
or IL-1 receptor antagonist also reduced (by 65%) IFN-γ production. Neutralization 
of TNF by TNF binding proteins resulted in only a 36% reduction of IFN-γ synthesis. 
In contrast, production of TNF and IL-8 was largely unaffected by these cytokine 
inhibitors. Thus, C. albicans stimulates IFN-γ production in an IL-18-, IL-12-, and IL-
1β-dependent manner, whereas production of TNF and IL-8 is independent of these 
cytokines. Blocking the biologic activities of IL-18, IL-12, and IL-1β in patients (e.g., 
for treatment of autoimmune diseases) may result in increased susceptibility to C. 
albicans infection.
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INTRODUCTION
Infections caused by pathogenic fungi, especially Candida albicans, are being recog-
nized with increasing frequency in patients with a variety of underlying diseases [1]. 
Although new antifungal drugs have been developed, mortality due to disseminated 
candidiasis remains high, especially in immunocompromised hosts [2]. Therefore, a 
rational approach would be to develop therapeutic strategies aimed to augment and 
restore host defense mechanisms in these patients, in addition to administration of 
conventional antifungal therapy [3]. To achieve this, a better understanding of the 
existing intrinsic mechanisms responsible for the defense against invasive Candida 
infection is urgently needed.
The host response to C. albicans infection is a complex interplay between cellular 
and humoral immunity and usually provides a suffi cient defense against the microor-
ganism in the healthy host. Heat-killed C. albicans or mannoproteins derived from 
the yeast cell wall induce interferon (IFN)-γ production from human mononuclear 
cells [4, 5], and IFN-γ is a key cytokine for innate as well as acquired resistance to 
candidiasis [6]. In vitro studies have demonstrated stimulatory effects of IFN-γ on 
the phagocytosis and killing of C. albicans by neutrophils and macrophages [7, 8], 
and administration of IFN-γ to mice infected with C. albicans has had a benefi cial 
effect on the outcome of the infection [6]. The important role of endogenous IFN-γ 
in the resistance against both gastrointestinal and systemic candidiasis has also been 
demonstrated by the increased susceptibility of knockout mice, defi cient in IFN-γ or 
IFN-γ receptors, infected with the yeast [9-12]. In addition to IFN-γ, proinfl ammatory 
cytokines such as tumor necrosis factor (TNF) and interleukin (IL)-1 and chemokines 
such as IL-8 also play an important role in the host defense against C. albicans infec-
tion [7, 13, 14].
Despite its crucial importance for defense against candidiasis, little is known about 
regulation of IFN-γ after stimulation of leukocytes by C. albicans. An important step in 
the regulation of IFN-γ production is the synthesis of IL-12 after stimulation of mono-
cytes and macrophages by C. albicans [15]. However, although IL-12 is required for 
IFN-γ production and the development of a protective Th1 response during Candida 
infection [11], recent studies show that additional costimuli are needed for an effi cient 
synthesis of IFN-γ. IL-18 is a newly described cytokine that serves as a costimulus for 
IFN-γ production in the context of microbial stimulation [16-19] and that, unlike IL-12, 
is constitutively expressed in human cells [20]. When endogenous IL-18 is blocked 
by administration of neutralizing antibodies or IL-18 binding protein, there is little, 
if any, IFN-γ production, despite the presence of normal IL-12 concentrations [21]. 
These fi ndings have been confi rmed by studies of IL-18- or IL-1β converting enzyme 
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(ICE)-defi cient mice [22-24]. In addition, several studies report that IL-1β, although 
not able to induce IFN-γ production by itself, has an important costimulatory activ-
ity on the IL-12-mediated induction of IFN-γ by T lymphocytes [25-27] and NK cells 
[28]. Similarly, TNF is also a costimulus of IFN-γ production in the context of IL-12 
or bacterial stimulation [27, 29]. To our knowledge, the role of these cytokines in the 
regulation of IFN-γ synthesis by C. albicans remains unknown. 
In this study, we investigated how much of IFN-γ induction by C. albicans results 
from direct fungal stimulation, and we assessed the relative importance of indirect 
stimulation through endogenous IL-12, IL-18, IL-1β, and TNF in this process. Because 
both IL-18 and IL-1β are secreted as inactive precursors, which require cleavage by 
ICE to generate the mature active forms, we examined the effect of a specifi c inhibitor 
of this enzyme (caspase-1) to assess its contribution to their processing and subse-
quently to the Candida-induced production of IFN-γ. The role of specifi c cytokine in-
hibitors for the modulation of IFN-γ synthesis was assessed by the use of monoclonal 
antibodies (MAbs) and/or natural antagonists such as IL-18 binding protein (IL-18BP), 
IL-1 receptor antagonist (IL-1Ra) and TNF binding proteins (TNFbps). In addition, 
because each of these cytokines stimulates production of proinfl ammatory cytokines 
and thereby has potent infl ammatory properties, we also assessed their effects on 
TNF and IL-8 production induced by C. albicans. 
METHODS 
Volunteer selection. 
The study population comprised 9 healthy, nonsmoking men aged 23-45 years. The 
volunteers were free of infectious or infl ammatory disease and had abstained from 
cyclooxygenase inhibitors for 2 weeks before the study. Blood was collected by ve-
nipuncture into heparinized syringes (sodium heparin; fi nal concentration, 10 U/mL; 
Elkins-Sinn). 
Reagents. 
We purchased the reversible ICE inhibitor (ICEi) Ac-Tyr-Val-Ala-Asp-2,6-dimethylben-
zoyloxymethylketone (Alexis). The ICEi was reconstituted in 10 mM dimethyl sulfoxide 
(DMSO) and subsequently was diluted to the desired concentration in RPMI. Recombi-
nant IL-18BP (expressed in CHO cells with carboxyl his
6
) was produced as described 
elsewhere [30]. Recombinant human IL-1Ra was a gift of D. Tracey (Upjohn). Recom-
binant human TNFbp (4 domain p55 soluble TNF receptor) [31, 32] was provided by 
C. Edwards (Amgen). The mouse anti-human IL-12 MAb was purchased from R&D 
Systems. Mouse anti-human IL-1β MAb was provided by Cistron Biotechnology. An 
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irrelevant mouse anti-human IgG antibody was used as a control and did not infl uence 
cytokine release. RPMI culture medium (Gibco BRL) was supplemented with 10 mM 
L-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin (Gibco). 
C. albicans. 
C. albicans UC820, a clinical isolate that has been well described [33], was maintained 
on agar slants at 4°C. Earlier experiments showed that strain UC820 can develop hy-
phae and pseudohyphae in vitro and in vivo to the same extent as a panel of virulent 
control C. albicans. C. albicans UC820 was inoculated into 100 mL of Sabouraud 
broth and was cultured for 24 h at 37°C. After 3 washes with pyrogen-free saline by 
centrifugation at 1500 g, the number of yeast cells was counted in a hemocytometer; 
occasional strings of 2 yeasts were counted as 1 cfu of C. albicans. The suspension 
was diluted to the appropriate concentration with pyrogen-free saline. Microscopy 
confi rmed that the suspension consisted of blastoconidia. The blastoconidia were 
heat killed during 30 min at 100°C. 
Whole-blood cytokine culture. 
We added 0.5 mL of heparinized blood to 75 × 10-mm polypropylene tubes (Falcon). 
The cytokine inhibitors were added in various concentrations and mixed, and, after 
10 min, 0.5 mL of RPMI culture medium or heat-killed C. albicans blastoconidia (fi nal 
concentration, 107 organisms/mL) was added. This optimal concentration of C. albi-
cans for cytokine induction was chosen after a pilot experiment with dose-dependent 
C. albicans stimulation. Each sample was incubated in duplicate. After 24 or 48 h of 
stationary incubation at 37°C in the presence of 5% CO
2
, 0.5 mL of blood was mixed 
with Triton X-100 (1% fi nal concentration; Bio-Rad Laboratories) to disrupt cell mem-
branes and lyse all cells. Samples were kept at -70°C until cytokine measurement. 
Total cytokine concentrations were measured in the lysed blood samples treated with 
Triton X-100 [34]. In a pilot experiment, the effects of the various cytokine antagonists 
on spontaneous release of cytokines were tested. The spontaneous release of IFN-γ 
was below the detection limit in the majority of samples, and the cytokine inhibitors 
did not infl uence this process. Similarly, no effect of the cytokine antagonists on the 
spontaneous production of TNF or IL-8 was observed (data not shown). 
In a separate experiment, the differential effect of an ICE inhibitor on intracellular and 
extracellular IL-1β production was investigated. The intracellular IL-1β concentration 
was investigated by centrifuging the blood after stimulation with C. albicans for 24 h, 
discarding the supernatant (plasma), and adding an identical volume of RPMI medium 
on the cell pellet. After the tubes were vortexed, we added Triton X-100 and measured 
the intracellular cytokines in the cell lysates. The release of extracellular IL-1β was 
measured in the plasma separated from the cells during the fi rst step of the procedure. 
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Cytokine measurements. 
Human IFN-γ, TNF, and IL-8 concentrations were measured by electrochemilumines-
cence, as described elsewhere [34, 35]. IL-1β was measured by a commercial ELISA 
kit (Cistron) specifi c for mature IL-1β. The cross-reactivity of the ELISA with proIL-1β 
is <20%. We measured IL-12 p40 (both p40 and p40/35 complexes) concentrations by 
commercial ELISA (R&D Systems). 
Statistical analysis. 
Data are expressed as mean ± SE. Differences between groups were analyzed by 
Mann-Whitney U test, using the Bonferroni correction for multiple comparisons. 
RESULTS 
Inﬂ uence of ICE inhibition on C. albicans-stimulated cytokine production. 
We investigated the effects of a specifi c inhibitor of ICE (caspase-1) on the production 
of Candida-induced IL-1β and IFN-γ. Stimulation of blood with C. albicans induced 
synthesis of signifi cant amounts of IL-1β (2225 ± 514 pg/mL) and IFN-γ (3762 ± 1038 
pg/mL). The ICE inhibition dose dependently decreased C. albicans-stimulated pro-
duction of IFN-γ, up to a maximal inhibition of 63% (Fig. 1; P < .03). The addition 
of the ICE inhibitor to the whole-blood culture also signifi cantly reduced Candida-
induced secreted IL-1β (76% inhibition; P < .02) but not intracellular IL-1β (data not 
shown). The ICE inhibitor’s lack of effect on intracellular IL-1β also demonstrates 
the lack of cell toxicity of the minute amounts of DMSO present in the ICE inhibitor 
preparation, since toxicity would have released IL-1β from the cells, with subsequent 
depletion of IL-1β from the intracellular compartment.
Eﬀ ect of IL-18BP on C. albicans-induced IFN-γ production. 
Previous studies demonstrated that mature IL-18 is required for the lipopolysaccha-
ride (LPS)-induced production of IFN-γ, even in the presence of IL-12 [23, 24]. To 
investigate the role of endogenous IL-18 for the Candida-induced IFN-γ synthesis, 
increasing concentrations (7.8-500 ng/mL) of IL-18BP were added to the whole-blood 
cultures. IL-18BP reduced C. albicans-induced IFN-γ production in a dose-dependent 
manner (Fig. 2). IC
50
 of C. albicans-induced IFN-γ production was achieved by 125 
ng/mL of IL-18BP, which was therefore used (unless otherwise indicated) in addi-
tional experiments in which we studied the effects of IL-18BP and other cytokine 
inhibitors. Concentrations of IL-18BP >500 ng/mL did not further reduce IFN-γ pro-
duction (data not shown). 
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Role of endogenous IL-1β, IL-12, and TNF in Candida-induced IFN-γ production. 
Because IL-18BP was not able to block the induction of IFN-γ by C. albicans by 
>72% (see above), we assumed that other cytokines must be involved in this process. 
Recent studies suggest that IL-1, although not able to induce IFN-γ by itself, is an 
important costimulus of IFN-γ production [25-27]. As shown in fi gure 3A, when IL-1 
receptors were blocked by IL-1Ra (10 mg/mL), there was a signifi cant reduction in 
the stimulation of IFN-γ by C. albicans. IL-18BP and IL-1Ra had additive inhibitory 
Figure 1. Eﬀ ect of interleukin (IL)-1β converting enzyme (ICE) inhibitor on interferon (IFN)-γ production. Whole-blood was stimulated with 
heat-killed Candida albicans in the presence of increasing ICE inhibitor concentrations (in μM). IFN-γ level was measured 48 h later. Data are 
mean ± SEM (n = 5 healthy volunteer blood donors), expressed as percentage of baseline C. albicans-stimulated cytokine production (3762 ± 
1038 pg/mL of IFN-γ). *P < .05, Mann-Whitney U test.
Figure 2. Eﬀ ect of interleukin-18 binding protein (IL-18BP) on interferon (IFN)-γ production. Whole-blood was stimulated with heat-killed 
Candida albicans in the presence of increasing concentrations of IL-18BP (in ng/mL). IFN-γ level was measured 48 h later. Data are mean ± SEM 
(n = 5 healthy volunteer blood donors), expressed as percentage of the baseline C. albicans-stimulated IFN-γ production (3543 ± 729 pg/mL). *P 
< .05, Mann-Whitney U test.
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effects on IFN-γ production. To differentiate between the effects of endogenous IL-1α 
and IL-1β, we compared the inhibitory action of IL-1Ra with that of a MAb against 
human IL-1β on Candida-induced IFN-γ. IL-1Ra and the anti-IL-1β MAb were equally 
potent in inhibiting IFN-γ production induced by C. albicans (Fig. 3B), suggesting 
that blocking IL-1β and not IL-1α accounts for the ability of IL-1Ra to reduce Can-
dida-induced IFN-γ production.
Because the combination of IL-18BP and IL-1Ra was not able to completely block 
the induction of IFN-γ, we investigated the role of endogenous IL-12 and TNF in this 
process. Stimulation of blood with C. albicans induced 380 ± 103 pg/mL of IL-12. 
Anti-IL-12 antibodies signifi cantly inhibited (61% reduction of production) C. albi-
Figure 3. Eﬀ ect of endogenous interleukin (IL)-18 and IL-1β on interferon (IFN)-γ production. A, Whole-blood was stimulated with heat-killed 
Candida albicans in the presence of IL-18 binding protein (IL-18BP; 125 ng/mL) and/or IL-1 receptor antagonist (IL-1Ra; 10 μg/mL). IFN-γ 
was measured 48 h later. B, Diﬀ erential role of endogenous IL-1α and IL-1β, investigated by comparing the eﬀ ects of IL-1Ra (10 μg/mL) and 
anti-IL-1β monoclonal antibodies (aIL-1β; 1.25 μg/mL) on IFN-γ production induced by C. albicans. Data are mean ± SEM (n = 9 [A] or 5 [B] 
healthy volunteer blood donors), expressed as percentage of baseline C. albicans-stimulated IFN-γ production (3543 ± 729 pg/mL). *P < .05 vs. 
C. albicans production; #P < .05 vs. C. albicans + IL-18BP production, Mann-Whitney U test.
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cans-induced IFN-γ, and the effects of anti-IL-12 and IL-18BP were additive (Fig. 4A). 
A similar effect on IFN-γ, although less pronounced (36% inhibition), was found by 
blocking endogenous TNF by TNFbp (10 mg/mL; Fig. 4B). 
As shown above, endogenous IL-18, IL-1β, and IL-12 all appear to contribute to Candida-
induced IFN-γ. We next assessed whether IFN-γ production can be totally blocked by simul-
taneous inhibition of these 3 cytokines. The combination of IL-18BP, IL-1Ra, and anti-IL-12 
antibodies virtually abolished the production of IFN-γ induced by C. albicans (Fig. 5). 
Figure 4. Eﬀ ect of endogenous interleukin (IL)-18, IL-12, and tumor necrosis factor (TNF) on interferon (IFN)-γ production. Whole-blood was 
stimulated with heat-killed Candida albicans in the presence of IL-18 binding protein (IL-18BP; 125 ng/mL) and/or anti-IL-12 antibodies (aIL-12; 
2.5 mg/mL) (A) or in the presence of TNF-binding proteins (TNFbp; 10 mg/mL) (B). IFN-γ level was measured 48 h later. Data are mean ± SEM (n 
= 9 healthy volunteer blood donors), expressed as percentage of baseline C. albicans-stimulated IFN-γ production (3543 ± 729 pg/mL). *P < .05 
vs. C. albicans production; #P < .01 vs. C. albicans + IL-18BP production, Mann-Whitney U test.
Figure 5. Maximal inhibition of interferon (IFN)-γ production. Whole-blood was stimulated with heat-killed Candida albicans in the presence 
of interleukin-18 binding protein (IL-18BP; 500 ng/mL), IL-1 receptor antagonist (IL-1Ra; 10 mg/mL), anti-IL-12 (aIL-12; 5 mg/mL), or a 
combination of all 3 cytokine inhibitors (Max inh). IFN-γ was measured 48 h later. Data are mean ± SEM (n = 4 healthy volunteer blood donors), 
expressed as percentage of baseline C. albicans-stimulated IFN-γ production. *P < .05 vs. C. albicans production; #P < .01 vs. stimulation by C. 
albicans, together with a single cytokine inhibitor; +P < .05 vs. unstimulated cells, Mann-Whitney U test.   
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Eﬀ ect of cytokine inhibitors on C. albicans-induced production of TNF and IL-8. 
C. albicans induces production of the proinfl ammatory cytokine TNF (2532 ± 611 
pg/mL) and of the chemokine IL-8 (112,005 ± 23,488 pg/mL) [5], which also play im-
portant roles in the defense against Candida infection [14, 36]. Therefore, we inves-
tigated the modulation of C. albicans-induced TNF and IL-8 in whole-blood cultures. 
No effect of IL-18BP, IL-1Ra, or anti-IL-12 antibodies on the Candida-induced TNF 
was observed, with the exception of a marginal inhibitory effect of IL-1Ra on TNF 
production (Fig. 6). Similarly, IL-8 production was not infl uenced by IL-18BP, IL-1Ra, 
anti-IL-12 antibodies or TNFbp (not shown). 
DISCUSSION 
In this study, we investigated the mechanisms by which C. albicans induces produc-
tion of IFN-γ in whole-blood cultures. The observation that a specifi c ICE inhibitor 
reduced the synthesis of IFN-γ demonstrates the importance of IL-18 and IL-1β in this 
process. Inhibition of IL-18 by its natural antagonist IL-18BP signifi cantly inhibited up 
to 72% of the production of IFN-γ stimulated by C. albicans. This shows the central 
role played by IL-18 for Candida-induced IFN-γ, IL-1β, IL-12, and TNF are additional 
endogenous costimuli of IFN-γ production. In contrast, induction of TNF and IL-8 by 
C. albicans is largely independent of secretion of these intermediary mediators. 
The pivotal role of endogenous IL-18 for the induction of IFN-γ by C. albicans is 
not surprising, given that absence of mature IL-18 in ICE-defi cient mice has been ac-
companied by severely impaired IFN-γ production after LPS stimulation, despite the 
presence of expected IL-12 concentrations [23, 24]. The central role of IL-18 for IFN-γ 
Figure 6. Eﬀ ect of cytokine inhibitors on tumor necrosis factor (TNF) production. Whole-blood was stimulated with heat-killed Candida albicans 
in the presence of interleukin-18 binding protein (IL-18BP; 125 ng/mL), IL-1 receptor antagonist (IL-1Ra; 10 mg/mL), or anti-IL-12 (aIL-12; 5 
mg/mL). TNF level was measured 24 h later. Data are mean ± SEM (n = 9 healthy volunteer blood donors), expressed as percentage of baseline C. 
albicans-stimulated TNF production (2532 ± 611 pg/mL). *P < .05, Mann-Whitney U test.
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synthesis is reinforced by data showing that IL-12 induction of IFN-γ is dependent on 
caspase-1 processing of the IL-18 precursor [37]. These fi ndings were confi rmed by 
experiments using IL-18-defi cient mice [22]. The blockade of IFN-γ production when 
IL-18BP was added to whole-blood cultures underscores the important potential role 
of this natural antagonist of IL-18 in the inhibition of the Th1 response stimulated by 
C. albicans [21]. 
The importance of IL-12 for the stimulation of IFN-γ and the development of a 
Th1 response is well described. C. albicans stimulates production of IL-12 in vitro 
[38], and IL-12 has a central role in the defense against systemic candidiasis [11, 15]. 
Stimulation of whole blood with C. albicans resulted in the production of IL-12, and 
blockade of endogenous IL-12 with MAbs led to decreased production of IFN-γ. This 
demonstrates an important role of endogenous IL-12 during the induction of IFN-γ 
by Candida. The synergy of IL-12 and IL-18 for IFN-γ production is partly due to up-
regulation by IL-12 of the α and βchains of the IL-18 receptor [39]. Others have shown 
that induction of CD40 expression and CD40/CD40L interactions are central for the 
stimulation of IL-12 by C. albicans [38]. 
An important observation is that blocking the action of endogenous IL-1 by either 
IL-1Ra or anti-IL-1β antibodies also reduced the stimulation of IFN-γ by C. albicans. 
IL-1 is a proinfl ammatory cytokine that has costimulatory effects on IFN-γ production 
[26, 27, 40]. The equal capacity of IL-1Ra and anti-IL-1β antibodies to inhibit IFN-γ 
suggests that IL-1β and not IL-1α plays a role in the induction of Candida-stimulated 
IFN-γ. Although IL-1β by itself cannot stimulate production of IFN-γ, recent data 
indicate that addition of IL-1β to IL-12 potentates the induction of IFN-γ [26, 27, 40]. 
The only data suggesting an IFN-γ-stimulating effect of IL-1α were obtained in murine 
cells [28], whereas IL-1β potentiates IFN-γ production by human cells [26].
Our data are supported by those of Hunter et al. [25], who reported inhibition of 
IFN-γ by anti-IL-1β antibodies when stimulation was induced by bacterial stimuli 
such as LPS, heat-killed Toxoplasma gondii, Salmonella typhimurium, Legionella 
pneumophila, and Yersinia pseudotuberculosis. In contrast, others were unable to 
fi nd an effect of anti-IL-1β antibodies when IFN-γ production was induced by Listeria 
monocytogenes [41] or heat-killed Staphylococcus epidermidis (R.J.L. Stuyt, unpu-
blished data). It is, therefore, likely that IL-1β plays an important costimulatory role 
for IFN-γ induction by some, although not all, microbial stimuli. In this respect, IL-1β 
acts similarly to IL-18, which may be explained by the similarities in the structure 
of their receptor complexes, which consist of a binding chain (IL-1R type 1 and IL-
18Rα) and a signaling chain (IL-1R accessory protein and IL-18Rβ, respectively) [42]. 
Both signaling chains contain the TLR/IL-1 receptor domain, which stimulates similar 
intracellular pathways [43, 44]. 
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Despite the important roles played by endogenous IL-18, IL-12, and IL-1β for the 
induction of IFN-γ after C. albicans stimulation, some stimulation of IFN-γ synthesis 
by C. albicans (independent of intermediary endogenous cytokines) is still present 
after simultaneous blockade with IL-18BP, IL-1Ra, and anti-IL-12 antibodies. Several 
mechanisms may explain this phenomenon. 
First, TNF can act as a stimulus of IFN-γ production [45], and TNFbp partially inhi-
bited Candida induction of IFN-γ. However, this inhibition was less effective than 
that provided by blockade of IL-18, IL-12, and IL-1β. Because TNF induces IL-1β, and 
IL-1β, but not TNF, can reconstitute IL-12 induced IFN-γ production in the presence 
of IL-10 [27], it has been suggested that, in addition to its direct effect, TNF may 
stimulate IFN-γ synthesis through intermediary induction of endogenous IL-1β [27]. 
Second, other cytokines (e.g., IL-15 or perhaps the IL-12-like cytokine IL-23) could 
play a mediator role, since both have costimulatory effects on IFN-γ synthesis [46, 
47]. The synergy of IL-15 with IL-12 for the induction of IFN-γ has been proposed to 
be due to increased expression of either IL-12Rβ1 or CD40 by IL-15 [48]. Therefore, 
it is possible that IL-15 plays a role in the induction of IFN-γ by C. albicans. Third, 
an additional mechanism circumventing the need for macrophage-derived costimula-
tory cytokines for IFN-γ stimulation is the possibility that C. albicans may directly 
stimulate lymphocytes and NK cells to synthesize IFN-γ via a non-major histocompat-
ibility complex (MHC)-dependent pathway [4]. A candidate C. albicans receptor on 
lymphocytes is CD11β/CD18 [49]. 
In addition to the role of endogenous cytokines in IFN-γ stimulation, we investigat-
ed the regulation of TNF and IL-8 during stimulation of whole blood with C. albicans, 
since these cytokines are important in the recruitment of neutrophils and monocytes, 
as well as in phagocytosis and killing of Candida during infection [7, 14]. In contrast 
to IFN-γ, induction of IL-8 was found to be independent of intermediary production 
of endogenous IL-18, IL-12, IL-1, and TNF. A marginal inhibition of Candida-induced 
TNF was exerted by IL-1Ra, which is in accordance with the stimulatory effects of 
IL-1 on TNF production [50]. TNF synthesis induced by Candida was independent of 
endogenous IL-18 and IL-12. 
The use of whole-blood cultures to study C. albicans-induced cytokine production 
has important advantages, because the culture conditions most closely recreate the 
in vivo situation. In this system, cell populations that are important for the defense 
against Candida organisms (e.g., neutrophils, monocytes, and lymphocytes, along 
with complement, antibodies, and other serum factors) can interact with each other 
and with the fungus. It has been proposed that initial phagocytosis of C. albicans by 
blood monocytes and neutrophils induces synthesis of proinfl ammatory cytokines 
such as IL-18, IL-12, and IL-1β, which, in turn, are able to stimulate IFN-γ synthesis 
from T lymphocytes. Additional signals may be given by TNF, which can stimulate 
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IL-1β synthesis, and by IL-15 and IL-23, which act as an additional IFN-γ costimuli 
[46-48]. 
The theoretical and practical consequences of our fi ndings may be important, since 
IFN-γ is a cytokine important for defense against invasive candidiasis. IFN-γ induces 
reactive oxygen intermediates [51], increases the candidicidal properties of granulo-
cytes [7], and potentiates the extracellular killing of candidal hyphae [52]. In addition, 
IFN-γ has a role in macrophage activation by induction of reactive nitrogen intermedi-
ates [53], enhancement of expression of MHC class II molecules [54] and Fc receptors 
[55], and enhancement of cytotoxicity [56]. Mice lacking IFN-γ or IFN-γ-R are more 
susceptible to both gastrointestinal and systemic candidiasis [9-12]. 
Recent studies demonstrate the central role played by proinfl ammatory cytokines 
such as TNF, IL-1β, and IL-18 for the pathogenesis of autoimmune diseases such as 
rheumatoid arthritis [57, 58] or Crohn’s disease [59, 60]. Large clinical trials show that 
blocking TNF and/or IL-1 is an effective therapeutic strategy in these diseases [61], 
and experimental data suggest benefi cial effects of IL-18 blockade [62, 63]. However, 
experimental data suggest that TNF, IL-18, and IL-1β are important for the defense 
against both bacterial [64, 65] and fungal [66] infections, including invasive candidiasis 
[67], and disseminated candidiasis has emerged as a rare, yet severe, complication of 
anti-TNF therapy [68]. Therefore, the possibility of the occurrence of fungal infections 
should be considered during anticytokine therapy. 
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ABSTRACT
In mice injected intravenously with Candida albicans, administration of anti-in-
terleukin-18 (IL-18) antibodies increased the yeast load in the kidneys. There was 
no effect on the organ load with Candida when gamma interferon (IFN-γ)-defi cient 
mice were treated with anti-IL-18 antibodies, suggesting that the protective effect of 
IL-18 is mediated through endogenous IFN-γ.
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Candida albicans or mannoproteins derived from the yeast cell wall induce gamma 
interferon (IFN-γ) production by human mononuclear cells, and IFN-γ is a key cy-
tokine for defense against candidiasis [1]. The important role of endogenous IFN-γ 
in the resistance to systemic candidiasis has been demonstrated in knock-out mice 
defi cient in IFN-γ, which are highly susceptible to C. albicans infection [2]. Moreover, 
administration of recombinant IFN-γ to wild-type mice infected with C. albicans im-
proves the outcome of the infection [1]. Interleukin-18 (IL-18) serves as a costimulus 
for IFN-γ production in the context of costimulation with microbial products [3]. 
When endogenous IL-18 is neutralized by administration of antibodies to IL-18 [4], 
there is little, if any, IFN-γ production after challenge with endotoxin. These data 
have led to the hypothesis that IL-18 is important for the host defense against dis-
seminated candidiasis.
The aim of the present study was to investigate whether endogenous IL-18 is in-
volved in host defense against Candida infection. IL-18 bioactivity was blocked 
by neutralizing anti-mouse IL-18 antibodies. In addition, we assessed whether the 
effects of IL-18 during disseminated candidiasis are mediated through production of 
IFN-γ, by studying IFN-γ-defi cient mice with disseminated candidiasis treated with 
anti-IL-18 antibodies. The role of tumor necrosis factor (TNF) in the subsequent IL-18 
synthesis was investigated with mice defi cient in TNF and lymphotoxin (LT).
CBA mice (females, 20 to 25 g, 6 to 8 weeks old) were purchased from Jackson 
Laboratories (Bar Harbor, ME). IFN-γ-/- mice and their wild-type littermates (Balb/c 
genetic background) were generously provided by Organon (Oss, The Netherlands). 
Homozygous TNF-/-LT-/- and wild-type TNF+/+LT+/+ mice (genetic background 
C57Bl/6J - 129sv) were obtained as mating pairs (kindly provided by Dr. F. Amiot, 
CEA, Fontenay-aux-Roses). Anti-mouse IL-18 polyclonal antibodies were produced 
in rabbits using recombinant mature murine IL-18 (Peprotech, Rocky Hill, NJ) [4]. 
Normal rabbit serum (NRS) was used in the control groups.
The mice were injected intravenously (i.v.) with C. albicans (strain UC 820, 1x105 
colony forming units (CFU)/mouse). EDTA-blood was collected from retroorbital 
plexus for plasma IL-18 concentration measurements at various time points: 1, 2, 4, 
8, 24, 48, and 72h after infection. Animals received either 200 μl of anti-IL-18 antise-
rum i.v. 10 minutes before infection, and on day 2 and 4 after infection, or a similar 
volume of NRS. Subgroups of 10 animals were killed on days 1, 3 or 7 of infection. 
The number of viable Candida cells in the kidneys was determined as previously 
described [5] and expressed as log CFU per gram tissue. 
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IL-18 concentrations were determined by electrochemiluminescence, using a bioti-
nylated rat anti-mouse IL-18 antibody (Igen, Gaithersburg, MD) and a ruthenilated 
goat anti-mouse antibody (Peprotech, Princeton, NJ). The reaction was quantitated 
using the Origen 1.5 Analyzer (Igen) [6]. IL-1β and TNF-α levels were determined 
by specifi c radioimmunoassays [7]. Murine IL-6 and IFN-γ concentrations were mea-
sured using commercial ELISA kits (Pelikine, CLB, Amsterdam, The Netherlands). 
Detection limits were 20 pg/ml (TNF, IL-1α, IL-1β and IL-6) and 40 pg/ml (IL-18 and 
IFN-γ). The differences between groups were analyzed by Mann-Whitney U test.
IL-18 concentrations were below detection limit (40 pg/ml) in both uninfected 
TNF+/+LT+/+ and TNF-/-LT-/- mice. Intravenous administration of C. albicans to 
TNF+/+LT+/+ mice induced circulating IL-18 concentrations, which reached peak 
elevations at 8h postinfection (279 ± 144 pg/ml) (Fig.1). In Candida-infected TNF+/
+LT+/+ mice, the circulating IL-18 concentrations were signifi cantly higher at 2, 4, 
8 and 24h post-infection compared to uninfected mice. Similar IL-18 concentrations 
were measured in CBA mice and IFN-γ+/+ Balb/c mice (not shown). TNF and/or LT 
was required for the induction of IL-18, since the peak of circulating IL-18 levels was 
absent in TNF-/-LT-/- mice (Fig.1). In TNF-/-LT-/- mice the IL-18 concentrations were 
slightly increased above background levels of uninfected mice at 24h after infection 
(98 ± 11 pg/ml), similar to the increase in TNF+/+LT+/+ mice. These fi ndings are in 
line with data showing that neutralization of endogenous TNF and LT using soluble 
TNFp55 receptors reduced circulating IL-18 following i.v treatment with conA [8].
Figure 1. Circulating IL-18 during disseminated candidiasis. Groups of 10 TNF+/+LT+/+ and TNF-/-LT-/- mice were injected i.v. with 1x105 C. 
albicans CFU. IL-18 concentrations in the serum of TNF+/+LT+/+ (closed circles) and TNF-/-LT-/- (open triangles) mice were measured by ECL at 
various time points after infection (the experiment was performed twice, with a total of 10 animals per time point). *p<0.05
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The role of endogenous IL-18 for the defense against C. albicans infection was investi-
gated by administering neutralizing anti-IL-18 antibodies to the mice prior to infection. 
C. albicans CFU in the kidneys decreased tenfold within 7 days of infection in mice 
injected with NRS, whereas neutralization of IL-18 by anti-IL-18 antibodies prevented 
the elimination of the microorganisms (Fig. 2). Circulating concentrations of IL-1α and 
IL-6 on days 1 and 3 of infection were not infl uenced by administration of anti-IL-18 
antibodies. However, the increased outgrowth of Candida in the organs of the anti-
IL-18-treated mice on day 7 was accompanied by higher circulating concentrations of 
IL-1α and IL-6 compared to NRS-treated mice (Fig. 3). TNF, IL-1β and IFN-γ concentra-
tions were below detection limit in all samples on days 1, 3, and 7 after infection.
These data imply an important role of endogenous IL-18 in the defense against dis-
seminated candidiasis, and such fi ndings are supported by other studies showing that 
IL-18 is essential for host defense against mycobacterial infections [9], Cryptococcus 
neoformans [10], Leishmania major [11], and Salmonella infections [12]. In a recent 
study, it has been shown that recombinant IL-18 restores the Th1-response to C. albi-
cans in caspase-1 defi cient mice, which are unable to process the inactive precursors in 
bioactive IL-18 and IL-1β [13]. Promising therapeutic properties of IL-18 in experimental 
infections with C. neoformans [14] or Leishmania spp. [11] have also been suggested.
To investigate whether the effect of IL-18 is mediated through endogenous IFN-γ, 
neutralizing anti-IL-18 antibodies were given to mice defi cient in IFN-γ before infec-
tion with C. albicans. In contrast to the effects in wild-type mice (Fig.2), there was 
Figure 2. The role of endogenous IL-18 in the defense against disseminated candidiasis. CBA mice received 200 μl of either normal rabbit 
serum (NRS) (closed circles) or anti-IL-18 antiserum (open triangles), and were thereafter injected i.v. with 1x105 C. albicans CFU. Outgrowth of 
the microorganism in the kidneys was assessed on day 1, 3, and 7 after infection in groups of 10 animals. *p<0.05
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no effect of anti-IL-18 antibodies on Candida outgrowth in the kidneys of IFN-γ-/- 
mice (94% compared to the outgrowth in IFN-γ−defi cient mice treated with NRS, 
p>0.05), demonstrating that the effects of endogenous IL-18 during disseminated 
candidiasis are mediated by IFN-γ. These fi ndings are consistent with previous data 
demonstrating the importance of IFN-γ for the protective effects of IL-18 during 
infection with C. neoformans [14] or Salmonella enterica serovar Typhimurium [12]. 
The fi nding that IL-18 has a relatively late effect, on day 7 of infection, is consistent 
with IFN-γ-mediated stimulation of macrophages, which is known to occur at least 7 
days after infection, as has been shown previously in IFN-γ-/- mice [2], whereas no 
effect of the anti-IL-18 antibodies was found during the fi rst phase of infection, when 
neutrophil-mediated mechanisms are more important [2]. However, since IFN-γ-/- 
mice are highly susceptible to disseminated candidiasis, it is possible that an additive 
effect of IL-18 on the anti-Candida defense through IFN-γ-independent mechanisms 
is diffi cult to substantiate in these mice. IFN-γ-independent effects of IL-18 have been 
described in lethal endotoxemia and experimental models of streptococcal cell wall 
arthritis [15, 16].
In conclusion, endogenous IL-18 plays a protective role in the defense against dis-
seminated infection with Candida albicans. The production of IL-18 during dissemi-
nated candidiasis requires endogenous TNF and/or LT, and its protective effects are 
likely mediated through intermediary stimulation of endogenous IFN-γ synthesis.
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Figure 3. Cytokine concentrations during disseminated candidiasis. CBA mice received 200 μl of either normal rabbit serum (NRS) (open 
bars) or anti-IL-18 antiserum (closed bars), and were thereafter injected i.v. with 1x105 C. albicans CFU. IL-1α (A) and IL-6 (B) circulating 
concentrations were measured on day 1, 3, and 7 after infection in subgroups of 10 animals. *p<0.05
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ABSTRACT
Endogenous interleukin (IL)-18 is necessary for host defense against candidiasis. 
Prophylactic treatment of Candida albicans-infected mice with recombinant (r) IL-18 
decreased mortality, which was accompanied by a decreased outgrowth of yeasts in 
the kidneys 1 day after infection. Therapeutic administration of rIL-18 also resulted 
in a decreased outgrowth of C. albicans in the kidneys and increased levels of 
interferon-γ, both in the circulation and after in vitro stimulation of splenocytes with 
C. albicans. Histopathologic analysis of the kidneys showed increased infl ammation 
and decreased growth of Candida in the rIL-18-treated mice. In conclusion, rIL-18 
improves outcome of disseminated candidiasis in mice and may prove useful as 
adjuvant immunotherapy of fungal infections.
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INTRODUCTION
Despite the development of new antifungal drugs, mortality associated with dissemi-
nated candidiasis remains high. Cell-mediated immunity is essential for a proper host 
defense against C. albicans infections; therefore, the development of immunotherapy 
aimed to enhance the anticandidal actions of the immune system would be of great 
value. The role of interferon (IFN)-γ in the resistance against systemic candidiasis has 
been demonstrated by the benefi cial effect of recombinant IFN-γ on the outcome in 
mice [1]. Knockout mice defi cient in IFN-γ show increased susceptibility to dissemi-
nated candidiasis. Interleukin (IL)-18 is a cytokine initially described as a stimulus 
for IFN-γ production in the presence of costimulation with IL-12, IL-15, or microbial 
products [2]. Recent studies have suggested that endogenous IL-18 may play a role 
during C. albicans infection [3-5]. In the present study, we have studied the potential 
protective effect of recombinant murine (r) IL-18 on experimental disseminated C. 
albicans infection in mice.
MATERIALS AND METHODS
Female CBA/J mice (20-25 g; aged 6-8 weeks) were purchased from Janvier (Le 
Genest St. Isle, France). Recombinant murine IL-18 was kindly provided by Dr. M. 
Kurimoto (Fujisaki Institute, Hayashibara Biochemical Labatories, Okayama, Japan). 
Mice were injected intravenously (i.v.) with C. albicans (strain UC820; 105 CFU/
mouse). rIL-18 (1 μg/mouse) was injected intraperitonially (i.p.) in 100 μl of sterile 
pyrogen-free PBS at various time points. Control mice were injected i.p. with 100 μl 
of sterile pyrogen-free PBS. Survival was assessed daily for 30 days in groups of at 
least 10 mice/group. In addition, subgroups of 5 mice were killed on various days 
after infection, and blood samples were collected on EDTA for measurement of 
plasma cytokine concentrations. The number of viable Candida cells in the tissues 
was determined, as previously described [6], and expressed as log colony-forming 
units per gram of tissue. From the same mice, the right kidney was fi xed in formalin 
(4%) and embedded in paraffi n, and serial sections were examined microscopically 
after staining with hematoxylin-eosin. 
For stimulation of splenic lymphocytes, spleen cells were obtained by gently 
squeezing spleens in a sterile 200 µm fi lter chamber. Microscopic examination of 
Giemsa-stained cytospin preparations showed that splenocytes consisted for 95 % of 
lymphocytes, 2 % monocytes and 3 % granulocytes. Splenocytes were washed and 
resuspended in RPMI-1640 medium and counted in a Bürker counting chamber, and 
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the number was adjusted to 1 x 107/ml. One-half milliliter of the cell suspension 
was stimulated with 1 x 107/ml heat-killed Candida albicans UC820 blastoconidia 
(effect-to-target ratio, 2:1) in 24-well plates (Costar, Corning Inc., Corning, NY). Mea-
surement of IFN-γ and IL-10 concentrations was performed in supernatants collected 
after 48h of incubation at 37°C in 5 % CO
2
. IL-1α, IL-1β, and tumor necrosis factor 
(TNF)-α were determined by specifi c RIAs, as previously described [7]. IL-6, IFN-
γ, and IL-10 concentrations were measured by commercial ELISA kits (Biosource, 
Camarillo, CA). The differences between groups were analyzed by Mann-Whitney U 
test. Survival curves were analyzed by Kaplan-Meyer log rank test. All experiments 
were performed at least twice, and the data reported represent cumulative results 
from all experiments performed.
RESULTS 
Prophylactic administration of rIL-18 (1 μg) one day before i.v. infection with 1x105 
CFU of C. albicans signifi cantly increased survival time in C. albicans-infected mice, 
compared with that in control mice (30-day survival, 20% vs. 0%, P<0.01; Fig.1A). 
On day 1 after infection, C. albicans colony-forming units in the kidney (Fig 
1B) and the spleen (3.49 ± 0.44 vs. 3.92 ± 0.15 log CFU/gram, respectively) were 
signifi cantly reduced in mice that had received a single i.p. injection of rIL-18 1 day 
before infection (P<0.05). On days 3 and 7 after infection, the outgrowth of Candida 
in the kidneys tended to be lower in the IL-18-treated mice, but the difference was 
not statistically signifi cant. A similar trend also was observed for rIL-18-treated mice 
versus control mice in the spleen (day 3: 3.02 ± 0.25 vs. 3.12 ± 0.41 log cfu/g) and 
the liver (days 1 and 3: day 1, 3.69 ± 0.36 vs. 3.92 ± 0.19 log cfu; day 3, 2.80 ± 0.19 
vs. 2.98 ± 0.25 log cfu/g) (P>0.05).
On day 1 after infection, concentrations of IL-6 in the circulation of C. albicans-
infected mice that had received a single dose of rIL-18 a day before infection were 
lower than those in control mice (460 ± 224 vs. 778 ± 374 pg/mL, respectively, 
P<0.05), whereas circulating concentrations of IFN-γ were higher in rIL-18-treated 
mice (3.9 ± 2.9 vs. 1.6 ± 1.4 pg/mL, respectively, P<0.01). No differences in concen-
trations of IL-6 were observed on days 3 and 7 after infection. Plasma concentrations 
of IFN-γ were undetectable on these days. Plasma concentrations of IL-1α, IL-1β, and 
TNF-α were below the detection limit at all time points.
Late administration of 1 μg of rIL-18 on days 5 and 7 after i.v. injection with 1x105 
CFU of C. albicans signifi cantly increased survival of mice (30 day survival, 50% vs. 
20%, P<0.05; Fig 1C). On day 7 after infection, a signifi cantly lower count of colony-
forming units of C. albicans was observed in the kidneys of rIL-18-treated mice, 
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Figure 1. Eﬀ ect of early and late treatment with recombinant murine interleukin (rIL)-18 on survival and outgrowth of Candida albicans-
infected mice. Mice were injected with 1 μg of rIL-18 or PBS i.p. either 1 day before (A, B) or on days 5 and 7 after (C, D) i.v injection of 1 x 105 
cfu of Candida albicans. Diﬀ erence in survival between rIL-18 () and control () groups (20 mice/group) was signiﬁ cant (Panel A, P<.01; 
Panel C, P<.05; Kaplan-Meier log-rank test). Outgrowth of C. albicans was assessed on various days of infection (B, D) in rIL-18-treated (black 
columns) or control mice (white columns). Columns represent mean ± SD of 10 mice. Diﬀ erences between IL-18-treated and control mice are 
indicated (*, P<.05; **, P<.001).
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compared to control mice (P<0.001). This effect was not sustained on day 9 after 
infection (Fig. 1D). The decreased outgrowth in the kidneys on day 7 was associated 
with increased concentrations of IFN-γ in mice that had received rIL-18 on days 5 
and 7 after infection (11 ± 6.6 pg/mL vs. undetectable levels, P<0.05). No differences 
in IL-6 concentrations were observed.
The production of IFN-γ and IL-10 by splenocytes in mice that had received rIL-18 
on day 5 and 7 of infection was signifi cantly greater than that of cells of control 
mice (IFN-γ: 149 ± 54 vs. 37 ± 24 pg/mL; P<0.01 and IL-10: 258 ± 123 vs. 42 ± 31 
pg/mL; P<0.05). IFN-γ and IL-10 levels were undetectable in control splenocytes not 
stimulated with C. albicans.
In control mice, i.v. injection of 1x105 CFU of C. albicans led to invasion of the 
kidneys, accompanied by hyphal transformation, with few infl ammatory cells (Fig. 
2A). In contrast, histopathologic analysis of the kidneys of mice treated with rIL-18 
on day 5 and 7 of C. albicans infection showed large infi ltrates of neutrophils and 
macrophages, with almost no growth of candidal hyphae and blastospores on day 
7 of infection (Fig. 2B). Therefore, it appears that the stronger infl ammatory reac-
tion induced by rIL-18 led to a more effective clearance of C. albicans from the 
kidneys. 
Figure 2. Histopathologic analysis of the kidneys of Candida albicans-infected mice. In control animals, i.v. injection of 1x105 CFU of C. albicans 
led to invasion of the kidneys, which was accompanied by hyphal transformation, with few inﬂ ammatory cells (A). Kidneys of recombinant 
murine interleukin (rIL)-18-treated mice on days 5 and 7 after C. albicans infection showed large inﬁ ltrates of neutrophils and macrophages, 
with almost no growth of candidal hyphae and blastospores on day 7 after infection (B). Hematoxylin-eosin stain (original magniﬁ cation, × 
400).
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DISCUSSION 
In the present study, we have shown that recombinant IL-18 protects against dis-
seminated C. albicans infection in mice. Protection against disseminated C. albicans 
infection led to a decreased outgrowth of the yeast in the kidneys of IL-18-treated 
mice after either early or late administration of rIL-18. Improvement in outcome was 
associated with higher concentrations of IFN-γ, both in the circulation and after in 
vitro stimulation of splenocytes with C. albicans. Histopathologic analysis of rIL-
18-treated mice with showed large infi ltrates of neutrophils and macrophages with 
few candidal blastospores present, which suggests that the stronger infl ammatory 
reaction led to a more effective control of the yeast growth.
The importance of IL-18 for the induction of IFN-γ production has been shown in 
in vivo and in vitro studies in various models. In a previous study, we have shown 
that endogenous IL-18 is important for anticandidal defense, because there was an 
increased outgrowth of C. albicans in the organs of anti-IL-18 treated mice on day 7. 
This effect was mediated by IFN-γ, as no effect of anti-IL-18-antibodies on candidal 
outgrowth was apparent in IFN-γ-defi cient mice [4]. Recently, it has been shown 
that rIL-18 restores the Th-1 mediated resistance to C. albicans infection in caspase 
1-defi cient mice [3], and our fi ndings are similar to those of a previous study that 
demonstrated a benefi cial effect of rIL-18 on experimental cryptococcal infection 
[8]. In vitro studies have shown a crucial role of endogenous IL-18 in C. albicans-
induced IFN-γ production [9]. The increased production of IFN-γ observed in the 
present study after administration of rIL-18 suggests that rIL-18 exerts its effects on C. 
albicans infection mainly through IFN-γ, which is known to be crucial for the early, 
innate host defense against candidiasis. rIL-18 not only stimulated the production of 
IFN-γ by lymphocytes but also led to enhanced production of IL-10. It appears that 
the functional consequences of increased IFN-γ production are overriding the higher 
IL-10 levels.
Neutrophils and macrophages are responsible for the host defense against invasive 
C. albicans infection [10]. Incubation of murine peritoneal phagocytes with rIL-18 
led to an enhanced intracellular killing of candidal blastospores by macrophages, but 
not granulocytes (data not shown). This is in agreement with earlier observations 
that IL-18 not only induces IFN-γ production by macrophages but also stimulates 
nitric oxide synthase and CD40 expression in these cells [11]. Of importance, the 
benefi cial effect of rIL-18 on fungal outgrowth was short-lived, and the reduction 
of organ burden was not sustained after discontinuation of rIL-18 administration, 
despite the observed survival benefi t.
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The proinfl ammatory properties of IL-18 may exert direct, IFN-γ independent, pro-
tective effects on systemic candidiasis. IL-18 is able to induce the release of pro-
infl ammatory cytokines and to up-regulate expression of the adhesion molecule 
intracellular adhesion molecule-1 [12]. TNF-α and IL-1 contribute to host resistance 
against C. albicans infection [13-15]. In the present study, IL-1 and TNF-α were 
undetectable in the circulation, suggesting that their production was restricted to the 
infected tissue. In contrast, the concentration of IL-6, an anti-infl ammatory cytokine 
known to be inhibited by IFN-γ, was signifi cantly lower on day 1 after infection in 
rIL-18-treated mice. 
In conclusion, recombinant IL-18, administered either early or late during infection, 
improves the outcome of disseminated C. albicans infection in mice, which is ac-
companied by decreased outgrowth of the yeast in the kidneys, which is probably 
mediated by IFN-γ.
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In this thesis, we present investigations dealing with the role of interleukin-18 (IL-
18) in the activation of the cytokine network, the direct proinfl ammatory properties 
of IL-18, and the role of IL-18 in severe infections by using various experimental 
models.
The importance of Staphylococcus-induced cytokine production is emphasized by 
the severity of two clinical syndromes caused by Staphylococci. In Staphylococcal 
sepsis and toxic shock syndrome (TSS), the systemic infl ammation caused by over-
whelming cytokinemia is thought to play a pivotal role. Whereas in the former the 
cytokine release is triggered by invasion of the blood by intact microorganisms, in 
the latter the staphylococci rarely invade the host and the cytokine production is trig-
gered by exotoxins acting as superantigens. In the fi rst two studies presented in this 
thesis, we investigated whether there is divergent activation of the cytokine network 
when either intact S. aureus or S. epidermidis microorganisms or the staphylococcal 
superantigens are used as stimuli in a whole-blood model. Cytokine production 
can effectively be studied in a whole-blood culture, and culture conditions closely 
resemble the in vivo situation because cells (e.g. monocytes, neutrophils, and lym-
phocytes) and serum factors (e.g. complement and antibodies) which are present are 
important for defense against infectious organisms.
In Chapter 2, we used whole staphylococcal microorganisms (heat-killed Staphylo-
coccus epidermidis and Staphylococcus aureus), and the staphylococcal components 
staphylococcal enterotoxin B (SEB), toxic shock syndrome toxin-1 (TSST-1), lipotei-
choic acid (LTA), and peptidoglycan (PG) as a microbial stimulus. The contribution 
of the cytokines IL-18, IL-1, tumor necrosis factor (TNF), and IL-12 in the induction 
of interferon-γ (IFN-γ), TNF, and IL-8 was investigated using specifi c cytokine inhibi-
tors such as IL-18 binding protein (IL-18BP), IL-1 receptor antagonist (IL-1Ra), TNF-
binding protein (TNFbp), and anti-IL-12 antibodies (anti-IL-12 Ab). Staphylococcus 
spp.-induced production of IFN-γ required the presence of endogenous IL-18, IL-12 
and TNF. This is probably due to effects exerted at the level of PG stimulation of cy-
tokine synthesis, as PG-induced production IFN-γ was inhibited by IL-18BP, IL-1Ra, 
and TNFbp. In contrast to Staphylococcus-induced IFN-γ synthesis, SEB-induced and 
TSST-1 induced IFN-γ was dependent only of endogenous IL-12 and not of IL-18, in-
dicating that IL-18 does not play a central role in superantigen-induced IFN-γ. Thus, 
this study shows that the mechanisms of IFN-γ stimulation by intact staphylococcal 
microorganisms and exotoxins differ, likely due to the different receptors which are 
triggered on the cell membranes. 
Chapter 3 shows that IL-18, IL-12 and TNF are important cytokines in the induc-
tion of IFN-γ by Staphylococcus epidermidis. In contrast, blocking endogenous IL-1 
with IL-1Ra had no effect on S. epidermidis-induced IFN-γ production. The induction 
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of TNF was dependent on endogenous production of IL-18 and IL-1, but not IL-12. 
S. epidermidis induced IL-8 production was not infl uenced by any of the cytokine 
inhibitors used.
Lethal endotoxemia has been extensively used as an experimental model of Gram-
negative septic shock. Lipopolysaccharide (LPS) is believed to be playing a key role 
in this disease. Binding of LPS to receptors on leukocytes triggers the production 
of the proinfl ammatory cytokines TNF, IL-1α and IL-1β, and the chemokines IL-8, 
macrophage infl ammatory protein-1α (MIP-1α) and MIP-2. Stimulation of cytokines 
and chemokines is of pivotal importance in the pathogenesis of sepsis, as they are 
believed to be the main endogenous mediators of organ injury in endotoxic shock. 
Recent data suggest that IL-18 has direct proinfl ammatory properties, independent 
of IFN-γ, by inducing production of these proinfl ammatory cytokines. We tested the 
hypothesis that these proinfl ammatory effects may contribute to disease by investi-
gating the role of IL-18 in adhesion molecule expression, lethal endotoxemia, and 
modulation of the acute-phase response.
Induction of expression of adhesion molecules is a crucial step in infl ammation. 
The role of IL-18 in induction of various adhesion molecules was investigated in 
freshly isolated peripheral blood mononuclear cells and human monocyte and T-cell 
lines (Chapter 4). IL-18 selectively upregulated intercellular adhesion molecule-1 
(ICAM-1) expression on freshly isolated human monocytes, but not on lymphocytes. 
The expression of other adhesion molecules was not affected. IL-12 had an additive 
effect on ICAM-1 induction by IL-18, and upregulation of ICAM-1 was partially de-
pendent on initial induction of TNF-α production. On the monocytic cell line THP-1 
and on the T-cell lines HSB-2 and Jurkat J16, no changes in adhesion molecule 
expression were observed. In addition, induction of ICAM-1 on monocytes by the 
microbial stimulus LPS was slightly, but signifi cantly, inhibited by blockade of either 
endogenous IL-18 or TNF-α with their specifi c inhibitors IL-18BP and TNFbp respec-
tively. Thus, IL-18 selectively upregulates the expression of ICAM-1 on monocytes, 
and this contributes to the proinfl ammatory effects of this cytokine.
In Chapter 5 we hypothesized that neutralization of IL-18 would have a benefi cial 
effect in lethal endotoxemia in mice. IL-1β converting enzyme (ICE)-defi cient mice, 
lacking ability to process mature IL-18 and IL-1β, were completely resistant to lethal 
endotoxemia induced by LPS derived from either Escherichia coli or Salmonella 
typhimurium. In contrast, both wild-type and IL-1β-/- mice were equally susceptible 
to the lethal effects of LPS, implicating that absence of mature IL-18 or IL-18-induced 
IFN-γ, but not IL-1β, in ICE-/- mice is responsible for this resistance. IFN-γ-defi cient 
mice, however, were not resistant to S. typhimurium LPS, suggesting an IFN-γ-inde-
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pendent role for IL-18. Anti-IL-18 antibodies protected mice after a lethal injection 
of either LPS. Anti-IL-18 treatment also reduced neutrophil accumulation in liver and 
lungs. The increased survival was accompanied by decreased levels of IFN-γ in the 
anti-IL-18 treated mice challenged with either LPS, whereas MIP-2 was decreased 
in the E. coli LPS challenged mice and TNF concentrations were decreased in S. 
typhimurium LPS challenged mice. In conclusion, neutralization of IL-18 during 
lethal endotoxemia protects mice against lethal effects of LPS. This protection is 
partly mediated through inhibition of IFN-γ production, but mechanisms involving 
decreased neutrophil-mediated tissue damage due to the reduction of either chemo-
kines (E. coli LPS) or TNF (S. typhimurium LPS) synthesis by anti-IL-18 treatment 
may also be involved.
The pyrogenic properties of recombinant IL-18 (rIL-18) were studied in a rabbit 
model of fever in Chapter 6. Moreover, the ability of rIL-18 to modulate other 
components of the acute-phase response such as leukocytosis, lipid profi les and glu-
cocorticosteroid production was assessed. rIL-18 did not cause fever when injected 
intravenously into rabbits. Injection of rIL-18 in mice did not induce leukocytosis, or 
modifi cation of circulating concentrations of lipoproteins, or corticosterone. These 
data indicate that IL-18 is not an endogenous pyrogen, and this notion is in agree-
ment with previous studies, showing no changes in temperature in animals injected 
with intraperitoneal IL-18. 
Despite the importance of IFN-γ, TNF, and IL-1 for host defense against candidiasis, 
the pathways leading to their stimulation by Candida albicans are unclear. Recent 
studies show that additional costimuli are needed for an effi cient synthesis of IFN-γ. 
Moreover, IL-18 may play a role during C. albicans infection. Therefore, in Chap-
ter 7 we assessed the contribution of endogenous IL-18, IL-1, TNF, and IL-12 in 
Candida-induced IFN-γ production. In a whole-blood model, IL-18 neutralization 
by IL-18BP decreased C. albicans-induced IFN-γ. Similarly, neutralization of IL-12 
or IL-1β by either neutralizing antibodies or IL-1Ra also reduced IFN-γ production. 
Neutralization of TNF by TNFbp resulted in only a marginal reduction of IFN-γ syn-
thesis. In contrast, induction of TNF and IL-8 by C. albicans was largely independent 
of secretion of intermediary mediators. Thus, C. albicans stimulates IFN-γ produc-
tion in an IL-18-, IL-12-, and IL-1β-dependent manner. In Chapter 8 we investigated 
whether endogenous IL-18 is involved in host defense against Candida infection by 
administering anti-IL-18 antibodies to mice prior to infection. In mice injected intra-
venously with C. albicans, administration of anti-IL-18 antibodies increased the yeast 
load in the kidneys. In IFN-γ-defi cient mice treated with anti-IL-18 antibo dies, no 
effect on the organ load with Candida was observed, suggesting that the protective 
effect of IL-18 is mediated through endogenous IFN-γ. In Chapter 9 we show that 
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prophylactic treatment of mice with rIL-18 decreased mortality following C. albicans 
infection, accompanied by a decreased outgrowth of yeasts in the kidneys one day 
after infection. Therapeutic administration of rIL-18 also resulted in a decreased 
outgrowth of C. albicans in the kidneys. Improvement of outcome was associated 
with increased levels of IFN-γ, both in the circulation and after in vitro stimulation 
of splenocytes with C. albicans. Histopathologic analysis of the kidneys showed 
increased infl ammation and decreased growth of Candida in the rIL-18-treated mice, 
which suggests that the stronger infl ammatory reaction led to more effective control 
of the yeast growth. A recent study by our group shows that IL-18-defi cient mice 
have an increased susceptibility to a systemic infection with C. albicans, whereas 
IL-12-defi cient mice only showed a marginal increase in fungal load in their organs 
[1]. 
PERSPECTIVE
IL-18 was fi rst described as an IFN-γ-inducing factor, which circulated during endo-
toxemia in mice preconditioned with a prior infection of Propionibacterium acnes. 
In our studies we have shown the importance of IL-18 in IFN-γ production induced 
by various microbial stimuli. Moreover, we found that IL-18 displays also proinfl am-
matory effects by increase in expression of the adhesion molecule ICAM-1. Further-
more, IL-18 plays a protective role in the defense against disseminated candidiasis. 
It has been shown that IL-18 serves a key role in controlling infections due to 
Mycobacterium, Cryptococcus, Salmonella, and Leishmania major organisms [2-5]. 
Recently, anti-cytokine strategies targeting excessive TNF-α or IL-1 have been suc-
cessfully incorporated in current pharmacotherapy of chronic infl ammatory diseases, 
such as rheumatoid arthritis and Crohn’s disease. In view of the proinfl ammatory 
properties of IL-18, it may be hypothesized that anti-IL-18 strategies can be used in 
auto-immune diseases. However, experimental data suggest that IL-18, TNF-α, and 
IL-1 contribute to host defense against infection. Blocking these proinfl ammatory cy-
tokines may lead to an increased risk of opportunistic infections, which has already 
been shown in reactivation of M. tuberculosis and other opportunistic infections in 
anti-TNF therapy [6, 7]. To obtain an answer to the question whether it is safe to 
block IL-18 in auto-immune diseases, studies on the role of IL-18 in clinical settings 
will be needed. 
Increased knowledge in the area of genomics has led to discovery of gene poly-
morphisms for cytokines and its receptors, leading to inborn susceptibility to infec-
tions. Given the role of IL-18 in host defense, it can be anticipated that patients 
with polymorphisms leading to defective IL-18 production, suffering from increased 
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susceptibility to infection (e.g. fungal infections) may be encountered. Likewise, 
genetic polymorphisms of the IL-18 receptor or its binding protein may contribute 
to the course of infections.
CONCLUSIONS
1. The role of IL-18 and other cytokines in the induction of IFN-γ by staphylococcal 
microorganisms and exotoxins diﬀ ers.
2. The proinﬂ ammatory properties of IL-18 are underscored by the selective upregu-
lation of ICAM-1 expression on monocytes by IL-18.
3. Reduction of IL-18 protects mice against the lethal eﬀ ects of LPS derived from E. coli 
or S. typhimurium.
4. IL-18 does not cause fever and does not modulate the acute-phase response.
5. IL-18 is important in the induction of IFN-γ by C. albicans, and it plays a protective 
role in the defense against disseminated infection with C. albicans.
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In dit proefschrift wordt onderzoek beschreven naar de rol van interleukine-18 (IL-
18) bij de activatie van cytokinen (de belangrijkste boodschappereiwitten van de 
afweer), de eigenschappen van IL-18 om ontsteking op te wekken en de rol van 
IL-18 tijdens ernstige infecties. Hiervoor is gebruik gemaakt van verschillende expe-
rimentele modellen. IL-18 is een cytokine. Een groot aantal cytokinen (meer dan 35) 
is thans bekend, en deze beïnvloeden elkaars productie en werking (het cytokinen-
netwerk)
De bacterie Staphylococcus aureus is een belangrijke ziekteverwekker voor de mens. 
Staphylococcen sepsis (bloedvergiftiging door het voorkomen van de bacterie in het 
bloed) en Toxische Shock Syndroom (”tamponziekte”) worden door deze bacterie 
veroorzaakt. Bij beide wordt verondersteld dat een algemene ontstekingsreactie met 
overweldigende hoeveelheden van cytokinen een centrale rol speelt. Terwijl in het 
eerste geval het vrijkomen van cytokinen wordt opgeroepen door het binnendrin-
gen van intacte staphylococcen in de bloedbaan, dringen de staphylococcen zelf 
in het andere geval zelden de gastheer binnen. De cytokinenproductie wordt dan 
veroorzaakt door exotoxinen, door de bacterie uitgescheiden gifstoffen, die met het 
afweersysteem reageren. Staphylococcus epidermidis is een staphylococ die minder 
ziekmakend is en alleen onder bijzondere omstandigheden ziekte veroorzaakt. In de 
eerste twee onderzoekingen in dit proefschrift onderzochten we de activatie van het 
cytokinen-netwerk wanneer intacte S. aureus of S. epidermidis micro-organismen of 
staphylococcen exotoxinen gebruikt worden als stimulus voor witte bloedcellen. De 
productie van cytokinen kan goed bestudeerd worden in een kweek van volbloed 
(dus waarin alle cellen aanwezig zijn). Kweekomstandigheden lijken hierbij op die 
van de situatie in het lichaam omdat de aanwezige cellen (monocyten, granulocyten 
en lymfocyten) en serumeiwitten (complement en antilichamen) belangrijk zijn voor 
de afweer tegen verwekkers van infecties.
In Hoofdstuk 2 gebruiken we intacte door verhitting gedode staphylococcen (Sta-
phylococcus epidermidis and Staphylococcus aureus) en de staphylococcen exotoxi-
nen staphylococcal enterotoxin B (SEB) en toxic shock syndroom toxine-1 (TSST-1) 
en de bestanddelen lipoteichoic acid (LTA) en peptidoglycan (PG) als stimulus. De 
bijdrage van de cytokinen IL-18, IL-1, tumor necrosis factor (TNF) en IL-12 bij het 
oproepen van interferon-γ (IFN-γ), TNF en IL-8 werd onderzocht met specifi eke 
remmers zoals IL-18 bindend eiwit (IL-18BP), IL-1 receptor antagonist (IL-1Ra), TNF-
bindend eiwit (TNFbp) en antilichamen tegen IL-12 (anti-IL-12 Ab). De door staphy-
lococcen geïnduceerde productie van IFN-γ heeft de aanwezigheid van IL-18, IL-12 
en TNF nodig. Waarschijnlijk wordt dit veroorzaakt door effecten als gevolg van 
peptidoglycan stimulatie van cytokine productie omdat peptidoglycan geïnduceerde 
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productie van IFN-γ geremd werd door IL-18BP, IL-1Ra en TNFbp. In tegenstelling 
tot de door staphylococcen geïnduceerde IFN-γ-synthese, is de door SEB en door 
TSST-1 geïnduceerde IFN-γ-productie afhankelijk van IL-12 en niet van IL-18. Ken-
nelijk heeft IL-18 geen centrale rol bij de door exotoxinen geïnduceerde IFN-γ-pro-
ductie. Dit onderzoek laat zien dat de IFN-γ-stimulatie door intacte staphylococcen 
verschilt van die door exotoxinen.
Hoofdstuk 3 toont dat IL-18, IL-12 en TNF belangrijke cytokinen zijn in de induc-
tie van IFN-γ door Staphylococcus epidermidis. Blokkade van door de cellen gepro-
duceerd IL-1 met IL1Ra bleek geen effect op door de S. epidermidis geïnduceerde 
IFN-γ-productie te hebben. De inductie van TNF was afhankelijk van de productie 
van IL-18 en IL-1, maar niet van IL-12. De door S. epidermidis geïnduceerde IL-8-
productie werd niet beïnvloed door één van de gebruikte remmers.
Dodelijke bloedvergiftiging met endotoxinen wordt vaak gebruikt als experimenteel 
model van Gram-negatieve sepsis. Met Gram-negatieve sepsis wordt de bloedvergif-
tiging veroorzaakt door darmbacteriën als Escherichia coli aangeduid. Van endotoxin-
en (lipopolysaccharide (LPS)) wordt verondersteld dat het een sleutelrol speelt in 
deze ziekte. Binding van LPS aan witte bloedcellen zet de productie van de cytoki-
nen TNF, IL-1α en IL-1β aan, en de z.g. chemokinen IL-8, macrofaag infl ammatoir ei-
wit-1α (MIP-1α) en MIP-2. Cytokinen en chemokinen zijn van groot belang bij deze 
sepsis: ze worden beschouwd de veroorzakers van orgaanschade te zijn. Recente 
gegevens laten zien dat IL-18 zelf ontsteking oproept onafhankelijk van IFN-γ. We 
testten de hypothese dat deze ontstekingseffecten kunnen bijdragen tot ziekte door 
de rol van IL-18 te onderzoeken in het oproepen van moleculen die de kleverigheid 
van witte bloedcellen versterken (adhesiemoleculen), dodelijke bloedvergiftiging en 
verandering van de ontstekingsreactie (”acute-fase respons”).
Inductie van adhesiemoleculen speelt een sleutelrol in ontsteking. De rol van IL-18 
hierbij werd onderzocht in witte bloedcellen (geïsoleerde mononucleaire cellen) en 
in humane monocyt en T-cellijnen (Hoofdstuk 4). IL-18 geeft selectieve verhoging 
van intercellulair adhesie molecuul-1 (ICAM-1) op verse geïsoleerde humane mo-
nocyten, maar niet op lymphocyten. De expressie van andere adhesiemoleculen 
werd niet beïnvloed. IL-12 had een additief effect op ICAM-1 inductie door IL-18. 
Het oproepen van ICAM-1 was voornamelijk afhankelijk van TNF-α-productie. Op 
de monocyt-cellijn (THP-1) en op de T-cellijnen (HSB-2 en Jurkat J16) werden geen 
veranderingen in adhesiemoleculen waargenomen. Daarnaast werd inductie van 
ICAM-1 op monocyten door LPS in geringe mate, maar wel signifi cant geremd door 
blokkade van IL-18 of TNF-α. IL-18 geeft dus selectieve verhoging van de expres-
sie van ICAM-1 op monocyten en dit draagt bij aan de ontstekingseffecten van dit 
cytokine.
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In Hoofdstuk 5 werd de hypothese onderzocht dat neutralisatie van IL-18 een gun-
stig effect zou hebben op dodelijke bloedvergiftiging met endotoxinen in muizen 
zonder IL-1β converting enzyme (ICE), welke de mogelijkheid missen om werk-
zaam IL-18 en IL-1β te maken. Deze muizen waren volledig beschermd tegen dood 
geïnduceerd door LPS afkomstig van Escherichia coli of Salmonella typhimurium. 
Daarentegen zijn zowel normale muizen als muizen zonder IL-1β even gevoelig voor 
de dodelijke effecten van LPS. Dit houdt in dat de afwezigheid van werkzaam IL-18 
of IL-18-geïnduceerde IFN-γ, en niet IL-1β, verantwoordelijk is voor bescherming 
tegen dood. Muizen zonder IFN-γ zijn echter niet resistent tegen S. typhimurium LPS, 
wat een IFN-γ-onafhankelijke rol voor IL-18 suggereert. Antilichamen tegen IL-18 
beschermden muizen tegen een dodelijke injectie van beide soorten LPS. Anti-IL-18 
behandeling verminderde ook de ophoping van witte bloedcellen (neutrofi elen) 
in lever en longen. De verhoogde overleving ging samen met lagere spiegels van 
IFN-γ in de met anti-IL-18 behandelde muizen die met beide LPS soorten werden 
ingespoten. MIP-2 was verlaagd in de met E. coli LPS behandelde muizen en TNF-
concentraties waren verlaagd in de met S. typhimurium LPS behandelde muizen. 
Concluderend, neutralisatie van IL-18 beschermt muizen tegen de dodelijke effecten 
van LPS. Deze bescherming komt deels tot stand door remming van IFN-γ-productie, 
maar mechanismen welke betrokken zijn bij verminderde weefselschade door witte 
bloedcellen, door verminderde aanmaak van zowel chemokinen (E. coli LPS) en TNF 
(S. typhimurium LPS) kunnen ook een rol spelen. 
De koortsverwekkende eigenschappen van recombinant IL-18 (rIL-18) werden be-
studeerd in konijnen in Hoofdstuk 6. Daarnaast werd onderzocht of rIL-18 andere 
onderdelen van acute ontsteking (”acute-fase respons”) zoals het aantal witte bloed-
cellen (leukocytose), vetsamenstelling van het bloed en productie van bijnierschors-
hormoon kon veranderen. rIL-18 veroorzaakt geen koorts wanneer het in de ader 
van konijnen wordt ingespoten. Injectie van rIL-18 in muizen geeft geen leukocytose 
of verandering van de vetsamenstelling of bijnierschorshormoon. Deze resultaten 
geven aan dat IL-18 geen koortsverwekkend hormoon (endogeen pyrogeen) is.
De gist Candida albicans is de belangrijkste veroorzaker van invasieve infecties 
door Candida (candidiasis). Ondanks het belang van IFN-γ, TNF en IL-1 voor de 
weerstand tegen candidiasis is het onduidelijk hoe C. albicans deze stoffen oproept. 
Recente studies laten zien dat verschillende stimuli nodig zijn voor een effi ciënte 
aanmaak van IFN-γ. Daarnaast speelt IL-18 mogelijk zelf ook een rol tijdens C. albi-
cans infectie. Daarom onderzochten we in Hoofdstuk 7 de bijdrage van IL-18, IL-1, 
TNF en IL-12 in de door Candida-geïnduceerde IFN-γ-productie. In volbloed werd 
de door C. albicans-geïnduceerde IFN-γ-productie verminderd door neutralisatie van 
IL-18 met IL-18BP. Neutralisatie van IL-12 of IL-1β reduceerde eveneens IFN-γ-pro-
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ductie. Neutralisatie van TNF resulteerde in een marginale reductie van IFN-γ syn-
these. De inductie van TNF en IL-8 door C. albicans was grotendeels onafhankelijk 
van intermediaire cytokinen. C. albicans stimuleert dus de IFN-γ-productie op een 
IL-18-, IL-12- en IL-1β-afhankelijke wijze. 
In Hoofdstuk 8 hebben we onderzocht hoe IL-18 betrokken is in de weerstand 
tegen een Candida infectie. Voorafgaande aan de infectie kregen muizen anti-IL-18 
antilichamen toegediend, vervolgens werden ze ingespoten met C. albicans. Voor-
afgaande toediening van anti-IL-18 antilichamen leidde tot een toename van de 
hoeveelheid schimmel in de nieren. In muizen zonder IFN-γ behandeld met anti-
IL-18 antilichamen werd geen effect waargenomen op de hoeveelheid Candida in 
de organen, hetgeen suggereert dat het beschermende effect van IL-18 berust op 
IFN-γ. 
In Hoofdstuk 9 laten we zien dat voorbehandeling van muizen met rIL-18 de 
sterfte van C. albicans infectie verlaagt. Dit gaat gepaard met een verminderde uit-
groei van schimmels in de nieren één dag na infectie. Toediening van rIL-18 na de 
infectie resulteert ook in een verminderde uitgroei van C. albicans in de nieren. De 
overleving was beter in muizen met verhoogde spiegels van IFN-γ in het bloed. Ook 
in kweken van miltcellen was de productie van IFN-γ onder invloed van C. albicans 
groter bij muizen waarbij rIL-18 was toegediend. Microscopisch onderzoek van de 
nieren toonde toename van ontsteking en verminderde uitgroei van Candida in de 
met rIL-18 behandelde muizen. Dit suggereert dat een sterkere ontstekingsreactie 
leidt tot een effectievere controle van de schimmelgroei. Een recent onderzoek van 
onze groep toont aan dat muizen zonder IL-18 een toegenomen gevoeligheid heb-
ben voor een systemische infectie met C. albicans, terwijl muizen zonder IL-12 
slechts geringe toename van de hoeveelheid schimmel in hun organen tonen [1]. 
TOEKOMST
IL-18 werd aanvankelijk beschreven als een ‘IFN-γ-inducing factor’, die aanwezig was 
in het bloed bij muizen die waren geïnfecteerd met de bacterie Propionibacterium 
acnes. In ons onderzoek hebben we het belang van IL-18 bij de IFN-γ-productie 
geïnduceerd door verschillende microbiële stimuli laten zien. Daarnaast toonden we 
aan dat IL-18 ook een toename van expressie van het adhesiemolecuul ICAM-1 te-
weegbrengt. Verder heeft IL-18 een beschermende rol in de afweer tegen uitgezaaide 
candidiasis. Door anderen is aangetoond dat IL-18 een sleutelrol speelt in de afweer 
tegen infecties veroorzaakt door bacteriën zoals mycobacteriën en salmonella, de 
schimmel Cryptococcus en de protozo Leishmania major [2-5]. 
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Recent zijn behandelingen gericht tegen overmatige aanwezigheid van TNF-α of 
IL-1 met succes opgenomen in de farmacotherapie van chronische ontstekingsziek-
ten zoals rheumatoïde arthritis en de ziekte van Crohn. Gezien de ontstekingseigen-
schappen van IL-18 kan men veronderstellen dat tegen IL-18 gerichte behandelingen 
gebruikt kunnen worden bij autoimmuun ziekten. Onderzoek suggereert echter dat 
IL-18 bijdraagt aan de gastheerweerstand tegen infectie. Het blokkeren van IL-18 
kan dus leiden tot een verhoogd risico op infecties, zoals dit ook is opgetreden bij 
anti-TNF therapie [6, 7]. Om een antwoord te verkrijgen op de vraag of het veilig is 
om IL-18 te blokkeren bij autoimmuun ziekten is verder onderzoek nodig. 
Toename van genetische kennis heeft geleid tot de ontdekking van genafwijkingen 
voor cytokinen en hun receptoren. Dergelijke afwijkingen leiden tot verhoogde ge-
voeligheid voor infecties. Gezien de rol van IL-18 in de afweer kan verwacht worden 
dat patiënten met gebrekkige IL-18-productie, een verhoogde gevoeligheid voor 
infecties (bijvoorbeeld schimmelinfecties) vertonen. Eveneens kunnen genetische 
afwijkingen (mutaties en polymorfi smen) van de IL-18-receptor of van het bindend-
eiwit van IL-18 bijdragen aan abnormal beloop van infecties.
CONCLUSIES
1. De rol van IL-18 en andere cytokinen in de inductie van IFN-γ door staphylococcen 
en exotoxinen verschilt.
2. De ontstekingseigenschappen van IL-18 bestaan onder meer uit de selectieve toe-
name van ICAM-1 op monocyten.
3. Tekort aan IL-18 beschermt muizen tegen de dodelijke eﬀ ecten van LPS afkomstig 
van E. coli of S. typhimurium.
4. IL-18 veroorzaakt geen koorts en beïnvloedt de acute-fase respons niet.
5. IL-18 is belangrijk bij de inductie van IFN-γ door C. albicans en speelt een bescher-
mende rol in de afweer tegen uitgezaaide infectie met C. albicans.
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